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RESUME (en français) 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESUME (en français) 
 
Introduction générale : 
Le lupus érythémateux disséminé (ou « Systemic lupus erythematosus » en anglais, 
d’où l’abréviation SLE*) est une maladie autoimmune systémiques, et souvent considéré 
comme le « prototype » de cette famille de pathologies. Contrairement aux maladies 
autoimmunes spécifiques d’un tissu, le SLE se caractérise par son potentiel d’atteindre 
(simultanément ou séquentiellement) de multiples organes. De fait, pratiquement tous les 
organes peuvent être sujet aux manifestations pathologiques, avec certains patients montrant 
des lésions de la peau ou des articulations, alors que d’autres souffrent de troubles 
neurologiques, cardiaques ou (surtout) rénales. Les pathologies rénales se traduisent par le 
développement de glomérulonéphrites (GN) par complexes immuns (IC), qui étaient jusqu’à 
récemment la principale cause de décès chez les patients atteints du SLE. 
Le SLE était jadis considéré comme une maladie assez rare, mais l’amélioration des 
méthodes de diagnostic a révélé que sa prévalence est de l’ordre de 1 : 2000 dans les 
populations caucasiennes. De plus, certains facteurs de risque, comme le sexe féminin ou la 
race noir ou hispanique, peuvent accroître massivement le risque de développer un lupus. 
Concrètement, le SLE est presque dix fois plus fréquent chez les femmes âgées de quinze à 
cinquante ans, que chez les hommes de la même tranche d’âge. Ces observations sur la 
disparité du lupus dans différentes populations avaient tôt fait de suggérer que des facteurs 
génétiques, comme par exemple le gènes du HLA, et des facteurs environnementaux 
pouvaient jouer un rôle dans la pathogenèse du SLE. Cependant, à ce jour aucun pathogène 
déclencheur n’a pu être identifié et le rôle des hormones sexuelles reste controversé. 
Parmi toutes les manifestations pathologiques décrites, la production d’autoanticorps 
anti-nucléaires (c’est-à-dire anti-DNA, anti-chromatine etc.) et le développement des GN 
lupiques se sont révélés être les symptômes les plus récurrents et les plus caractéristiques du 
SLE. La découverte que certaines souches de souris développaient spontanément un 
syndrome autoimmun, nommé par la suite « lupus murin », qui impliquait les mêmes 
manifestations, a grandement aidé la recherche sur les origines moléculaire de cette maladie. 
A l’aide de ces souris lupiques, il était devenu possible de disséquer des génomes entiers, 
d’isoler des gènes ou régions chromosomiques conférant un susceptibilité au lupus et de 
vérifier leurs rôles après transfert dans des souches de souris non-autoimmunes. Les gènes de 
                                                 
* Par souci de cohérence avec le reste de ce rapport, les abréviations anglais seront utilisées ici. 
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susceptibilité ainsi identifiés peuvent ensuite être analysés chez des patients humains atteints 
du SLE, et un exemple récent de la valeur de cette approche est la démonstration que le gène 
codant pour le récepteur inhibiteur FcγRIIB (voir ci-dessous) est impliqué dans la 
susceptibilité au lupus et chez la souris et chez l’homme. 
Il existe trois souches de souris qui sont des modèles « classiques » du développement 
du lupus : Les souris hybrides (NZB x NZW)F1 développent une maladie avec toutes les 
caractéristiques du SLE, probablement dû à la combinaison des contributions génétiques 
respectives des souches NZB et NZW. Cependant, il est intéressant de constater que ni les 
souris NZB, ni les souris NZW « pures » développent le lupus. Les hybrides (NZB x NZW)F1 
montrent une forte inégalité des deux sexes face au SLE, car les femelles F1 meurent 
beaucoup plus tôt (50% de mortalité à l’âge de 9 mois) que leurs homologues mâles (50% de 
mortalité à l’âge de 16 mois). La deuxième souche modèle du lupus murin se nomme MRL-
lpr/lpr et est caractérisée par la présence homozygote de la mutation récessive lpr (pour 
lymphoproliferation) dans le gène codant pour la molécule Fas, qui est indispensable pour 
l’apoptose. Il est généralement considéré que la défaillance d’induire l’apoptose des cellules 
autoréactives contribue au développement d’un lupus accéléré dans ces souris (50% de 
mortalité à l’âge de 5 mois pour les deux sexes). Finalement, le troisième modèle du lupus 
murin est la souche recombinante BXSB, qui a été initialement générée par un croisement 
entre des femelles C57BL/6 (B6) et un mâle SB/Le. Les mâles BXSB développent le SLE 
bien plus rapidement que les femelles (50% de mortalité à l’âge de 6 mois, contre 20 mois 
pour les femelles) et cette accélération est due à la présence de la mutation Yaa (pour Y-linked 
autoimmune acceleration) présent sur le chromosome Y provenant initialement de SB/Le, 
mais dont la fonction n’a pas encore été identifié. 
 
Introduction aux différentes chapitres de la thèse : 
Nous avons précédemment démontré que la mutation Yaa, isolée initialement dans des 
souris mâles BXSB, qui développent une forme accélérée du lupus, peut provoquer des 
phénotypes autoimmuns chez des souris prédisposées, mais habituellement asymptomatiques, 
ou accélérer le développement du SLE chez des souches lupiques. Cependant, le mécanisme 
moléculaire précis du défaut Yaa n’a pas pu être identifié. Il a été démontré que Yaa est 
exprimé dans des cellules B, mais pas dans des cellules T, et que Yaa peut abroger la 
protection de la maladie par des haplotypes non-permissifs du complexe majeur 
d’histocompatibilité. Une hypothèse, qui intègre ces observations, a proposé que Yaa pourrait 
favoriser les interactions spécifiques entre les cellules B et T, par exemple à travers 
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l’expression d’une molécule d’adhésion sur les cellules B. En opposition avec cette 
hypothèse, nos récents résultats présentés dans ce rapport favorisent un modèle dans lequel la 
mutation Yaa augmente la signalisation positive à travers le récepteur à l’antigène des cellules 
B (BCR), ce qui pourrait avoir une importance particulière dans des cellules B autoréactives 
de faible affinité. Cette dysrégulation de la signalisation dans les cellules B due à Yaa aurait 
pour conséquence des altérations de l’homéostase des cellules B et le développement 
d’autoimmunité. Néanmoins, il est important de garder à l’esprit que le BCR est étroitement 
contrôlé par de multiples co-récepteurs inhibiteurs présents sur la surface des cellules B. Par 
conséquence, le développement de l’autoimmunité pourrait être favorisé non seulement par 
l’augmentation directe de la signalisation positive à travers le BCR, mais aussi par des 
déficiences dans ces mécanismes régulateurs. 
L’un des récepteurs inhibiteurs qui a été étudié particulièrement en détail, est le 
récepteur Fcγ de type RIIB (FcγRIIB), qui fait partie de la famille des récepteurs Fc 
reconnaissant la portion Fc des Ig monomériques ou sous forme d’IC. Sa spécificité de liaison 
de faible affinité aux IgG et l’identification de sa capacité régulatrice sur la signalisation à 
travers le BCR (grâce au recrutement de la phosphatase SHIP), ainsi que le fait qu’il est le 
seul récepteur Fcγ exprimé à la surface des cellules B, ont suggéré un rôle pour FcγRIIB dans 
la terminaison des réponses anticorps des cellules B clonales spécifiques d’un antigène déjà 
contenu dans des IC. De plus, un autre rôle a été proposé pour FcγRIIB dans la maintenance 
de la tolérance périphérique des cellules B autoréactives générées suite aux mutations 
somatiques dans les centres germinatifs au cours d’une réponse immune contre des 
pathogènes microbiens. Finalement, des analyses génétiques ont révélé que certaines souches 
de souris propices au développement de l’autoimmunité portent un haplotype polymorphique 
du gène Fcgr2 responsable d’une expression diminuées de FcγRIIB après activation des 
cellules B. Mises ensemble, ces données suggèrent que des molécules FcγRIIB mutantes ou 
déficientes pourraient être responsables d’une régulation défaillante de la signalisation à 
travers le BCR, en particulier dans des cellules B potentiellement autoréactives, favorisant 
ainsi le développement de l’autoimmunité. En effet, des souris B6 déficientes en FcγRIIB, 
générées par recombinaison homologue, développaient spontanément un syndrome 
autoimmun rappelant le SLE, avec des anticorps antinucléaires et des GN. Cependant, des 
analyses plus approfondies ont démontré que des contributions génétiques supplémentaires 
par un fond génétique permissif étaient indispensable au développement d’une maladie 
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lupique complète, soulignant ainsi que FcγRIIB est un gène de susceptibilité au lupus, mais 
pas le seul. 
Un autre régulateur négatif de la signalisation à travers le BCR qui a été extensivement 
étudié est la molécule CD22. CD22 est un membre de la famille des molécules d’adhésion 
Siglec et reconnaît des glycoproteins contenant des acides sialiques fixés en α2-6 dans leurs 
chaînes latérales glucidiques. De plus, elle est dotée d’une capacité de signalisation 
régulatrice due à son domaine intracellulaire, qui peut recruter la phosphatase SHP-1. 
L’inhibition par CD22 de la signalisation dans les cellules B était évidente dans différents 
souris déficientes en CD22, qui affichaient un flux calcique intracellulaire augmentée et 
prolongée après stimulation du BCR, suggérant ainsi que CD22 pourrait plutôt être impliquée 
dans l’ajustement de l’intensité du signal à travers le BCR, que dans sa terminaison. Cette vue 
des choses a aussi été soutenu par l’analyse des capacités de liaison aux ligands de CD22 : A 
travers des interactions avec CD22L exprimés sur d’autres cellules du système immunitaire 
(surtout sur des cellules T), CD22 pourrait retenir les cellules B dans un compartiment 
lymphoïde propice à leur activation, comme les follicules spléniques. Par ce mécanisme, les 
informations sur le micro-environnement des cellules B, y compris sur des possibles 
interactions avec d’autres cellules, pourraient être traduites par CD22 et influencer le seuil 
d’activation des cellules B. Mis à part son rôle dans des interactions entre cellules (liaison en 
trans), CD22 peut aussi lier en cis des CD22L suffisamment sialylés et présents sur la surface 
de la même cellule B, y compris les IgM du BCR ou CD22 elle-même. Le contrôle de la 
liaison en cis, par exemple à travers la régulation de la α2-6 sialyltransférase, pourrait 
présenter un moyen pour moduler l’équilibre entre des CD22 liées, donc « masquées », et des 
CD22 libres, ou « non-masquées », disponibles pour des interactions en trans. En résumé, ces 
données suggèrent que CD22 intègre des informations sur l’environnement et l’état des 
cellules B et régule finement l’intensité de la signalisation à travers le BCR en fonction de ces 
derniers. Notamment, une des souches de souris déficientes en CD22 avec un fond génétique 
mélangeant des contributions B6 et 129 affichait des symptômes autoimmuns significatifs, 
rappelant le lupus. De plus, des souris haploinsuffisantes en CD22 étaient capables de 
produire des anticorps IgG anti-DNA en présence de la mutation Yaa. Ce fait indique 
clairement qu’une déficience partielle en CD22 peut prédisposer au développement du SLE 
en combinaison avec d’autres allèles de susceptibilité au lupus. 
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Résultats et discussion : 
(Par ordre d’apparition des différents chapitres au cours de cette thèse. Voir aussi les articles 
originaux pour plus de détails) 
 
A) La mutation Yaa modifie la maturation des cellules B et augmente les réponses immunes 
humorales 
Etant donné qu’il était difficile de démontrer un rôle direct de la mutation Yaa dans les 
interactions spécifiques entres des cellules B et T, nous avons décidé de rediriger notre 
recherche vers un possible mécanisme de Yaa propre aux cellules B, qui pourrait expliquer 
son pouvoir activateur. Plus concrètement, nous avons exploré si l’expression de la mutation 
Yaa influençait le développement et l’activation des cellules B portant des transgènes codant 
pour des autoanticorps IgM avec une spécificité soit anti-RBC (transgène 4C8), soit anti-DNA 
(transgène Sp6). Le choix de ces deux spécificités autoréactives paraissait prometteur parce 
qu’elles sont toutes les deux présentes dans un certain nombre de souches de souris propices à 
l’autoimmunité, et des publications antérieures avaient démontré que l’activation des cellules 
B1 péritonéales chez des souris B6 portant le transgène 4C8 déclanchait une réponse 
autoimmune puissante qui culminait dans le développement d’une anémie hémolytique 
autoimmune (AIHA). A l’opposé, les souris portant le transgène Sp6 spécifique du DNA, qui 
– à l’instar des RBC – devrait être un antigène ubiquitaire lors de l’induction de la tolérance 
centrale, manquaient de développer des réponses anti-DNA de type lupique à cause d’une 
induction d’anergie dans les cellules B transgéniques. 
Nous avons trouvé que la présence de la mutation Yaa n’augmentait pas la production 
des anticorps anti-DNA dans les souris trangèniques Sp6, suggérant ainsi que Yaa ne peut pas 
passer outre l’anergie dans ces cellules B. De façon intéressante, des souris B6.Yaa non-
transgéniques ne développaient pas non plus spontanément des autoanticorps anti-DNA, mais 
affichaient une réponse autoimmune contre la chromatine. Ces résultats suggèrent que l’effet 
d’Yaa dépend fortement de la nature moléculaire de l’autantigène disponible pour 
l’interaction avec le BCR sur les cellules B autoréactives. Il est possible que la présence de 
multiples épitopes autoantigèniques, par exemple à la surface des cellules apoptotiques (mise 
en évidence dans des autres études) ou sur la membrane des RBC (voir ci-dessous), facilite 
l’activation des cellules B autoréactives et l’action de Yaa. 
La découverte la plus singulière dans notre étude était le développement rapide d’une 
AIHA fatale dans les souris 4C8.Yaa. L’analyse de souris contrôle Yaa non-transgénique de 
même âge démontrait que la réponse autoimmune contre les RBC était propice à 
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l’amplification par Yaa, et l’augmentation de la sécrétion spontanée des IgM dans ces souris 
pouvait être assignée exclusivement aux cellules B2 dans la rate, mais pas aux cellules B1 
dans la cavité péritonéale. De plus, nous avons pu exclure la possibilité que la production des 
IgM 4C8 était dû à un dysfonctionnement de l’induction de la tolérance causé par Yaa, parce 
que l’arrêt du développement des cellules B dans la moelle osseuse était maintenu dans les 
souris 4C8.Yaa, et le nombre global de leurs cellules B dans différents organes lymphoïdes 
périphériques était tout aussi bas que celui des souris contrôles transgéniques non-Yaa. Ce 
dernier point confirmait à nouveau le postulat ancien que Yaa n’interfère pas avec les 
mécanismes apoptotiques à l’œuvre pendant l’induction de la tolérance. Nos résultats nous ont 
poussé à la conclusion que dans les souris 4C8.Yaa un nombre limité de cellules B spléniques, 
qui avaient atteint cet organe grâce aux fuites « normales » propres à l’induction de tolérance 
centrale, avaient été activées efficacement par l’action de la mutation Yaa tôt dans la vie et 
étaient à l’origine de l’AIHA. Cette activation précoce des cellules B autoréactives est 
clairement dépendante de leur spécificité à l’antigène et donc de la signalisation à travers le 
BCR. 
Ces résultats montrent sous un nouveau jour les conclusions que nous avons tirées d’une 
étude supplémentaire sur l’effet de la mutation Yaa sur la population des cellules B de la zone 
marginale (MZ) de la rate. Dans cette étude nous avons démontré que des souris mâles BXSB 
et B6.Yaa âgées de 2 mois, ainsi que des souris BXSB atteintes du lupus, ont un nombre très 
nettement diminué de cellules MZ B. Notamment, ce phénotype était accompagné d’une 
sécrétion spontanée d’IgM accrue et d’une accumulation de plasmocytes dans la rate. Une 
hypothèse attractive pour expliquer ce fait serait que la mutation Yaa accélère de façon rapide 
et sélectif l’activation des cellules MZ B, ce qui aurait pour résultat une déplétion 
préférentielle de cette souspopulation de cellules B, qui sont efficacement activées par des 
antigènes T-indépendant transportés avec le sang. Ceci pourrait aussi expliquer pourquoi un 
nombre presque normal de cellules MZ B est restauré chez des souris Sp6.Yaa, car les cellules 
B portant le transgène Sp6 anti-DNA sont apparemment anergiques dans la périphérie. 
L’hypothèse qu’une signalisation accrue à travers le BCR est impliquée dans la diminution 
des cellules MZ B observée dans les souris mâles B6.Yaa et BXSB est en accord avec des 
observations antérieures qui ont mise en évidence un rôle critique pour ce signal dans le 
développement des cellules MZ B. Toutefois, l’importance d’une possible activation des 
cellules MZ B par Yaa dans le développement accéléré d’un syndrome de type lupique 
demande encore à être formellement démontré. Il serait intéressant d’étudier si une déplétion 
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sélective des cellules MZ B pourrait inhiber la pathogenèse des maladies autoimmunes 
lupiques. 
 
B) Des rôles distincts pour l’apoptose et FcγRIIB dans la régulation des réponses de type 
facteurs rhumatoïdes (RF) et anti-DNA 
Les IC (contenant des IgG) et le DNA sont des autoantigènes biochimiquement fort 
différents, qui sont cependant tous les deux ciblés par des réponses autoimmunes impliquant 
des cellules B (au cours de la arthrite et du SLE, respectivement). L’activation des cellules B 
autoréactives à travers leurs BCR est une condition préalable indispensable pour la production 
d’autoanticorps. Chez des sujets non-autoimmuns, les cellules B autoréactives sont 
empêchées d’attaquer l’hôte par des mécanismes de contrôle qui peuvent globalement être 
assignés aux processus d’induction de tolérance centrale ou périphérique. Un mécanisme 
important dans la tolérance centrale est l’induction de l’apoptose, tandis que des corécepteurs 
inhibiteurs sur des cellules B jouent un rôle critique pour la tolérance périphérique. 
L’un des plus importants récepteurs inhibiteurs sur les cellules B est FcγRIIB, qui est 
censé être capable de terminer tous types de réponses anticorps (y compris, par exemple, 
contre des antigènes nucléaires), et par conséquence une production spontanée d’anticorps 
anti-DNA a été observé chez des souris B6 déficientes en FcγRIIB. Notre analyse dans ces 
mêmes souris a révélé que FcγRIIB contrôlait non seulement les réponses anti-DNA mais 
aussi les réponses RF d’une manière dépendante des haplotypes H2, et ceci était en accord 
avec des résultats antérieurs sur les contributions génétiques aux réponses autoimmunes par 
des souches spécifiques. A cet égard, il est tentant de spéculer que le contrôle des réponses RF 
par FcγRIIB est dû à la reconnaissance directe par ce dernier des IgG contenus dans des IC. 
L’efficacité du contrôle de l’activation des cellules B par FcγRIIB était mise en évidence par 
l’introduction de la mutation Yaa, qui est censé augmenter la signalisation à travers le BCR 
après reconnaissance de l’antigène : Des souris suffisantes en FcγRIIB avec ou sans Yaa 
étaient négatives pour la production de RF, tandis que chez des souris haploinsuffisantes en 
FcγRIIB (c’est-à-dire un niveau hétérozygote pour l’expression du récepteur) Yaa était 
capables de promouvoir ce type de réponse autoimmune, et aussi la production d’anticorps 
anti-DNA. Ces résultats suggéraient à nouveau que la mutation Yaa contribue à l’activation 
des cellules B en augmentant les signaux générés à travers le BCR qui sont insuffisamment 
contrôlés. En outre, nous avons démontré que l’opsonisation par C3 du complément joue 
apparemment un rôle important dans les réponses de type anti-DNA, mais pas de type RF. 
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Tout ceci indique que chaque réponse autoimmune peut être régulée différemment par des 
corécepteurs au BCR distincts, soulignant ainsi l’importance des caractéristiques moléculaires 
des autoantigènes dans le développement spontanés des réponses autoanticorps du SLE. 
Nous avons aussi analysé le rôle de l’apoptose dans la prévention des réponses 
autoimmunes de type RF et anti-DNA en introduisant un transgène codant pour la protéine 
anti-apoptotique Bcl-2, en même temps que la mutation Yaa. Cette étude a démontré qu’une 
défaillance dans l’apoptose était suffisante pour induire une production d’anticorps anti-DNA, 
mais que des réponses RF nécessitaient des contributions génétiques supplémentaires, venant 
par exemple du génome NZW. Comme l’allèle du gène Fcgr2 présent chez les souris NZW 
n’est probablement pas déficient, des autres facteurs génétiques de NZW doivent encore être 
impliqués dans le développement spontané des RF chez les souris (B6 x NZW)F1 
surexprimant Bcl-2. En net contraste avec les réponses anti-DNA, qui étaient augmentées par 
Yaa chez des souris transgéniques pour Bcl-2 quelque soit leur fond génétique, la mutation 
Yaa était incapable d’augmenter les réponses RF dans les souris utilisées dans cette étude, qui 
étaient toutes FcγRIIB+/+. Cependant, nous avons observé que la production des RF pouvait 
être induite même dans des souris B6.Yaa si celles-ci étaient partiellement déficientes pour 
l’expression de FcγRIIB (voir ci-dessus). Ces résultats soulignent encore l’importance 
cruciale de l’équilibre entre des régulateurs négatifs et positifs du BCR dans le déclenchement 
et la persistance des réponses autoimmunes spontanées de type lupique. En conclusion, tous 
nos résultats viennent conforter l’idée i) que Yaa contribue le plus efficacement au 
développement de l’autoimmunité quand le contrôle de la signalisation à travers le BCR est 
perturbé par de quelconques défaillances, ii) que les réponses anti-DNA et RF sont régulées 
différemment, probablement à cause des caractéristiques moléculaires des antigènes, et iii) 
que FcγRIIB joue un rôle particulièrement important dans le contrôle des RF en liant 
directement les IC contenant des IgG. 
 
C) Des différences dans l’expression et la régulation du récepteur inhibiteur CD22 dans la 
souris soulignent son rôle dans la susceptibilité au lupus
Au moins trois formes polymorphiques de CD22 ont été identifiées dans la souris : 
CD22a est exprimée dans des souris NZW, NZB et DBA/2, CD22b dans des souris B6 (entre 
autres), et CD22c dans des souris BXSB et SB. L’analyse des souris rétrocroisées B6 x (NZW 
x B6.Yaa)F1 a montré que le locus majeur de susceptibilité au lupus dans la souche NZW 
était situé près du gène Cd22 sur le chromosome 7, et l’importance de cette région a aussi été 
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confirmé par l’analyse de souris rétrocroisées B6 x (NZB x B6.Yaa)F1. Des variations 
polymorphiques identifiées dans NZW, NZB et BXSB suggèrent que les souris Cd22a et 
Cd22c pourraient exprimer des formes aberrantes de CD22 avec des défauts fonctionnels au 
niveau du site de liaison au ligand. En effet, notre analyse par cytométrie en flux dans des 
souris Cd22a avec l’anticorps monoclonal (mAb) CY34 capable de lier ce site a révélé une 
coloration plus hétérogène, en comparaison avec des souris Cd22b, que nous avons interprété 
comme une conséquence de l’expression de formes aberrantes de CD22. Plus important par 
rapport à la fonction de CD22, nous avons montré que les molécules CD22a étaient plus 
fréquemment « non-masquées » (c’est-à-dire moins de CD22 était lié aux IgM de surface) et 
que les cellules B des souris Cd22a affichaient des flux calciques intracellulaires prolongés 
après activation. Comme tous ces résultats argumentent en faveur d’un rôle de CD22a dans la 
défaillance de la régulation négative du signal à travers le BCR rencontrée dans 
l’autoimmunité systémique, il serait important de générer des souris B6.Yaa portant l’allèle 
Cd22a des souris non-autoimmunes DBA/2 pour analyser en profondeur son rôle dans le 
développement spontané des maladies autoimmunes de type lupique. 
Notre étude sur la régulation de l’expression de CD22 après différents stimuli 
d’activation a également réconforté l’idée que le système immun utilise CD22 comme un 
commutateur pour régler finement l’activation des cellules B. A cet égard, la comparaison de 
l’effet de différents mitogènes pour cellules B sur l’expression de CD22 par des cellules B1 et 
B2 a fourni un exemple édifiant : Alors que la stimulation avec un mAb anti-IgM diminuait 
l’expression de CD22 sur les cellules B2, en accord avec une augmentation de l’activation des 
cellules B2 à travers le BCR, le même stimulus ne modifiait pas l’expression de CD22 dans 
les cellules B1. A l’opposé, la stimulation avec LPS augmentait l’expression de CD22 dans 
les cellules B2, mais la diminuait dans les cellules B1, ce qui était conforme avec le rôle 
proposé pour les cellules B1 dans la première vague de défense contre des pathogènes 
bactériens. En plus, il était intéressant de voir que les réponses calciques après stimulation 
avec des anti-IgM étaient tout aussi bas dans les cellules B1 provenant des souris CD22-/- que 
dans celles provenant des souris CD22+/+, suggérant ainsi que la régulation de l’activation 
des cellules B par CD22 n’était pas forcément un mécanisme employé dans toutes les 
souspopulations des cellules B. Cependant, il a été démontré récemment que le nombre des 
cellules MZ B, qui ont une ressemblance fonctionnelle avec les cellules B1, était diminué 
dans les souris CD22-/-. Une analyse complète du rôle de CD22 dans les souspopulations 
spécialisées des cellules B, et de son possible rôle dans le développement des ces cellules, 
aiderait très certainement à mieux comprendre le rôle biologique de ce corécepteur. 
 9
Conclusions générales : 
Le caractère polygénique évident du SLE chez des patients humains et du syndrome 
lupique chez la souris implique qu’un grand nombre de mécanismes moléculaires, qui 
pourraient contribuer à l’hyperactivité des cellules B et à l’autoimmunité systémique, doivent 
être analysés. Par conséquence cette thèse a abordé un nombre conséquent d’aspects de la 
biologie des cellules B, y compris le rôle de la spécificité à l’antigène et de l’induction de la 
tolérance dans l’autoimmunité, la maturation des différentes souspopulations des cellules B, 
l’induction des fonctions effectrices (surtout la production d’anticorps), la régulation négative 
de la signalisation à travers le BCR, et l’ajustement du seuil de réponse des cellules B en 
intégrant des informations extracellulaires. Nos données soutiennent l’idée que le BCR joue 
un rôle central dans l’établissement de l’autoimmunité systémique due aux anticorps, en 
contribuant la spécificité à l’antigène et en générant efficacement un signal d’activation. Il 
faudrait maintenant élucider quelle combinaison de contributions génétiques apportant une 
susceptibilité au lupus est le plus souvent impliquée dans la pathogenèse du SLE. Des études 
supplémentaires dans des souris transgéniques pourraient donc aider les chercheurs à 
identifier des cibles moléculaires potentielles, qui devront ensuite être validées en milieu 
clinique. Ceci devrait permettre de développer de nouvelles approches thérapeutiques contre 
le SLE, qui pourraient s’attaquer aux mécanismes impliqués dans la pathogenèse, plutôt que 
d’atténuer les symptômes néfastes d’une maladie déjà établie. 
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I) INTRODUCTION 
 
The mammalian immune system is both a fascinating and intimidating subject of 
scientific research: Given its complexity, the fact that it usually functions so well should be 
considered as a source of enchantment, because we are still far from understanding how all 
the cellular and molecular players in an immune response work together (1, 2). Nevertheless, 
over the last decades, tremendous, often “nobelized” progresses have been made in our 
understanding of immunological processes and it would be tempting to consider immunology 
as a “Best of”-compilation of modern biological sciences, including cellular biology (e.g. 
MHC-restriction of T cells), genetics (e.g. creation of antibody diversity) or biochemistry (e.g. 
intracellular signaling in lymphocytes). There is nevertheless a particularity in immunology, 
which puts it apart from other biological disciplines: Historically it has often been a loss-of-
function mutant that gave hints to researchers as to the role played by the mutated protein in a 
given biological process. In immunology, however, the reasons why control mechanisms, 
which are supposed to regulate immune responses, “lose their function” and the ensuing 
development of autoimmunity still rank among the least well understood phenomena. 
Autoimmunity is defined as a state in which the immune system of an individual loses 
its tolerance, i.e. its natural unresponsiveness, against constituents of the immunological 
“self”. A persistent autoimmune response can then lead to the development of a chronic and 
deteriorating autoimmune disease. The variety of autoimmune symptoms seen in the clinic are 
classified by the type of effector mechanism involved (cellular or antibody-mediated) and by 
the structures attacked by these mechanisms. Systemic lupus erythematosus (SLE), as 
outlined below, is the prototypic systemic autoimmune disease, in which autoantibodies 
attack a variety of disseminated autoantigens throughout the body, leading to a multitude of 
clinical symptoms (3-5). Fundamental research on mouse models of SLE should help to 
unravel the mechanisms involved in the loss of self tolerance in this autoimmune condition 
and ultimately contribute to the development of specific therapies for patients that are until 
now mainly treated with general immunosuppressive agents or empirically designed protocols 
(4, 6). 
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Part 1: SLE and Mouse Models 
 
1) Systemic vs. organ-specific autoimmune diseases 
There are several degrees of severity when the immune system goes awry: 
Disproportioned immune responses to innocuous environmental antigens are known as 
hypersensivity reactions and are classified into different types according to the involved 
effector mechanisms that cause tissue damage. Allergic reactions implicating IgE secretion 
and mast-cell activation (i.e. type I hypersensivity) are a well-known example of this broad 
family and are due to excessive activation and/or defective inhibition of immune effector cells 
(7). Things may become more menacing in the case of immune responses in the absence of 
infection and exogenous antigens: Indeed, autoimmunity is defined as a state in which the 
immune system is mounting a response to self antigens, i.e. normal constituents of the host 
body. In contrast to normal immune responses, in which the original source of the eliciting 
antigen – exogenous pathogens or infected cells – is ultimately eliminated, autoimmune 
responses are directed against self antigens that are by definition continuously supplied and 
cannot be eliminated. Moreover, the existence of autoreactive lymphocytes in the periphery is 
a normal feature of the immune system, because central tolerance induction in T and B cells is 
not foolproof. However, “naturally” occurring autoimmunity is tightly controlled in normal 
individuals due to the effectiveness of peripheral mechanisms ensuring tolerance, including 
induction of apoptosis or anergy, functional ignorance and editing of antigen receptors (8-10). 
Autoimmune disease arises, and is usually diagnosed no earlier, when a chronic 
autoimmune response has led to tissue pathology in a patient. At this moment, the control 
mechanisms described above, which are supposed to inhibit the activity of autoreactive 
lymphocytes, are already largely corrupted, and this is one of the major problems in the study 
of the events leading to autoimmune diseases in human patients (along with the overall rarity 
in the population of a number of autoimmune conditions). Animals models are therefore of 
primary importance in the study of the development of autoimmune diseases, even more so  
because of the possibility to easily conduct genetic studies (11, 12). Autoimmune diseases are 
classified (similar to hypersensivity reactions) according to the immunopathogenic 
mechanisms involved. Roughly, one can distinguish two main groups of autoimmune 
diseases: those in which pathologic manifestations are owed to direct action of effector T cells 
on defined target organs and those in which autoantibodies secreted by autoreactive B cells 
play a prominent role. 
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Organ-specific autoimmune diseases include such well known conditions as insulin-
dependent diabetes mellitus (IDDM; also called autoimmune or type 1 diabetes), rheumatoid 
arthritis (RA) or multiple sclerosis (MS), in which T cells are at least one of the immune 
effector cell types that participate in the attack of pancreatic β cells, joints or axonal myelin 
sheaths, respectively. However, it should be mentioned that even these autoimmune 
conditions, in which the pathogenic mechanisms seem relatively straightforward, are far from 
being uniform: For example, it is admitted that both CD8+ CTL  (or “killer” T cells) and 
CD4+ TH1 cells (or “inflammatory” T cells) play a critical role in the pathogenesis of IDDM 
and MS, but the relative contributions of these cell types to the pathologies are unclear. 
However, even in T-cell mediated autoimmune diseases tremendous advances are still to be 
made in order to understand e.g. why T cells escape tolerance induction or in which way B 
cells could contribute to the disease (10, 13-15). 
Among the autoimmune diseases, which are characterized by the presence of pathogenic 
autoantibodies secreted by autoreactive B cells, a further distinction needs to be made that 
concerns the specificity of these autoantibodies: Autoantibodies may mediate their pathogenic 
potential by direct binding of their target structures on cell surfaces or on the extracellular 
matrix. A good example of this mechanism is autoimmune hemolytic anemia (AIHA) or 
autoimmune thrombocytopenia, in which autoantibodies bind to surface structures on red 
blood cells (RBC) or platelets, respectively, which ultimately leads to complement-mediated 
lysis or FcγR-mediated phagocytosis of these opsonized cells. Another group of autoantibody-
dependent autoimmune diseases exists, in which the target antigen is a cell surface receptor on 
which the autoantibody acts either as an activatory or inhibitory ligand. Typical examples for 
this family of diseases are Graves’ (or Basedow’s) disease, in which antibodies against the 
thyroid-stimulating hormone receptor lead to overproduction of thyroid hormones and thus 
hyperthyroidism, and myasthenia gravis, in which autoantibodies block the acetylcholine 
receptor of skeletal muscles. As for T-cell mediated organ-specific autoimmune diseases, the 
main challenge with diseases involving autoantibodies against cell surface self antigens is to 
know why the antibody-secreting autoreactive B cells escape tolerance induction, while, in 
contrast, the immunopathogenic mechanisms itself are quite clear. However, this latter 
assumption cannot be made for SLE. 
As mentioned above (and described in depth in the following section), SLE is the 
prototypic systemic autoimmune disease. It is characterized by the production of 
autoantibodies that are not directed against surface epitopes present only on well defined 
tissues or cell types, but that recognize ubiquitous self antigens present in all cells throughout 
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the body. More precisely, it is often supramolecular antigens of nuclear origin (like histone-
complexed DNA, RNP etc.) which act as self epitopes in SLE responses, and these soluble 
molecules can be encountered in considerable quantity everywhere in the body, thus 
explaining why SLE is considered a systemic disease (as opposed to organ-specific). It is 
important to mention that it is not the primary binding of lupus autoantibodies to their target 
molecules that is pathogenic, but the generation of immune complexes (IC), which are defined 
as multimeric structures made up of bivalent autoantibodies and highly abundant antigenic 
material “crosslinking” the antibodies. In summary, SLE is a relatively frequent systemic 
autoimmune disease and its pathogenesis is dependent on the presence of IC containing 
nuclear antigens and autoantibodies secreted by autoreactive B cells. 
 
2) Systemic lupus erythematosus – the prototypic systemic autoimmune disease 
The following sections summarize briefly the current knowledge on SLE in human 
patients and focus on the etiology of the disease, its clinical characteristics and possible 
genetic vs. environmental contributors. 
 
2.1. Etiology of SLE 
The reasons why in some individuals relatively common autoimmunity gives rise to 
full-blown SLE with multiple tissue pathologies are still largely obscure (5). An additional 
difficulty resides within the definition of the disease itself: Indeed, in SLE patients a 
multitude of organs can be directly involved, causing a wide variety of possible clinical 
manifestations. Among the tissues targeted by the disease are skin, joints, kidneys, brain, 
serosal surfaces (e.g. the pericardia), blood vessels and cells (mainly erythrocytes and 
platelets), lungs and heart (4). Given the disseminated nature of the disease, there is a 
considerable phenotypical overlap with other autoimmune diseases, e.g. with RA for the joint 
pain, and some specialists claim that it is virtually impossible to determine whether SLE 
represents a single pathogenic entity or, in contrast, describes a group of related conditions 
(3). It is clear, however, that the earlier in life SLE develops and the more organs are 
involved, the worse the overall diagnosis for the course of the disease is. Nevertheless, even 
in human SLE, which is more heterogeneous than the available murine models of lupus, two 
characteristic pathologic traits stand out, namely the production of IgG autoantibodies against 
nuclear antigens (present in 95% of patients) and the development of nephropathy that can 
lead, in the worst case scenario, to kidney failure due to severe glomerulonephritis (GN; see 
below). 
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Even though SLE is less well known by the broad public than IDDM or RA it is far 
from being a rare condition. Indeed, estimates claim that the overall prevalence of lupus in 
North American and European populations is as high as 1:2000. However, this number 
occults that SLE is far more frequent in populations that present one or more out of several 
known risk factors, like female gender or Afro-American origin. Consequently, the risk for 
developing SLE in their lifetime may be as high as 1:300 for black women living in 
westernized societies. The gender imbalance for SLE is particularly pronounced: Over 80% of 
all cases occur in women during their childbearing years and the female to male ratio between 
puberty and ca. 50 years of age is >8:1. These findings indicate that both genetic and 
environmental factors play a crucial role in the development of SLE. This fact was also 
corroborated by studies in twins supposed to elucidate the respective importance of genetic 
and environmental elements in the pathogenesis of lupus (16, 17). Dizygotic twins have a 
concordance rate that is comparable to that of other family members, but is heavily increased 
compared to unrelated persons, thus revealing the overall familiar predisposition. Importantly, 
in monozygotic twins the concordance rate was only between 30 and 50%, confirming again 
that both genetic and environmental factors are involved in the pathogenesis of SLE. 
Among the environmental factors, sex hormones are apparently important players and it 
has been claimed that globally estrogens worsen and androgens inhibit lupus pathogenesis, 
but the experimental results are inconclusive (18-20). However, studies in lupus-prone (NZB 
x NZW)F1 mice seem to confirm the respective roles of these hormones on autoantibody 
production against nuclear antigens and GN (21, 22). Additionally, there have been studies 
exploring whether a transmissible infectious agent could possibly be a key environmental 
factor and elicit a immune response, during the course of which there would be cross-
reactivity with self antigens. Indeed, it has been shown that pet dogs belonging to SLE 
patients have increased titers of anti-DNA autoantibodies (23-25). However, no precise 
infectious pathogen was identified as a possible trigger for the development of SLE (26, 27), 
even though one of the proposed candidates, Epstein-Barr virus, is a potent polyclonal B cell 
activator (28-31). In summary, it is hard to say which environmental factors are crucial for the 
development of SLE. 
Given the increased lupus-susceptibility in defined ethnic populations, there have been 
extensive population and family studies trying to identify critical mutations or genetic 
polymorphisms that would predispose to SLE (32-35). One of the recurrent results was that 
there was a strong association of susceptibility to SLE with certain polymorphic HLA alleles 
of the MHC class II, as already known for other autoimmune diseases (see below). However, 
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there were also found linkages of defined pathological traits with a multitude of loci on 
different chromosomes, which were still far too big to define single susceptibility genes (36, 
37). Again, this is a domain in which rodent lupus models play a crucial role due to the 
possibility to perform extensive genetic analysis in order to identify these genes (38-40). 
Consequently, there is a impressive body of literature that describes the onset of lupus-like 
autoimmune syndrome in mice transgenic (either deficiency or overexpression) for a given 
gene. Even though it is virtually impossible to discuss all these mouse models of 
autoimmunity, it is possible to classify the targeted molecules according to the cellular 
function they are associated with. The majority of genes studied encodes proteins implicated 
in intracellular signaling in B cells (41-66), while others code for proteins involved in 
apoptosis (67-82), components of the complement system (83-87) or cytokines (63, 64, 88, 
89). The finding that alterations in such a diverse range of molecules can lead to B-cell 
hyperactivity reflects the fact that B cells are more than just the precursors of antibody 
producing cells, but play a central role in the immune system, e.g. by expressing 
costimulatory molecules, secreting cytokines or acting as antigen presenting cells (APC). 
Conclusively, one can reasonably claim that SLE is a disease under polygenic control 
and characterized by a number of dichotomies: First, abnormalities in many well-known 
genes can trigger systemic autoimmunity by dysregulating B cell function, as has been shown 
in many different mouse models. In this respect it is important to notice that, because of the 
extremely high cellular turnover in the B cell compartment, an only moderate genetic 
dysfunction (i.e. due to a polymorphism rather than a null mutation) could be sufficient to 
cause autoimmunity with time (5). However, there are still a number of unknown background 
modifying loci, which dramatically alter the development of autoimmunity induced in these 
mouse models (37, 40, 48). Accordingly, an attractive hypothesis predicts that the overall 
genetic predisposition and the time needed to develop overt autoimmunity are inversely 
related (5). The second dichotomy is that, on the one hand, SLE is characterized by systemic 
(and thus disseminated) autoimmunity, which, on the other hand, will cause typical and 
defined tissue pathology. It may therefore well be possible that some lupus-susceptibility 
genes are responsible for the development of general autoimmunity characterized by the 
production of autoantibodies, while others act distal of the initial lymphocyte dysfunction and 
contribute to the onset of end organ disease mediated by circulating IC, like GN. The 
identification of the respective contributions of the lupus-susceptibility genes identified so far 
should therefore tremendously increase our understanding of the etiology and pathogenic 
mechanisms of SLE. 
 16
2.2. Hallmarks of SLE and pathogenic mechanisms 
This section briefly describes the two hallmarks of SLE, i.e. the production of anti-
nuclear autoantibodies due to the onset of autoimmunity in the B cell compartment and the 
ensuing end organ disease due to deposition of IC, most typically illustrated by GN. 
 
2.2.1. Autoantibodies 
Anti-nuclear autoantibodies of IgG class are the most characteristic species of 
autoreactive immunoglobulins produced in SLE, even though a wide variety of other 
autoantibodies can be found both in patients and lupus-prone mice (4, 90). Non-nuclear 
epitopes include surface molecules on RBC and platelets, and complement-dependent lysis or 
FcγR-mediated phagocytosis of these cells can lead to anemia and thrombocytopenia, 
respectively, which is found in some lupus patients (91-93) and certain lupus-prone mouse 
strains (90, 94-98). Another species of autoantibodies is directed against membrane 
phospholipids (preferentially cardiolipin complexed with β2-glycoprotein 1) (99, 100). These 
autoantibodies are at the origin of the SLE-associated antiphospholipid syndrome encountered 
in a fraction of lupus patients and in autoimmune-prone (NZW x BXSB)F1 mice (98, 101-
103). Clinical complications of this syndrome include thrombosis, thrombocytopenia, 
hemolytic anemia and recurrent fetal loss in females (100). 
Nevertheless, IgG autoantibodies against nuclear constituents are the hallmark of SLE 
and can be found in virtually all human patients and in all three “classical” models of murine 
lupus, i.e. BXSB, MRL and (NZB x NZW)F1 mice, as well as in a number of mouse models 
with features of B-cell hyperresponsiveness (45, 48, 64, 75, 90, 104, 105). The nuclear 
constituents involved are diverse and include DNA (either double- or single-stranded), 
histones or RNP, such as Sm (for Smith antigen) or Ro and La (named after the initials of the 
patients in which these autoantibodies were originally discovered). Anti-Ro autoantibodies in 
pregnant patients are known to indicate a major risk for congenital heart block in the newborn 
(106), but the precise pathogenic roles of the previously mentioned RNP-associated protein 
antigens is not known. Finally, it should be noted that antinuclear autoantibodies can also be 
found in a number of other rheumatic diseases or transiently in some drug reactions (107). 
However, their sole concentration appears to have only a limited predicative value for the 
clinical course of SLE. 
The fact that the vast majority of anti-nuclear autoantibodies in SLE are of IgG (but not 
IgM) isotype indicates that the B cells secreting them are a product of the germinal center 
(GC) reaction, which is characterized by somatic hypermutation, affinity maturation and class 
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switching from IgM to other classes (108-110). This would suggest that the antinuclear B cell 
responses in lupus are dependent on CD4+ T-cell help (111), because these cells are 
obligatory players in the GC reaction (112-114). Indeed, it has been shown that treatment of 
lupus-prone mice with anti-CD4 monoclonal antibody (mAb) inhibits or retards the 
development of lupus-related autoimmune syndrome (115-118). A similar result was 
observed in MRL mice deficient in MHC class II and thus lacking antigen presentation to 
CD4+ T cells (119). Moreover, the association of lupus with certain MHC class II alleles (38, 
39) suggests that the presentation of antigenic determinants by APC to CD4+ T cells and the 
resulting T-cell help may play a critical role in lupus pathogenesis. However, the precise role 
of T cells in SLE is still unclear even though new concepts concerning a possible 
dysregulation of autoreactive T cells in autoimmunity are currently emerging (120). 
In contrast to T cells, the features of autoreactive B cells in SLE have been more 
extensively studied, in part because their activation yields an immediately tangible “result” in 
the form of autoantibodies (5, 121-123). One of the major questions concerning the mode of 
action of B cells in lupus was to know whether autoantibody secretion was due to polyclonal 
B-cell activation or rather the result of a specific immune response to the nuclear antigens 
described above. The hypothesis favoring a polyclonal activation - thus in first place 
independent of a particular antigen - is supported by the fact that such a variety of 
autoantibodies with different specificities can be found in SLE (124) and that the implicated 
autoantigens can be of completely different biochemical nature (e.g. proteins, nucleic acids or 
lipids). In this respect, different polyclonal activators, like cellular stress or superantigens 
have been proposed to play a role (125-127). Additionally, an interesting study has shown that 
back-mutation to germline of mutated Ig genes that code for anti-DNA autoantibodies results 
in the loss of DNA-binding capacities (128). All these facts could be explained by the 
assumption that autoreactive B cells arise through somatic hypermutations during the course 
of a “normal” immune response, then somehow escape from tolerance induction (i.e. 
apoptosis or anergy), and finally initiate an autoimmune response. In contrast to the 
polyclonal activation hypothesis, there is also evidence that specific B cell responses to 
nuclear antigens do play a role in the initiation of autoantibody production in lupus. For 
example, it has been shown that anti-DNA autoantibodies in SLE have an increased number 
of arginine residues in their antigen binding site, which enhance their binding to DNA (129). 
This illustrates that such high-affinity autoantibodies may indeed be the result of an antigen-
driven response (130, 131). Moreover, it is intriguing that biochemically different targets of 
autoantibody production can be found on the same autoantigen particle (e.g. DNA and 
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histones in chromatin or membrane lipids and surface proteins on apoptotic debris) and that 
lupus patients frequently develop autoantibodies to more than one determinant on a single 
molecule, e.g. anti-RO and anti-La from RNP (132). 
If one admits that autoreactive B cells do specifically respond to lupus autoantigens in 
the course of the development of systemic autoimmunity, two major questions remain open: 
First, are the inciting antigens really the self constituents or is the immune system confused by 
some sort of molecular mimicry between an unknown infectious agent and the host 
molecules? This questions points back to the search for the so far unknown environmental 
factors that favor the development of SLE (see above). Second, why is it that nuclear 
molecules can encounter B cells and act as self antigens when they should normally be 
contained within the nucleus of intact cells or disposed of in a highly controlled fashion 
following apoptotic cell death? For this second question some elements of response have 
emerged recently: Indeed, it seems that defects in mechanisms involved in the disposal of 
cellular debris, and thus increased concentrations of otherwise unavailable autoantigens, can 
lead to the development of lupus-like autoimmunity (133, 134). Experimental evidence for 
this hypothesis came from mice deficient in DNase (135), receptors for apoptotic bodies (87, 
136-138), C1q of complement (83, 139, 140), serum amyloid P (SAP) component (141) and 
secreted “natural” IgM (142, 143). Further studies should try to clarify why autoantibody 
responses are initiated in SLE, and this knowledge would be of considerable value because 
the implication of anti-nuclear autoantibodies in the development of lupus nephritis makes no 
doubt. 
 
2.2.2. End organ disease 
Anti-DNA autoantibodies of IgG class are associated with the development of GN in 
SLE, because these autoantibodies are readily detected in diseased glomeruli (3, 4). However, 
the mode of action through which they contribute to the development of nephropathy is not 
clear. Indeed, it seems that simple “obstruction” of the glomeruli by immune complexes is not 
the only mechanism, because anti-DNA autoantibodies ccould also bind to DNA held back in 
the kidney, followed by in situ complex formation (144-146). Additionally, genetic studies in 
(NZB x NZW)F1 mice have suggested a role for immune complexes containing 
autoantibodies directed against a glycoprotein (gp70) encoded by an endogenous retrovirus 
(anti-gp70:gp70 IC) in the development of lupus nephritis (90, 147-150). Even though the 
exact mechanisms responsible for the development of GN are poorly understood, the 
histopathological changes in itself are well described and can be quantified according to the 
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number of glomeruli involved and the severity of glomerular inflammation and/or destruction. 
In humans, even though GN is not encountered in all SLE patients, severe nephropathy is 
directly related to a poor prognosis for the further course of the disease (151, 152) and 
ultimately dialysis and renal transplantation can be the only therapeutic options (153, 154). 
Nevertheless, it is important to note that death in SLE patients is nowadays rarely owed 
to renal failure, but rather due to opportunistic infection (155). This is because the treatment 
of lupus is still mainly based on the use of general immunosuppressors, including cytotoxic 
compounds like cyclosphosphamide, or anti-inflammatory steroid hormones like 
glucocoricoids. As the latter treatments have severe side effects, it would be desirable to 
dispose of more specific therapies, which should already act at the onset of chronic 
autoimmunity in the B cell compartment and not only dampen symptoms of overt SLE. 
Although new therapies are occasionally tested and described (156-158), we certainly still 
need to learn more about the basic pathogenic mechanisms involved in SLE, including its 
genetic basis. 
 
2.3. Dissecting the genetic basis of SLE 
This section briefly summarizes our current knowledge of the genes which are critically 
implicated in the development of SLE. As mentioned before in the section dealing with the 
etiology of lupus, these genes can roughly be divided into genes encoded in the MHC locus 
and other genes scattered throughout the genome that favor B cell hyperactivity or act 
downstream of autoantibody secretion. 
 
2.3.1. MHC genes 
The humane MHC region, called HLA, extends over approximately 4 million base pairs 
in the genome, contains more than 200 identified gene loci and is located on chromosome 6 
(159), while the corresponding mouse region is named H2 and located on chromosome 17. At 
the origin of the name of this region are the genes that code for the two subunits (α- and β-
chain) of the MHC class II proteins (along with MHC class I and III), which are expressed on 
APC and present antigen-derived peptides to CD4+ T cells. These MHC class II genes are 
present in three copies in humans (HLA-DP, -DQ, -DR) and two copies in mice (I-A and I-E); 
they are highly polymorphic throughout the human population, whereas the inbred laboratory 
mouse strains routinely used in immunological studies have stable and defined H2 haplotypes 
(12, 103). It is interesting to note that the widely used C57BL/6 (B6) strain (H2b haplotype) 
lacks cell-surface expression of I-E dimers due to a deletion in the promoter region of the Eab 
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gene without ensuing immunological deficits (160), indicating functional redundancy in the 
MHC class II system. 
Studies in populations and families with an in creased risk for SLE helped to identify 
specific MHC class II alleles among the wide range of polymorphic alleles, which were 
associated with an increased susceptibility to develop SLE, like DR3 (32, 34, 161-163). Due 
to this observations it was tenting to postulate that lupus-associated HLA alleles would code 
for MHC class II molecules with a tendency to present peptides derived from self antigens (or 
from exogenous antigens mimicking host proteins), thus initiating an autoimmune response. 
However, extensive studies in mouse models of SLE proved that this simplified view was 
probably wrong: For example, (NZB x NZW)F1 hybrid mice are of mixed H2d/z hapoltype 
(with H2d from NZB and H2z from NZW), which is clearly associated with the development 
of SLE in this model. They can therefore express a variety of MHC class II molecules at the 
cell surface encoded by the two (codiminant) H2 loci, namely I-Ad, I-Ed, I-Az and I-Ez. 
Researchers have since long hypothesized about the possible importance of antigen 
presentation by mixed-haplotype MHC class II molecules (e.g. AαzAβd or EαdEβz etc.) in 
SLE pathogenesis in these lupus-prone mice (164). However, when genetically engineered 
mice with an NZB-type MHC haplotype were capable of forming mixed haplotype I-A or I-E 
heterodimers due to Az or Ez transgene expression, no accelerated development of 
autoimmune disease was observed (165, 166). This was also true in (NZB x NZW.H2d)F1 
mice carrying a Abz transgene (167). Collectively these studies suggested that expression of 
mixed-haplotype MHC class II and thereby altered antigen presentation were unlikely to 
explain the association of H2d/z heterozygosity with SLE in this model. 
Nevertheless, studies in congenic (NZB x NZW)F1 mice carrying recombinations inside 
the H2 region pointed to the possible importance of genes that encoded proteins with immune 
functions, even though they were not MHC molecules but only located in their vicinity. 
Indeed, the sequencing of the human HLA locus suggested that 40% of all its expressed loci 
coded for immune system constituents (159). A well characterized example for these MHC-
associated loci is the gene Tnfa coding for the proinflammatory cytokine TNF-α, which is 
known to play a prominent role in autoimmune conditions like RA (168, 169). With respect to 
SLE, it has been shown that reduced levels of TNF-α worsen the course of SLE, and that the 
polymorphic Tnfa allele of NZW-origin is associated with a decreased TNF-α production 
(170, 171). Consequently, congenic (NZB x NZW)F1 mice lacking the TnfaNZW allele 
displayed delayed lupus nephritis, thus suggesting that Tnfa gene polymorphism can function 
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as a H2-linked predisposing genetic element modulating the initiation of renal disease (172). 
Further support for the importance of MHC-associated gene loci comes from studies of 
hereditary complement-deficiencies in human SLE patients, because the incriminated genes 
coding for C2 and C4 are located in the MHC class III region (86, 173, 174). 
Finally, Izui and co-workers have extensively studied a model system in which a precise 
configuration of the MHC class II locus can confer protection from SLE in otherwise lupus-
prone mice due to alterations in antigen presentation - though in a more subtle way than 
initially suspected (i.e. presentation of self antigens by lupus-associated MHC class II alleles): 
Male BXSB mice, which develop full-blown SLE, carry the same H2 haplotype as B6 (H2b) 
and consequently lack cell-surface expression of I-E dimers (see above) (160). Comparison of 
BXSB (H2b) with congenic BXSB.H2d mice revealed that the latter were almost protected 
from SLE and thus suggested a protective role for I-Ed heterodimer expression (175, 176). 
This was confirmed in BXSB (H2b) mice transgenic for the Eαd chain, in which the transgene 
successfully “replaced” the defective endogenous Eab gene (177). Interestingly, no protection 
was observed in heterozygous BXSB.H2b/d mice, indicating that the mere expression of 
EαdEβb (along with “normal” EαdEβd) and the associated alterations in antigen presentation 
and/or T-cell selection were unlikely to explain the protective effect of the Ead transgene 
(175). Moreover, it was shown that the protection from SLE was directly related with the 
copy number of the Ead transgene (178) and previous studies had demonstrated that Eαd-
derived peptides had a high affinity for I-A dimers and were readily presented by them (179, 
180). Considering these facts, a now well-accepted hypothesis was proposed, according to 
which the protection by the H2d haplotype or the Ead transgene is due to competition of Eαd-
derived peptides with autoantigen-derived peptides for presentation by I-A molecules (177, 
181) and this hypothesis was further corroborated in additional lupus-prone mouse strains of 
different H2 haplotypes (182). Finally, more detailed studies on the competition between Eαd-
derived peptides and four different model antigens have shown that these peptides mediate 
protection in an epitope-dependent manner, but without modulation of I-E expression, thereby 
further supporting the competition hypothesis (183). 
In conclusion, our current knowledge on the role of genes coded within the MHC region 
in SLE pathogenesis highlights two general aspects: First, one has to take into account the 
MHC genes stricto senso because modified presentation of antigens can indeed contribute to 
or protect from the development of SLE, even though the mechanisms involved my be more 
subtle than initially imagined. Second, given the tremendous gene density in the MHC region 
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and the high proportion of genes in it that code for immune system constituents, the 
association of lupus with a particular MHC haplotype can be related to polymorphisms in 
such genes (like Tnfa), which “by chance” are co-located in the MHC region but have no 
direct relation with antigen presentation. Indeed, one can postulate that genes of this kind 
could also be located anywhere outside the MHC and the following section will describe the 
identification of lupus-susceptibility loci scattered throughout the entire genome. 
 
2.3.2. Non-MHC genes 
As described in the section dedicated to the etiology of SLE, a multitude of genes have 
been identified that can be implicated in the development of lupus-like autoimmune 
syndrome. While in monogenic diseases the identification of the responsible gene in sick 
patients through family studies can be a successful approach (184-186), the polygenic nature 
of SLE prompts for different techniques, including a consequent number of subjects with 
well-defined disease manifestations, in order to perform genome-wide linkage analysis. 
Consequently, several linkage studies in lupus-prone mouse strains have been performed, 
because these animals fulfil the prerequisites described above (40). After identification of 
murine susceptibility loci and ideally single genes researchers can then proceed with the 
analysis of their human counterparts, and therefore these linkage analysis in mice are of 
tremendous interest (36, 187). 
Up to date there have been published the results of around 20 linkage analyses yielding 
around 30 SLE susceptibility loci scattered all over the murine genome (40). Usually, these 
studies use simple sequence length polymorphisms to cover the entire genome of back- or 
intercross cohorts of mice and identify genomic loci linked to single autoimmune traits (GN, 
anti-DNA autoantibodies or IC etc.). It is interesting to note that in most linkage analyses sets 
of several susceptibility loci were identified and named according to the mouse strain 
analyzed, e.g. Nba1, Nba2 and Nba3 (now up to Nba5) for New Zealand black autoimmunity, 
respectively associated with specific disease manifestations (188-191). It is generally admitted 
that the different susceptibility loci of a given lupus-prone mouse contribute by epistatic 
interactions in a threshold-dependent manner to full-blown SLE (39, 192). One of the best 
examples for epistasis is the (NZB x NZW)F1 lupus-prone mouse strain, where neither 
parental strain develops severe GN. In addition, susceptibility loci have been identified that 
seemed to simultaneously control multiple autoimmune traits, e.g. the Sle1 interval (193, 
194). However refined studies revealed that Sle1 contained a cluster of three non-overlapping 
loci controlling individual autoimmune manifestations (195). Therefore, the question whether 
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a “super-susceptibility gene” exists in SLE is still not answered, even though the current data 
suggest that its existence is unlikely. 
Nevertheless, there seem to be “hot spots” of lupus susceptibility in the murine genome, 
because several chromosomal locations have been repeatedly identified in independent 
linkage analyses in different mouse strains. For example, the loci Bxs3, Swrl-1, Sle1, Lbw7, 
Sbw1, Nba2 all co-localize to region comprised between 71-99 cM on chromosome 1 (189, 
193, 196-199). Interestingly, the Nba2 locus is particularly rich in genes and contains, among 
others, the genes Fcgr2 and Ifi202 (192, 200, 201), where Fcgr2 codes for the murine Fc 
gamma receptor type IIB (FcγRIIB; see below) and Ifi202 for an interferon-inducible gene. 
The latter has been proposed as a lupus candidate gene (like Fcgr2), because mice transgenic 
for IFN-γ develop GN with antinuclear autoantibodies (202) and NZB mice with an interferon 
receptor deficiency have less severe autoimmune disease (203). 
Even though it is still a long way from defining a susceptibility interval to identifying a 
single susceptibility gene, it seems reasonable to assume, that most of these genes are 
implicated either in intracellular B-cell signaling or mechanisms of apoptosis, while a smaller 
number of genes might have a role in the complement system and/or antigen disposal, or 
could influence cytokine balance (5, 40, 173). Finally, it should be noted, that the design of 
the linkage analysis trials has also allowed researchers to identify both contributing alleles 
from non-autoimmune mouse strains (190, 196, 204, 205) and suppressive alleles from SLE-
prone mice (206, 207), thus illustrating again the extreme complexity of the polygenic nature 
of lupus pathogenesis. Breaking down this complexity still remains one of the key issues in 
lupus research and mouse models are without doubt ideally suited to achieve this goal. 
 
3) Mouse models of SLE 
Admittedly the three “classical” mouse models of SLE – (NZB x NZW)F1, MRL and 
BXSB – have already been mentioned throughout the previous sections of this introduction, 
because the study of these animals has provided results of general interest concerning the 
pathogenesis of SLE. Nevertheless, it might still seem useful to present each of them briefly 
in a specially dedicated section. 
 
3.1. General interest of the study of murine SLE 
The interest of the use of murine models of SLE for the elucidation of the pathogenic 
mechanisms of the disease has already been stressed in previous sections. Briefly, mouse 
models present the possibility i) to study the development of the disease at defined stages of 
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its (cryptic) progression, but before overt end organ disease, ii) to dispose of large, 
synchronous populations, iii) to perform linkage analyses in populations with defined genetic 
backgrounds and subsequently produce single- or multicongenic strains and, finally, iv) to 
benefit from all the other advantages that designate mice as the “ideal” laboratory animal 
(robust, reduced costs, short generation time, availability of gene “knock-outs” etc.). 
 
3.2. (NZB x NZW)F1, MRL-lpr/lpr and BXSB mice 
Both NZB and NZW mice were developed in New Zealand from a murine stock of 
undefined background by selection for black or white coat color, respectively. NZB mice 
develop early AIHA (208), but neither NZB nor NZW mice develop a typical lupus-like 
syndrome. However, (NZB x NZW)F1 hybrid mice are the “classical” mouse model of SLE 
and develop a disease with all the pathological features described above (209), probably due 
to the combination of the mutually contributed susceptibility loci. Female F1 mice succumb 
much earlier (50% mortality after 9 months) than their male counterparts (50% mortality after 
16 months), suggesting a prominent role for sex hormones in this SLE model (21, 22). 
The MRL strain of mice is principally derived from the LG/J strain (75%), with additional 
contributions from AKR/J (12.6%), C3H/Di (12.1%) and B6 (0.3%). The most distinctive 
genetic feature of MRL mice is the homozygous presence of the recessive lpr (for 
lymphoproliferation) mutation affecting the apoptosis receptor Fas (CD95) (68, 69, 210). A 
defect in Fas may lead to an accumulation of potentially autoreactive B and T cells, thereby 
facilitating the development of SLE. Accordingly, MRL mice display a remarkably 
accelerated development of full-blown lupus in both sexes, with a 50% mortality rate at 5 
months of age (67, 71, 123, 211). 
The BXSB strain is a recombinant inbred strain that was originally generated by a 
crossing of a B6 female with an SB/Le male. BXSB males develop full-blown lupus much 
earlier than females (50% mortality after 6 months vs. 20 months) due to the presence of the 
as yet unidentified Yaa mutation (for Y-linked autoimmune acceleration), which was 
originally inherited from the Y-chromosome of the SB/Le male (212, 213). The Yaa mutation 
has been shown to be responsible for the acceleration of SLE in BXSB mice and in their F1 
hybrids with NZB, NZW and MRL (103, 214-216). While BXSB and MRL have in a 
common that a single mutation (Yaa or lpr, respectively) has a key role in the development of 
murine lupus, the Yaa mutation is particular in that it cannot affect non-autoimmune mice like 
B6, whereas the lpr mutation can induce autoantibodies in a variety of genetic backgrounds 
(214, 217, 218). 
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3.3. Transgenic autoantibodies as experimental tools 
One of the biggest advancements in modern biological science was undoubtedly the 
establishment of the technique for creating mice deficient in defined genes (“knock-out” 
mice) using homologous recombination and selection of embryonic stem cells (219-222). This 
technique was further refined by its combination with the Cre/lox-system, which allowed to 
target the site and time of gene ablation (223, 224). Similarly, the (over-) expression of a 
transgene randomly inserted into the mouse genome after microinjection into the pronucleus 
can also be confined to specific tissues by choosing an appropriate gene promoter. Moreover, 
transgenic mice carrying and expressing an exogenous gene construct present the advantage 
of being more easily and more rapidly produced than “knock-out” mouse, even though ideally 
a complete analysis of a gene’s function should include both of these experimental 
approaches. 
In immunology, a particularly interesting variation of transgenic animals are those mice, 
in which is introduced an already functionally rearranged Ig gene (mostly of µa allotype) 
specific for a defined antigen. According to the rules of allelic exclusion there will be no (or 
little) rearrangement of the endogenous Ig genes still in germline configuration and the 
“transgenic specificity” will remain the major B-cell specificity in these mice. In an 
experimental setup designed to explore the mechanisms of tolerance induction in B cells, the 
Ig transgenic mice can the be crossed with animals carrying a transgene coding for an 
exogenous antigen recognized by the transgenic Ig. As mentioned before, it is possible to 
express the antigen in an site-specific manner or within a selected time frame using tissue-
specific or inducible promoters, respectively. One of the best experimental models developed 
in this way is the HEL (hen egg lysozyme)/anti-HEL system of Goodnow and colleagues 
consisting of mice expressing transgenic antibodies specific for HEL and transgenic HEL 
itself as corresponding “pseudo-autoantigen” (225-227). 
In one of the publications presented in the present report we have made use of IgMa-
transgenic mice, in which the introduced antibody specificities were of potentially pathogenic, 
autoimmune nature (228), i.e. the transgenic IgM autoantibodies were specific for 
constitutively available autoantigens (in contrast to HEL). The first system, developed by 
Honjo and co-workers, is characterized by anti-RBC IgM autoantibodies and has been used to 
determine the possible sites of autoantibody secretion, as well as possible environmental 
factors (like inflammation) capable of influencing their production (229-232). The second 
system used was originally set up by Rolink et al. and uses Sp6 IgM autoantibodies capable 
of cross-reacting with both an irrelevant hapten (TNP) and the autoantigen DNA (233). 
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Part 2: The Yaa Mutation
 
1) Acceleration of SLE by the Yaa mutation
The BXSB strain of lupus-prone mice presents the particularity that males develop the 
disease much faster than female littermates (216), and this feature contrasts with the sex bias 
of SLE observed in human patients and the (NZB x NZW)F1 mouse model, which may be 
due to the influence of sex hormones (3, 21, 22, 90). The acceleration in BXSB males has 
been attributed to the Yaa mutation located on the Y-chromosome (212, 234) and was 
originally contributed by the paternal SB/Le strain (212, 213). It is clear that the 
characterization of Yaa will give valuable information on the general mechanisms implicated 
in the development of B-cell mediated autoimmunity. However, due to its location on the Y-
chromosome, it is not possible to delimit the chromosomal location of the Yaa mutation using 
meiotic recombination (“cross-over”), followed by conventional positional cloning. 
In order to functionally characterize the molecular nature of the Yaa defect, the latter 
has been transferred to the “conventional”, non-autoimmune B6 background (235): BXSB 
males have been crossed with B6 females, and the resulting hybrid males have been 
backcrossed for more than 10 generation with B6 females in order to obtain genetically 
“pure” B6 mice carrying the Y-chromosome of BXSB, including the Yaa mutation (B6.Yaa). 
Using B6.Yaa mice as a tool, it was clearly shown in the following years that the Yaa 
mutation is capable of accelerating lupus-like autoimmune disease in male mice with a 
genetic background predisposing to autoimmunity, like (NZW x B6)F1 hybrids or B6.Sle1 
congenics, but not in non-autoimmune mice like B6 or CBA/J (96, 235, 236). This clearly 
indicated i) that Yaa alone is incapable of inducing lupus-like autoimmune responses and ii) 
that in the presence of other autosomal susceptibility loci Yaa can accelerate the progression 
of SLE. This “selective” autoimmune enhancing activity of the Yaa mutation contrasts 
stunningly with the “generalized” potential of the lpr mutation to induce autoantibody 
production, suggesting that Yaa was not implicated in the Fas-mediated apoptosis pathway 
(96, 213, 217). 
Refined analyses showed that the effect of the Yaa mutation was dependent on the 
levels of spontaneously secreted autoantibodies in the tested strains, with Yaa-mediated 
acceleration being most pronounced in mice displaying only limited initial autoantibody 
production (90, 96, 213, 237). Moreover, the comparison of congenic (NZB x BXSB)F1 mice 
carrying either the H2b or H2d haplotype of MHC revealed that the development of SLE was 
preferentially accelerated by Yaa in H2d mice, which displayed only limited titers of 
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autoantibodies in the absence of Yaa, while there was no notable effect of Yaa on H2b mice, 
which spontaneously secreted high amounts of autoantibodies (176). This result was 
corroborated by the finding that Yaa potentiated immune responses against foreign antigens 
only in mice that were genetically (MHC-linked) low-responding for the antigens tested 
(238). Taken together, these observations led to the attractive hypothesis that the Yaa 
mutation might contribute to the development of autoimmunity by improving cognate 
interactions between B cells and T cells, which were specific for minor autoantigenic 
determinants and could therefore escape central tolerance induction (215).  
Studies in double bone marrow chimeric mice using mixtures of Yaa+ and Yaa- donor 
cells showed that only Yaa+ B cells participated in the production of anti-DNA autoantibodies 
(239), even after selective depletion of Yaa+ T cells (240), indicating that the Yaa mutation is 
functionally expressed only in B cells, but not in T cells. Thus, the aforementioned hypothesis 
postulating “improved” interaction between Yaa+ B cells and autoreactive T cells was refined: 
It was proposed that the Yaa mutation might increase the expression of an adhesion molecule 
on B cells, favor the secretion of B-cell cytokines activating T cells or induce any other 
mechanism susceptible to improve B cell-T cell interactions, resulting finally in T-cell help 
for autoreactive B cells and production of lupus autoantibodies. However, reports published in 
the second half of the 1990s showed that lupus-like autoimmunity could also be detected in 
genetically engineered mice lacking or overexpressing molecules implicated in the regulation 
of B-cell antigen receptor (BCR) signaling, like CD22-/-, Lyn-/-, SHP-1-/- or CD19-
transgenic (42, 45, 46, 51, 65, 66, 241, 242). As some of these mice with lupus-like 
autoantibody production were characterized by hyperresponsiveness to antigenic stimulation, 
it was tenting to hypothesize that the Yaa mutation could have a direct enhancing effect on 
BCR signaling and thereby “kick-start” the cascade of events leading to murine SLE (see 
below). 
 
2) A possible mode of action for the Yaa mutation 
In order to discuss a putative role for Yaa-mediated increased BCR signaling in the 
pathogenesis of SLE, it is first necessary to briefly describe our current understanding of the 
biology of the BCR. Consequently, the following sections will summarize important aspects 
of B-cell subpopulations and BCR-induced signal transduction, but only in a very synthetic 
way. 
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2.1. B-cell maturation and subpopulations 
The development of “conventional” B (or B2) cells has been extensively studied and the 
key events in their life cycle, from common lymphoid stem cells in the bone marrow to 
mature B cells in the periphery and finally antibody-secreting plasma cells, are well 
understood (243-245). In this respect, special attention has been paid to the immunogenetic 
events involved (246, 247), the cell surface markers expressed (248) and the role played by 
BCR signaling at different stages of B-cell development (249, 250): Briefly, pro-B cells start 
to rearrange the heavy chain gene segments of the Ig locus, allowing subsequent expression of 
a pre-BCR consisting of a rearranged heavy chain and a surrogate light chain at the pre-B cell 
stage. Pre-B cells with a functionally rearranged Ig heavy chain proceed with the 
rearrangement of the Ig light chain gene segments and become immature B cells expressing a 
unique surface IgM. Qualitative and quantitative signals delivered via the BCR, the specificity 
of which is defined by the surface IgM, play a crucial role during tolerance induction at the 
immature B-cell stage (8, 251). Once a immature B cell has passed tolerance induction, it can 
exit from the bone marrow to the secondary lymphoid organs of the periphery to become an 
IgM+IgD+ mature B cell. These mature B2 cells, typically encountered in the follicles of the 
spleen, then participate in T-dependent responses, i.e. directed against pathogenic proteins. 
In parallel to the “conventional” B2 cells, there exists another population of mature B 
cells, termed B1 cells. While the development of B1 cells is less well understood than that of 
their B2 counterparts and gave rise to different hypotheses (252-255), their immunological 
functions and particular features are well characterized (229, 253, 255): B1 cells are 
preferentially located in the peritoneal and pleural cavities (as well as gut lamina propria), 
where they are easily identified due to the expression of specific surface markers (CD11b+ 
and CD5+). They have the capacity to self-renew in these compartments, even though their 
ontogenetic origin seems to be the fetal liver (rather than bone marrow). It has been proposed 
that the self-renewal of B1 cells in situ is dependent on BCR signaling (256), and in this 
respect it is important to note that B1 cells have only a limited repertoire of antigen 
specificities, which is implemented by spontaneously produced polyreactive IgM. It is 
generally admitted that B1 cells play an important role in the first line of defense against 
microbial infections, because of their capacity to directly recognize T-independent antigens 
on bacterial cell walls. Interestingly, functional similarities have been discovered between B1 
cells and a specialized population of B2 cells located in the marginal zone of the spleen (257-
259). 
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2.1.1. Marginal zone B cells 
The marginal zone of the spleen is a specialized site with strategic importance in the 
immune response: It contains dendritic cells, macrophages and marginal zone (MZ) B cells 
located at the junction of white and red pulps, which all constitute a first line of defence 
against blood-borne pathogens. MZ B cells are characterized by a particular cell surface 
phenotype (IgMhighIgDlowCD21highCD23neg/lowCD1highCD9high), which distinguishes them from 
“conventional” recirculating follicular B cells (IgMintIgDhighCD21intCD23highCD1lowCD9low) 
(260-263). Moreover, they share functional characteristics with the B1 cell population 
described above, like an increased sensibility to bacterial antigens inducing differentiation 
into plasma cells, which suggested that both B1 and MZ B cells were part of a so-called 
“natural immune memory” in charge of fighting evolutionally conserved pathogens (257-
259). Interestingly, this kind of response is mediated by these specialized (B1 or MZ) B cell 
population autonomously, without help provided by CD4+ T cells, which may be a 
prerequisite for its rapid kinetics (257, 264, 265). 
The developmental pathway of MZ B cells has long remained as elusive as its B1 
counterpart, but reports presenting some elements of response have been published recently: 
Mice deficient in the tyrosine kinase Pyk-2 specifically lack MZ B cells, which helped to 
define their role in T-independent immune responses (266). In contrast, deficiency in BAFF, a 
cytokine of the TNF-superfamily, is responsible for the loss of both follicular and MZ B cells 
in the peripheral lymphoid organs (267). RBP-J, a mediator of the Notch signaling pathway 
known to regulate cell fate determination in various lineages, has been shown to play a key 
role in the commitment to MZ B cell differentiation, because in mice that lacked RBP-J 
expression MZ B cells were absent, with a concomitant increase in follicular B cells (268). 
Most importantly, a zinc finger DNA-binding protein, Aiolos, has been identified that also 
regulates the follicular vs. marginal cell fate decision, because numbers of MZ B cells were 
greatly reduced in Aiolos-mutant mice (269). Studies in Aiolos-deficient and CD21-/- mice 
suggested an inverse relationship between the strength of BCR signaling and MZ B cell 
development, because maturation signals delivered via the BCR were enhanced in the absence 
of Aiolos, thereby favouring differentiation into follicular over MZ B cells (270). 
The unique features of MZ B cells, and in particular their capacity to secrete antibodies 
in the absence of CD4+ T-cell help, has prompted researcher to analyze a possible role for 
these cells in the production of pathogenic autoantibodies and several recent studies have 
claimed their importance in systemic autoimmunity: (NZB x NZW)F1 mice were reported to 
have increased numbers of CD1high MZ B cells producing large amounts of IgM anti-DNA, in 
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relation to the Nba2 locus (271, 272). In addition, it has been shown that the SLE-like 
syndrome observed in mice overexpressing BAFF is associated with a marked increase in MZ 
B cells (63, 64, 273). Finally, it has been shown that autoreactive B cells are accumulated in 
the MZ, in particular in a model of estrogen-induced murine lupus (274, 275). Nevertheless, 
the question whether MZ B cells indeed play a critical role in the development of 
autoimmunity has not yet been conclusively answered. 
 
2.1.2. Plasma cells 
Plasma cells are the last known stage of B-cell development and could be considered as 
the “bête noire” of B-cell immunologists. Indeed, research in this field was long hampered by 
the fact that no clear and reliable cell surface phenotype could be established, because plasma 
cells downregulate most of the surface-markers of mature B cells, including B220. 
Consequently, the identification of CD38 and CD138 (Syndecan-1) molecules on lymphomas 
derived from plasma cells in the 1990s was a great advancement for flow-cytometric 
approaches, even though functional assays of plasma-cell activity, like ELISA (to determine 
serum Ig) or ELISPOT (to assess the frequency of antibody-secreting cells), still remain 
standard tools. Plasma cells can be defined as specialized B cells that have reached the last 
stage of their developmental program (276). This stage is characterized by the total metabolic 
commitment of these cells to antibody production, including the development of an enlarged 
endoplasmatic reticulum, and the cessation of cell division. Consequently, plasma cells that 
remain in the extrafollicular regions of the secondary lymphoid organs are short-lived (2-4 
days). In contrast, plasmablasts that leave these sites and migrate to the bone marrow are 
longer-lived, thereby maintaining persistent humoral immunity (277, 278). The capacity of 
the latter cells to produce large amounts of antibodies over a long period of time has prompted 
researchers to consider them as possible players in the pathogenesis of systemic autoimmunity 
by establishing an “autoimmune memory” (278, 279). 
Fortunately, during the very last years several molecules have been identified, which 
intervene in the differentiation of mature B cells into plasma cells (276). Reports analyzing 
the expression pattern (280) and molecular function of the transcriptional repressor Blimp-1 
have clearly demonstrated its highly important role (281): First, increased levels of Blimp-1 
result in decreases in CIITA production, which is necessary for the transcription of MHC 
class II genes, thus providing an explanation for the arrest of antigen presentation in plasma 
cells (282). Second, transfection of Blimp-1 into B cell lymphoma lines induces the 
phenotypic changes associated with B-cell differentiation into plasma cells, like upregulation 
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of CD138 or increased cell size and granularity, as well as antibody secretion (283). Third, the 
B-cell specific deletion of Blimp-1 in a very recent report conclusively demonstrated that it is 
indeed indispensable for the formation of plasma cells (and pre-plasma memory B cells), and 
that Blimp-1 might be the master switch for this differentiation step, because XBP-1 could not 
rescue plasmacytic differentiation of Blimp-1 deficient B cells (284). In this respect, XBP-1 
had previously been identified as another transcription factor implicated in plasma-cell 
differentiation due to results obtained in transgenic B-cell lines and XBP-1 deficient mice 
(285, 286), and its precise molecular mode of action has been resolved (286, 287). A third 
transcription factor, to which a role in plasma-cell differentiation was assigned, is the IRF4 
molecule; however the latter seems to play a role in both the B- and T-cell compartment (288, 
289). Finally, a permissive cytokine environment containing (among others) interleukin-6 has 
also been shown to be of importance (290, 291). 
 
2.2. BCR signaling 
The study of the intracellular molecules and mechanisms implicated in the transduction 
of signals, which are initiated through the binding of appropriate ligands to immune receptors 
on B or T cells, is an incredibly vast field, in which tremendous advances have been made 
during the last two decades (292, 293), making it virtually impossible to review them 
comprehensively in the present report. Consequently, the following section only aims to 
summarize briefly the most important principles of transmembrane signaling through the 
antigen receptor of B cells, i.e. the BCR. The BCR is composed of an IgM or IgD, which 
contributes the binding specificity for the antigenic ligand, and two associated Igα/Igβ 
(CD79a/CD79b) heterodimers, which are essential for the initiation of signal transduction and 
BCR internalization, which is followed by antigen processing and presentation (294-296). Igα 
and Igβ are transmembrane proteins with a consequent intracellular domain (in contrast to the 
Ig heavy chains) that contains an ITAM motif, the key feature of which are two tyrosine 
residues that can become phophorylated (297-299). Indeed, tyrosine phosphorylation and 
dephosphorylation by tyrosine kinases and phosphatases, respectively, is the most commonly 
used molecular switch in signal transduction pathways of lymphocytes and other cell types 
(300-302). 
Phosphotyrosine kinases can be grouped into families of related molecules according to 
structural features, and are named after the prototypic family member, like in the case of the 
Src, Syk, and Btk family. Kinases of these latter three families have all been shown to co-
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localize with the BCR after its ligation and to be indispensable for the downstream signaling 
pathways. In contrast, tyrosine phosphatases are generally charged of controlling or 
terminating the same signaling cascades. More precisely, kinases that belong to the Src 
family, including Lyn, Fyn, Blk, Lck, Hck and Fgr, are the first to be activated after BCR 
ligation and phosphorylate the ITAM motifs of Igα/Igβ (303-306). All kinases of the Src 
family are characterized by the presence of the so-called SH2 domain, which allows their 
association and mutual activation during this early phase of the signaling cascade (307, 308), 
but despite this strong structural homology, it seems that Lyn plays the most important role in 
the initiation of BCR signaling, as well as in B-cell development (65, 66, 309). The 
phosphorylated ITAM motifs then allow the binding and activation of the Syk kinase (310, 
311), which is - like Lyn - also crucial in both B-cell signaling and differentiation (312, 313). 
Activated Syk in turn phosphorylates the B-cell specific adaptor protein BLNK/SLP-65 (314-
316), which has also been shown to be important during B-cell development (317, 318), and 
the nature of the signaling events further downstream slightly changes: The initial signal has 
now successfully crossed the membrane (and entered the cytoplasm) and is no longer 
“simply” transduced, but tremendously increased through the production of second 
messengers. 
The second messengers encountered in B and T lymphocytes after antigen binding are 
not different from those identified in other signal transduction pathways, initiated for example 
through receptor tyrosine kinases or seven-spanning G protein-linked receptors. They include 
phosphoinositol metabolites like diacylglycerol (DAG) and inositol trisphosphate (IP3) 
generated by activated phospholipase C-γ from phosphatidylinositol bisphosphate (PIP2). IP3 
can then stimulate an increase in intracellular Ca2+ concentration, thereby directly activating 
Ca2+-dependent enzymes. Together with DAG, Ca2+ can also activate protein kinase C, which 
can phosphorylate intracellular proteins on serine and threonine residues, thus providing a 
second way of diversifying the initial signaling pathway. Third, the activation of Rho-family 
guanine-nucleotide exchange factors (or GTPases) downstream of Syk can lead to the 
production of small G proteins and the ensuing induction of the MAP-kinase pathway, which 
can the migrate to the nucleus. Ultimately, all of these intracellular signaling pathways should 
lead to the activation of transcription of genes, the expression of which is appropriate in 
response to the antigenic stimulus. 
Despite the accumulation of all the molecular details described above, there remains an 
intriguing point that has withstood elucidation so far:  How is it that the same initial stimulus, 
i.e. antigen binding by the Ig part of the BCR, transduced by an essentially identical set of 
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intracellular signaling molecules, including Lyn, Syk and BLNK/SLP-65, can yield 
fundamentally different cellular outcomes according to the developmental stage of the B cell? 
Indeed, recognition of self antigen during B-cell maturation in the bone marrow should induce 
apoptosis, anergy or receptor editing, while antigen encounter by a mature B cell in the 
periphery should trigger its activation and differentiation into a plasma and/or memory cell. 
Different hypotheses have been proposed in order to explain how the same set of cellular 
molecules can mediate different outcomes during B-cell development or an adaptive immune 
response, taking into account parameters like the affinity/avidity or the time frame of antigen 
encounter (319). However, this problem basically still remains unsolved and its elucidation 
would undoubtedly increase our understanding of the establishment of autoimmunity (251). 
 
2.3. Working hypothesis 
Taking into account all the points developed throughout the second part of this 
introduction, we have tried to refine our understanding of the molecular mechanism of the 
Yaa defect by proposing the following hypothesis: It seems possible that Yaa-mediated 
acceleration of disease in lupus-prone mice and development of autoantibody responses in 
non-autoimmune mice (103, 214, 215) is due to a B-cell autonomous action of the Yaa gene 
product on BCR signaling. More precisely, it appears conceivable that Yaa increases the 
overall strength of a BCR-derived signal, which would be in agreement with the impaired 
development of MZ B cells and increased spontaneous IgM secretion in BXSB and B6.Yaa 
males (320). This hypothesis could also explain why Yaa induces antibody production not in a 
polyclonal manner, but in a way dependent on the antigen specificity of the “accelerated” B-
cell clones (75). Finally, the proposed enhancement of BCR signaling by Yaa points to a 
possible mechanism for the very advent of systemic autoimmunity: Quiescent (i.e. anergized) 
autoreactive clones might be able to transduce an activatory BCR signal due to the positive 
contribution of Yaa, thus overriding the concomitant inhibitory signals that normally keep 
them under control. In this respect, it is important to mention that multiple inhibitory 
signaling pathways have been identified in B cells. 
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Part 3: Inhibitory Receptors of BCR Signaling 
 
1) Mechanisms of inhibitory signaling 
While positive signaling via the BCR is obviously important in order to induce B cell 
effector functions, the fine-tuning and termination of this signal is just as crucial (319). This 
negative signaling is achieved through the engagement of inhibitory cell surface receptors and 
the ensuing induction of tyrosine phosphatases (302). FcγRIIB (CD32) and CD22 are two 
examples for these inhibitory receptors and have been extensively studied during the last 
years, including analyses of their respective roles in the prevention of autoimmunity (321-
323). While it seems appropriate to discuss FcγRIIB and CD22 in more detail in the following 
sections, the general principles of negative regulation of intracellular signaling can be 
summarized as follows: To major tyrosine phosphatases, SHP-1 and SHIP, have been 
identified that dephosphorylate signaling intermediates in different transduction pathways (51, 
53, 324). As their names indicate (SHP-1 for SH2-domain containing protein tyrosine 
phosphatase-1; SHIP for SH2-domain containing inositol polyphosphate-5 phosphatase), 
these phosphatases are characterized by the presence of the SH2 domain, which enables them 
to bind the tyrosine residues of ITIM motifs contained in the cytoplasmic domains of 
inhibitory receptors, once these tyrosines have been phosporylated following receptor 
engagement (325-328). 
Detailed studies have suggested SHP-1 interrupts tyrosine phoyphorylation cascades 
“close” to the BCR (329), because Igα, Igβ, Syk and BLNK/SLP-65 have been identified as 
its potential targets (330, 331). The existence of the motheaten mouse strains carrying 
spontaneous mutations in the SHP-1 gene has greatly facilitated the in vivo analysis of the 
role of this phosphatase in negative signaling and the prevention of autoimmunity, but also in 
B-cell differentiation and survival (50, 51, 332, 333). Interestingly, the percentage of 
spontaneously activated peripheral B cells is increased in SHP-1 deficient mice, and these 
cells are deviated to the B1 type known for its production of natural autoantibodies (see 
above). Accordingly, motheaten mice display a number of autoimmune characteristics, like 
increased autoantibody production and deposition of IC in renal glomeruli. Finally, SHP-1 has 
been identified as a key mediator of the inhibitory signaling pathway initiated through CD22, 
along with the Lyn kinase, which actually seems to play a dual role in both activatory and 
inhibitory cascades due to its capacity to phosphorylate both ITAM and ITIM motifs (334-
337). 
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The role of the SHIP phosphatase in regulation of BCR signaling has also been explored 
in more detail (338, 339): It is now well documented that SHIP is the actor of an inhibitory 
pathway distinct from that of SHP-1 (52) and plays a prominent role in negative signaling 
initiated through FcγRIIB (53, 324, 340). The molecular targets of SHIP are inositol 
polyphosphates (341), and the activation of SHIP ultimately results in reduced levels of PIP3, 
which facilitates the relocalization of the kinase Btk to the cell membrane. As non-
membranous Btk is known to favor IP3 production and elevated intracellular Ca2+ levels, its 
recruitment to the membrane seems a plausible mechanism for the negative regulation of BCR 
signaling (342, 343). This model is also in agreement with the immunodeficient phenotype 
observed in the Btk-deficient Xid strain or mice deficient in key molecules for positive 
signaling, like BLNK/SLP-65 (60, 344). Obviously, SHIP and its inducer FcγRIIB are of 
primary importance not only in the delicate balance of protective immunity vs. 
immunodeficiency, but also in the control of autoimmunity owed to exacerbated B-cell 
activation (321, 323). 
 
2) The Fcγ receptor family in mice
Fc receptors are a group of cell surface receptors that are characterized by their capacity 
to bind the Fc-parts of Ig molecules, and belong to the Ig-superfamily of receptors (345-347). 
Three classes of Fc receptors for IgG have been identified, FcγRI, II and III. They differ in 
their structure, cellular distribution, binding affinity for the different IgG isotypes, as well as 
the effect of their ligation, and notable differences between men and mice exist in both 
structural details and nomenclature (348, 349). In the mouse, the activatory receptors FcγRI 
and FcγRIII, which have also in common their multi-chain architecture, are opposed to the 
single chain receptor FcγRIIB, which has gained particular interest in autoimmunity research 
due its inhibitory potential (321). The “B” added in the murine nomenclature of FcγRII(B) is 
due to the homology with its synonymous human counterpart. However, this is the only 
murine FcγR type II known to date (although splice variants exists), while in humans three 
distinct genes (A, B, C) have been identified (plus expressed splice variants). 
 
2.1. Activatory Fcγ receptors on immune effector cells 
The Fcγ receptors type I and III are expressed on a wide range of immune cell types, but 
not on B cells (346, 349). FcγRI seems to play a role in antigen presentation by professional 
APC, because it is constitutively expressed by macrophages and dendritic cells. FcγRI has the 
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highest affinity for monomeric IgG of all known Fcγ receptors, preferentially for the murine 
IgG2a isotype (350). On the cell surface, the FcγRI-specific recognition α chain is co-
expressed with common γ chains, each of which carries two ITAM motifs (351). 
Consequently, engagement of FcγRI induces an activatory signaling cascade and triggers 
cellular effector functions, like phagocytosis and ADCC by macrophages, or increased 
antigen processing and presentation by APC (352, 353). However, it should stressed that 
macrophages express all three types of Fcγ rectors (I and III, but also II) and that their 
respective contributions to effector function are still an issue of debate (350, 354-356). 
Murine FcγRIII is also characterized by a specific recognition α chain, but its 
multimeric complex on the cell surface comes in more variations than FcγRI. Nevertheless, 
the principle of ITAM-dependent activatory signaling is conserved, even though different 
dimeric combinations of the “signaling” chains γ, β and ζ have been reported (351). FcγRIII is 
a so-called low-affinity receptor, which preferentially binds polymeric IgG, and is expressed 
on NK cells and mastocytes, along with macrophages and granulocytes (357). In agreement 
with its more heterogeneous distribution, the effector functions reported for FcγRIII are more 
varied than those of FcγRI: They include triggering of phagocytosis, cytokine production and 
antigen presentation by macrophages, but also NK-mediated ADCC and degranulation of 
mastocytes (358-361). Collectively, these brief examples underline the importance of 
activatory signaling by FcγRI and FcγRIII via their ITAM motifs and the ensuing intracellular 
phosphorylation cascade for cellular effector function in inflammatory responses (354, 362-
364). 
 
2.2. The inhibitory FcγRIIB on B cells 
Inflammatory effector cells express both activatory (FcγRI and FcγRIII) and inhibitory 
(FcγRIIB) Fcγ receptors, either constitutively or after induction (349), and there is strong 
evidence that the balance of positive and negative signals is responsible for the intensity and 
duration of the inflammatory response (348, 365). In contrast, murine B cells express FcγRIIB 
as their only Fc receptor, which suggested a specific role for this negative signaling pathway 
in the control of B-cell responses and antibody production (366). In this respect, the study of 
FcγRIIB has benefited greatly from the availability of FcγRIIB-deficient mice (49), which 
provided a means to control the previously established concepts. In less than 10 years, a 
wealth of data on the role of FcγRIIB in feedback-inhibition of antibody production, control 
of B cell (affinity) maturation through apoptosis and prevention of systemic autoimmunity has 
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been generated (321, 348), and the following sections intend to give a concise overview of 
these advancements. 
 
2.2.1. Molecular structure of FcγRIIB 
Mouse FcγRIIB presents a number of distinctive features, which clearly put it apart 
from the activatory receptors FcγRI and FcγRIII: First, it is composed of a single α chain, in 
which the two extracellular recognition domains are directly linked to the intracellular 
signaling domain that carries an ITIM motif (367, 368). Second, the splice variant FcγRIIb1, 
which is the only Fcγ receptor expressed on B cells, is characterized by an intracellular 19- or 
47-amino acid insertion that prevents its endocytosis (369-371). This contrasts with the co-
expression of b1 with another splice variant (b2), which can be internalized, on inflammatory 
effector cells (372). Third, the ligation of FcγRIIB has early been shown to induce an 
inhibitory signal via its ITIM motif that was capable of controlling in trans the activatory 
signaling through BCR or the other Fcγ receptors (366, 368). Finally, even though only a 
single Fcgr2 gene has been cloned in mice (in contrast to the three genes A, B and C in 
humans), at least two polymorphic alleles, named Ly17.1 and Ly 17.2, have been identified in 
different mouse strains that confer structural differences in the extracellular recognition 
domain (373, 374). 
 
2.2.2. Intracellular signaling events initiated via FcγRIIB 
The intracellular signaling cascade triggered by mouse FcγRIIB does not fundamentally 
differ from that initiated through other ITIM-containing inhibitory immune receptors, the 
principles of which have been outlined above (375, 376). Briefly, the engagement of FcγRIIB 
leads to phosphorylisation of its ITIM by Lyn (336, 337), thereby creating an SH2 recognition 
domain, which serves as a binding site for the recruitment of SHIP (53, 324, 368, 370). SHIP 
then proceeds with the dephosphorylation of signaling intermediates including PIP3, and 
reduced PIP3 levels result in the relocalization of kinases of the PH domain class, including 
phospholipase C-γ and Btk (342, 343, 377). Ultimately, this mechanisms decreases the 
intracellular concentration of second messengers like Ca2+, which are indispensable for 
positive signaling through the BCR (338). Moreover, BCR-triggered proliferative responses, 
which result from signaling through the MAP-kinase pathway and recruitment of the Akt 
kinase, are also abrogated as a consequence of the activation of SHIP after FcγRIIB 
phosphorylation (54, 378-380). 
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Besides Ca2+ inhibition and arrest of proliferation, a third inhibitory activity of FcγRIIB 
has been reported that is independent of the ITIM/Lyn/SHIP-pathway. The latter may be of 
particular interest, because the need for Lyn in phosphorylation of the ITIM motif could 
suggest that FcγRIIB-mediated inhibition can only be triggered in case of simultaneous 
engagement of ITAM-containing activatory receptors, like BCR or FcγRI and III (324, 366, 
381). This ITIM-independent inhibitory activity has been discovered upon homo-aggregation 
of FcγRIIB. Indeed, experimentally clustered FcγRIIB generate a proapoptotic signal through 
their transmembrane sequence, which can be blocked by SHIP recruitment in the case of co-
ligation of BCR and FcγRIIB (340). As this activity has only been seen in B cells, it was 
attractive to suggest that it plays a specific role in B-cell responses by controlling affinity 
maturation. According to this hypothesis, B cells undergoing somatic hypermutations in the 
GC that lose the specificity for the targeted antigen, present in IC on follicular dendritic cells, 
are subject to apoptosis due to the sole clustering of their FcγRIIB, thereby eliminating low-
affinity and potentially autoreactive B-cell clones. In contrast, hi-affinity B cells would 
preferentially engage the rearranged BCR along with FcγRIIB and survive in this particular 
setting, resulting in positive selection through the same IC. 
 
3) Study of mice deficient in FcγRIIB
The following sections describe the observations that have been made in mice deficient 
for FcγRIIB, which have initially been generated and analyzed by Ravetch and co-workers. 
Due to the interest of our laboratory in autoantibody-mediated pathologies, special attention is 
paid to the possible role of FcγRIIB in the prevention of systemic autoimmunity (321). 
 
3.1. Rationale for FcγRIIB as a lupus-susceptibility gene 
Several lines of evidence indicate a possible role for FcγRIIB in the control of 
autoimmunity: First, given the fact that FcγRIIB is the only known Fc receptor on B cells and 
considering its singular inhibitory signaling properties, it was appealing for researchers to 
suggest that FcγRIIB was implicated in negative feedback inhibition of antibody production 
(376). This negative feedback of secreted antibodies on activated B cells had been proposed in 
order to explain the long-standing experimental observation that normal antibody responses 
are self-limiting with time (382-384). More precisely, IC containing antigen molecules bound 
by specific antibodies are supposed to be able to engage both BCR (via the antigen) and 
FcγRIIB (via antibody Fc portions), thus resulting in downregulation of B-cell activity by the 
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mechanisms described above. In contrast, a defect in feedback inhibition would result in 
sustained and uncontrolled antibody secretion by activated B cells, reminiscent of the 
situation in systemic autoimmunity. Second, the observed capacity of FcγRIIB to induce a 
proapoptotic signal in B cells of the GC (340) led to the proposition of a role of FcγRIIB in 
the maintenance of peripheral tolerance by negative selection of potentially autoreactive B 
cell clones generated during the GC reaction (see above). 
Third, genetic evidence in mouse models corroborated the proposed role of FcγRIIB in 
the prevention of autoimmunity. Backcross studies in autoimmune-prone NZB mice identified 
the Nba2 locus on chromosome 1, which was particularly rich in genes, as a susceptibility 
locus for SLE that was linked with elevated serum levels of multiple autoantibodies, including 
anti-DNA and anti-gp70 (200). Further analysis demonstrated that the Fcgr2 gene coding for 
FcγRIIB was located in the Nba2 locus, however along with other genes (39, 192). Moreover, 
it has been shown that B cells in the GC of NZB mice display decreased surface expression of 
FcγRIIB in comparison to other strains, due to a polymorphism in the promoter of Fcgr2 
(385). This observation was in the following extended to other lupus-prone mouse strains, 
including BXSB and MRL (but also SB/Le and NOD), thereby defining a specific 
autoimmune haplotype of the Fcgr2 promoter region (386-388). Finally, very recent studies in 
human patients suffering from SLE or RA also indicated a role for FcγRIIB polymorphisms in 
human autoimmune disease (389-391). 
 
3.2. Observations in FcγRIIB-deficient mice 
Mice deficient in FcγRIIB due to homologous recombination displayed elevated serum 
Ig levels in response to thymus-dependent and -independent antigens, as well as an increased 
sensitivity for mast cells degranulation triggered via FcγRIII (49). Concerning this second 
point, further analyses of the role of FcγRIIB in inflammatory responses showed, that the ratio 
of ITIM- to ITAM-containing Fcγ receptor expression provided a regulatory mechanism to set 
thresholds for IC sensitivity (56, 365, 392). Considering the proposed role of FcγRIIB in the 
prevention of autoimmunity, highly interesting studies on the development of autoimmune 
disease have been conducted: Models of induced autoimmune disease revealed that deficiency 
in FcγRIIB rendered otherwise non-permissive mice susceptible to the induction of collagen-
induced arthritis or autoimmune GN (Goodpasture’s syndrome) by immunization with the 
corresponding antigen (393, 394). 
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With respect to the putative role of FcγRIIB in SLE, it was shown that FcγRIIB-
deficient B6 mice spontaneously produce anti-nuclear autoantibodies and die of fatal GN by 
the age of 8 months, and the autoimmune phenotype could be transferred by FcγRIIB-/- bone 
marrow cells. However, this lupus-like autoimmune disease is dependent on epistatic genetic 
modifiers, because FcγRIIB-deficient mice with a BALB/c or 129 background fail to develop 
the syndrome, in contrast to B6 background (48). A more detailed study on these possible 
modifying genes was performed using hybrids between FcγRIIB-/- B6 and mice bearing 
autoimmunity-promoting mutations (or loci) and revealed that the Yaa mutation significantly 
enhances disease by modifying the specificity and pathogenicity of anti-nuclear 
autoantibodies. Moreover, two novel, recessive loci contributed by the B6 genome have been 
identified that are required for the autoimmune phenotype, with the locus contributing the 
strongest effect situated in the H2 region of chromosome 17 (395). Additionally, a separate 
study indicated that B6-lpr/lpr mice, which are resistant to the development of SLE due to B6 
suppressor genes(s), develop full-blown lupus upon introduction of the FcγRIIB null mutation 
(104). 
 
4) The immune regulator CD22 
Like FcγRIIB, CD22 is among the negative regulators of B cell activation that have 
been the most extensively studied (241). The following sections give an overview over its 
structure, its function as a signal regulator and adhesion molecule and its possible 
implications in the prevention of systemic autoimmunity. 
 
4.1. Structure, function and polymorphism 
CD22 is a transmembrane protein that is specifically expressed by B cells and is part of 
the Siglec family of molecules (for sialic acid binding Ig-like lectins), which in turn belong to 
the Ig-superfamily of immune receptors according to the structure of their extracellular 
domains (396). As a lectin, CD22 is capable of binding α2-6 linked sialic acids on 
glycoproteins (397) due to its extracellular receptor part consisting of seven Ig-like domains 
in men and mice (398-401). An expressed splice variant with only five extracellular domains 
has been described in humans, but is rare and seems to bind ligands less efficiently (402, 
403). More precisely, the binding of ligands containing α2-6 linked sialic acids is owed to last 
two N-terminal Ig-like domains, which constitute the binding site of CD22 (404, 405). 
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Interestingly, the intracellular domain of CD22 contains three ITIM motifs, of which only the 
two C-terminal ones seem to be important for downstream signal transduction (241, 406-408). 
CD22 is characterized  by a intriguing functional dichotomy (241): On the one side, 
ligand binding characteristic for a Siglec owed to the structure of its extracellular domain, and 
on the other side signal transduction mediated by the intracellular ITIM motifs. The 
“extracellular” aspect presents a number of particularities that are discussed in a separate 
section, while the mechanisms implicated in CD22-dependent inhibitory signaling are 
reminiscent of the general principles identified previously (292, 319). Briefly, BCR ligation 
leads to the activation of Lyn, which in turn phosphorylates tyrosine residues in the 
intracellular domain of CD22 (334, 409, 410). SHP-1 is then recruited to the phosporylated 
ITIM motifs and ultimately inhibits BCR signaling through dephosphorylation of early 
signaling intermediates (411-413). While the use of the ITIM/Lyn/SHP-1 pathway for 
inhibitory signaling by CD22 is not a surprise (319, 335), its need for close association with 
the BCR to ensure engagement of the above pathway seems to be a particularity of CD22. 
Sequestration of CD22 away from the BCR by the use of anti-CD22 coated beads 
significantly lowered the threshold for B cell activation through anti-IgM (410). Inversely, 
forced association of CD22 with surface IgM resulted in reduced intracellular Ca2+ flow and 
inhibition of the MAP-Kinase pathway (334, 414). Finally, B cells in CD22-deficient mice 
displayed an anergic phenotype reminiscent of chronic BCR engagement (226, 415, 416), as 
well as increased intracellular Ca2+ concentrations upon BCR restimulation (46, 322). 
Collectively, these data suggest that CD22 plays a prominent role in the regulation of B-cell 
activation by setting the threshold  for activatory BCR signaling. 
In mice, at least three polymorphic forms of CD22 have been identified: CD22a is 
expressed by mice of the NZB, NZW or DBA/2 strain (among others), while CD22b can 
found in B6, BALB/c and CBA/N mice, and Cd22c in BXSB and SB mice (417, 418). 
Relevant genetic and structural differences exist between these allelic variants, with important 
consequences for the expression of and ligand binding by CD22: The CD22a protein carries a 
six amino-acid deletion and eight amino-acid substitutions in the first Ig-like domain, as 
compared to CD22b (401). In addition, the Cd22a gene contains a short interspersed 
nucleotide element insertion in the second intron (418), which leads to the synthesis of 
abnormally processed Cd22 mRNA. These mRNA carry intronic insertions of ~20-120 
nucleotides and/or deletions of ~100-190 nucleotides in exon 4 that encodes the first Ig-like 
domain. Therefore, B cells of Cd22a mice could express aberrant forms of CD22 with 
functional defects, due to the differences in the N-terminal sequences constituting the ligand-
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binding site (404, 405, 419, 420). It is tempting to speculate that the expression of aberrant 
forms of CD22 with decreased ligand binding capacities on potentially autoreactive B cells 
might contribute to the development of systemic autoimmunity. 
 
4.2. The CD22-ligand (CD22L) and CD22:CD22L interaction 
Given its extracellular, lectin-type binding domain specific for α2-6 linked sialic acids 
(397), CD22 could have been considered as a “conventional” lymphocyte adhesion molecule 
capable of binding to a wide variety of glycoproteins carrying the appropriate sugar side chain 
(397, 421). However, concomitantly with the unravelling of the role of CD22 in signal 
transduction, the identification of possible CD22 ligands (CD22L) yielded a number of 
surprises. CD22-Ig fusion protein used as a probe to determine cellular distribution of the 
ligands revealed that CD22L was expressed on T, but also on B cells. Immunoprecipitation 
assays then identified the detected CD22L as the phosphatase CD45RO on T cells and as 
CD75 on B cells (422, 423). Other CD22L were discovered in the following, including on B 
cells B220, surface IgM and CD22 itself, as well as not yet characterized molecules on non-
lymphoid cell types like endothelial cells (405, 424, 425), indicating that CD22 was able to 
bind ligands both in trans (CD22L on non-B cells) and in cis (CD22 and CD22L on the same 
B cell). Concerning CD22L expression on endothelial cells, it was recently proposed that 
CD22 could act as a homing receptor for the relocation of mature B cells into the bone 
marrow, which might have implications for the establishment of B-cell memory (425-427). 
Until now, studies on CD22-mediated cell-cell interactions have mainly focussed on the 
role of CD22 in the interplay between T and B cells and in signal transduction via the 
respective antigen receptors (408, 423). As a result of these studies a dual role for CD22 was 
proposed: As an adhesion molecule, CD22 would favour the retention of lymphocytes in 
appropriate microenvironments; and as a regulator of cell activation, CD22 would associate in 
the cell membrane with antigen receptors or their accessory molecules. In more concrete 
terms, it has been shown that mice deficient in α2-6-sialyltransferase, which lack the 
appropriate glycans on CD22L protein “backbones” to allow binding of CD22, display 
attenuated B cell responses to thymus-dependent and –independent antigens (428). This was 
complementary to the observation of lower BCR signaling thresholds after sequestration of 
CD22 with anti CD22-coated beads in vitro (410), and added weight to the hypothesis that an 
appropriate lymphoid microenvironment containing B and T cells expressing surface CD22L 
facilitates initiation of BCR signaling by keeping CD22 away from surface IgM. Further 
studies analyzing the interaction between phosphatase CD45RO (on T cells) and CD22 (on 
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antigen presenting B cells) suggested that the capacity of CD22 to bind in trans might play a 
role in the regulation of T-cell responses as well (423, 429-431). 
Binding of CD22 in cis to CD22L on the same B cell surface has also been studied by 
several groups: Through the use of non-lymphoid cells transfected with α2-6 sialyltransferase 
and/or CD22 and analysis of their binding to different cell types it was established that the 
level of unbound CD22 can be fine-tuned by regulating the activity of the enzyme adding the 
sugar residues needed for recognition (424, 432). Further research in this field firmly 
established that the balance between “masked” CD22, which is unavailable for cell-cell 
interactions due to cis-binding of CD22L, and “unmasked” (i.e. unbound) CD22 can control 
the predisposition of B cells for activation (433, 434). Moreover, specific B-cell 
subpopulations, like MZ B cells, were shown to have unusual ratios of unmasked over 
masked CD22 (426, 435). Collectively, all these studies showed that CD22 integrates the 
information on antigen binding by the BCR and on the nature of the microenvironment of B 
cells, including possibly engaged cell-cell interactions, into the regulation of B-cell signaling 
(408, 436). 
 
4.3. CD22 and autoimmunity 
The role of CD22 as a negative regulator of BCR signaling has been confirmed in 
CD22-deficient mouse strains produced by independent laboratories (46, 47, 322, 415, 437), 
e.g. through enhanced and prolonged Ca2+ flow after BCR stimulation. The molecular 
mechanism of this feature was recently elucidated, as it was shown that CD22 can activate the 
membrane calcium ATPase PMCA, thereby promoting calcium efflux from the cell (438). 
Accordingly, a role for CD22 in the maintenance of tolerance and prevention of autoimmunity 
was proposed. In agreement with this, a lupus-susceptibility locus mapped to a region of 
chromosome 7 that included the Cd22 gene in a backcross study of NZW mice, which bear 
the Cd22a allele conferring dysregulated expression of CD22 (418, 439). Previously, the same 
chromosomic location had already been identified in a genetic study in (NZB x NZW)F1 mice 
and was associated with autoantibody production (193). 
Indirect evidence was also added by the fact that deficiencies in Lyn and SHP-1, which 
are part of the CD22 signaling cascade, resulted in SLE-like autoimmune pathologies (66, 
332, 335, 440). However, while Lyn-deficient or SHP-1 deficient motheaten mice displayed 
increased spontaneous IgM (Lyn-/-) or IgG (motheaten) secretion, produced autoantibodies 
and developed IC-mediated glomerular lesions and splenomegaly (Lyn-/- only), the 
phenotype in CD22-null mice was less severe: The main autoimmune trait detected was the 
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production of anti-DNA autoantibodies in aged mice (45). However, differences in the genetic 
backgrounds of the individual CD22-deficient strains prompt for a more thorough analysis of 
the development of lupus-like autoimmunity in these mice, taking into account the possible 
need for background genes. Moreover, a recent report revealed that during inflammation the 
increased sialylation of glycoproteins on potential target cells carrying autoimmune epitopes 
repressed B cell activation (441). Therefore it seems conceivable that CD22 is critically 
implicated in the prevention of autoimmunity in a particular physiological context, like 
inflammation, rather than in “general” adaptive immune responses. Clearly, this possibility 
needs further investigation in order to understand the putative role of CD22 in the control of 
autoimmune B cells, and to increase our understanding of the mechanisms contributing to the 
onset of systemic autoimmunity in SLE. 
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II) AIM OF THE STUDY 
 
 
 
 
 
 
 
 
 
 
 
 
 
II) OVERALL AIMS OF THE STUDY 
 
SLE is a complex autoimmune condition, in which a number of both identified proteins 
and as yet unassigned genetic loci contribute to the development of full-blown disease (3, 39). 
The use of mouse models has enabled researchers to identify a selection of genes that, when 
deregulated or missing, favor B cell dysfunction and can subsequently contribute to the 
development of murine SLE (40, 442). The present study aims to analyze the role of several 
lupus-susceptibility genes and their interplay in autoimmune responses critically implicated in 
SLE. This is achieved through the use of transgenic mice rendered deficient for a precise gene 
by homologous recombination (“knock-out mice”) or carrying a defined gene, e.g. a 
rearranged IgM with autoreactivity. Another useful tool in immunology are congenic mice 
from a non-autoimmune background that carry a susceptibility locus for autoimmunity. A 
particular case of such congenic strains are mice carrying the Yaa mutation. Indeed, it has 
been shown that this locus, originally discovered on the Y-chromosome of lupus-prone BXSB 
mice, is capable of accelerating lupus-like autoimmune syndrome (103, 214). Analysis of Yaa 
mice should also help to define the molecular nature of the Yaa mutation, which is still poorly 
understood. 
 
A) The Yaa mutation modifies B cell maturation and potentiates humoral autoimmune 
responses 
B cells undergo a number of distinct stages during their life cycle, from immature B 
cells in the bone marrow to mature B cells in secondary lymphoid organs (113) and ultimately 
to antibody secreting plasma cells (443). At the mature B cell stage, different B-cell 
subpopulations – in particular follicular and MZ B cells – can be distinguished in the spleen 
(261). Using male B6 mice carrying the Yaa mutation from BXSB, we investigated whether 
Yaa influences the differentiation of B cells into these two distinct splenic populations of 
mature B cells, as it has been proposed that MZ B cells may play a critical role in the 
production of lupus-autoantibodies (273-275). To further clarify this issue and to better 
characterize the molecular nature of the Yaa defect, we created mice combining Yaa and 
transgenic IgM specific either for RBC or DNA. The activation of autoreactive B cells in 
these transgenic mice was assessed in the context of the Yaa mutation by determining 
antibody secretion. 
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B) Differential roles for apoptosis and FcγRIIB in the regulation of rheumatoid factor and 
anti-DNA responses 
The spontaneous development of autoantibodies can be strongly influenced by the 
nature of the autoantigens. More concretely, RF autoimmune responses could be highly 
limited for two reasons: First, RF-specific B cells could be efficiently eliminated through 
negative selection (or be anergized) because of abundance of IgG autoantigens. Second, the 
activation of RF-specific B cells could be selectively inhibited due to the expression of 
FcγRIIB, which downregulates the activation of B cells in case of simultaneous engagement 
of FcγRIIB and BCR by RF autoantigens, i.e. IgG immune complexes (324, 444). Therefore, 
we analyzed in which way transgenic expression of the anti-apoptotic Bcl-2 protein would 
influence the production of RF, in comparison with anti-DNA autoantibody responses. This 
analysis was conducted in different strains of mice with or without a lupus background and/or 
the Yaa mutation. In addition, we have performed a direct analysis of the role of FcγRIIB in 
the prevention of RF and anti-DNA autoantibody production. Using B6.FcγRIIB-/- mice (49), 
we explored the impact of this deficiency in combination with Yaa, lack of complement C3 
and the H2 haplotype of MHC class II, in order to determine whether FcγRIIB was critical for 
the control of these autoimmune responses. 
 
C) Differential expression and regulation in mice of the inhibitory receptor CD22 underlines 
its role in lupus-susceptibility
CD22 is one of the coinhibitory receptors controlling signal transduction thresholds 
initiated through BCR in response to antigen (241, 301). Indeed, some CD22-/- mice 
apparently produce autoantibodies reminiscent of SLE (45), and Cd22a-bearing autoimmune-
prone NZB and NZW mice show dysregulated Cd22 mRNA expression, as compared with 
mice bearing the Cd22b allele (418). In order to study the possible role of CD22 in the 
prevention of lupus-like disease, we investigated the regulation of CD22 expression following 
activation by different B-cell mitogens in conventional splenic B2 and peritoneal B1 cells, as 
these B-cell subpopulations are known to be implicated in adaptive and innate immunity, 
respectively. In addition, we analyzed the possible defective expression of CD22 in lupus-
prone mice bearing the Cd22a allele by flow cytometry, in combination with the assessment 
of Ca2+ responses following BCR-mediated activation of B cells from Cd22a or Cd22b mice. 
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OBJECTIVES: 
In view of a possible role for Yaa as a positive regulator of BCR signaling, and to better 
define the molecular basis of the Yaa defect, we have explored whether the expression of the 
Yaa mutation affects the development and activation of transgenic B cells expressing either 
4C8 IgM anti-RBC or Sp6 IgM anti-DNA autoreactive specificities. 
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Differential Activation of Anti-Erythrocyte and Anti-DNA
Autoreactive B Lymphocytes by the Yaa Mutation1
Thomas Moll,* Eduardo Martinez-Soria,* Marie-Laure Santiago-Raber,* Hirofumi Amano,*
Maria Pihlgren-Bosch,* Dragan Marinkovic,† and Shozo Izui2*
An as-yet-unidentified mutation, Y-linked autoimmune acceleration (Yaa), is responsible for the accelerated development of lupus-
like autoimmune syndrome in mice. In view of a possible role for Yaa as a positive regulator of BCR signaling, we have explored
whether the expression of the Yaa mutation affects the development and activation of transgenic autoreactive B cells expressing
either 4C8 IgM anti-RBC or Sp6 IgM anti-DNA. In this study, we show that the expression of the Yaa mutation induced a lethal
form of autoimmune hemolytic anemia in 4C8 transgenic C57BL/6 mice, likely as a result of activation of 4C8 anti-RBC auto-
reactive B cells early in life. This was further supported, although indirectly, by increased T cell-independent IgM production in
spleens of nontransgenic C57BL/6 mice bearing the Yaa mutation. In contrast, Yaa failed to induce activation of Sp6 anti-DNA
autoreactive B cells, consistent with a lack of increased IgM anti-DNA production in nontransgenic C57BL/6 Yaa mice. Our results
suggest that Yaa can activate autoreactive B cells in a BCR-dependent manner, related to differences in the form and nature of
autoantigens. The Journal of Immunology, 2005, 174: 702–709.
I t has been well established that the development of autore-active B cells can be regulated by different mechanisms in-cluding clonal deletion, clonal anergy, and receptor editing in
the bone marrow and peripheral lymphoid organs, depending on
the nature of the autoantigen, its concentration in different sites,
and the affinity of autoantibodies. Because the induction of self-
tolerance is not complete, it has been proposed that dysregulated
and excessive activation of B cells predisposes to the development
of autoantibody-mediated autoimmune diseases, such as systemic
lupus erythematosus (SLE)3 and autoimmune hemolytic anemia
(1). This has been supported by the finding that the production of
anti-DNA autoantibodies is a common feature of genetically ma-
nipulated mice, in which B cells become abnormally hyperrespon-
sive to antigenic stimulation (2–4).
The Y-linked autoimmune acceleration (Yaa) mutation has been
shown to be responsible for the acceleration of the lupus-like au-
toimmune syndrome in BXSB mice and in their F1 hybrids with
NZB or NZW mice (5). Yaa by itself is unable to induce significant
autoimmune responses in mice without an apparent SLE back-
ground (6, 7), whereas it can induce and accelerate the develop-
ment of SLE in combination with autosomal susceptibility alleles
present in lupus-prone mice (8). Analysis of Yaa and non-Yaa
double bone marrow chimeric mice has demonstrated that anti-
DNA autoantibodies were selectively produced by B cells bearing
the Yaa gene, and that T cells from both Yaa and non-Yaa origin
efficiently promoted anti-DNA autoantibody responses (9, 10).
These data suggest that the Yaa defect is functionally expressed in
B cells, but not in T cells. The expression of Yaa in the B cell
lineage is likely responsible for a marked reduction of the marginal
zone (MZ) B cell compartment early in life in spleens of mice
bearing the Yaa mutation (11).
The molecular mechanism of the Yaa mutation in the acceler-
ated development of lupus-like autoimmune syndrome has been
poorly understood. The expression of the Yaa gene in B cells, but
not in T cells, suggests that the Yaa defect is likely to be directly
involved in the excessive activation of B cells. It can be speculated
that the action of the Yaa mutation may be to decrease the thresh-
old for BCR-mediated signaling or to facilitate interactions be-
tween T and B cells, thereby triggering and excessively stimulating
autoreactive B cells (5). This is consistent with a previous report
showing that B cells bearing the Yaa mutation exhibited a hyper-
reactive phenotype, as judged by higher proliferative responses
following stimulation with LPS, anti-IgM, or CD40L (12). To bet-
ter define the molecular basis of the Yaa defect, we determined the
effect of the Yaa mutation on the development and activation of
transgenic autoreactive B cells expressing either 4C8 IgM anti-
RBC or Sp6 IgM anti-DNA. We observed that the Yaa mutation is
unable to inhibit clonal deletion of autoreactive B cells in the bone
marrow. However, it is able to activate 4C8 anti-RBC autoreactive
B cells in the periphery, but not Sp6 anti-DNA B cells, suggesting
a differential effect of the Yaa mutation on autoreactive B cells
with different specificities.
Materials and Methods
Mice
C57BL/6 (B6) mice bearing the 4C8 anti-RBC IgMa transgene or the Yaa
mutation have been previously described (7, 13). Sp6 anti-DNA IgMa
transgenic BALB/c mice (BALB.Sp6) were obtained from Dr. A. Rolink
(Pharmazentrum, Basel, Switzerland) (14). B6 mice were purchased from
The Jackson Laboratory. The presence of the 4C8 or Sp6 transgene was
detected by surface staining of peripheral blood B cells with biotinylated
anti-IgMa (RS-3.1). The inheritance of the 4C8 transgene in mice that died
prematurely was assessed by PCR using the following primers: forward
primer (5-CTACGCATTTAGTAGTGACTGG-3) and reverse primer
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(5-TGCAGAGACAGTGACCAGAG-3). Their gender was determined
by PCR for the Y chromosome-specific gene Zfy (15) using the following
primers: forward primer (5-AAGATAAGCTTACATAATCACATGGA-
3) and reverse primer (5-CCTATGAAATCCTTTGCTGCACATGT-3).
Flow cytometric analysis
Flow cytometry was performed using two- or three-color staining of bone
marrow, spleen, mesenteric lymph node (MLN), peritoneal cavity (PeC),
and peripheral blood cells, and analyzed with a FACSCalibur (BD Bio-
sciences). The following Abs were used: anti-B220 (RA3-6B2), anti-IgMa
(RS-3.1), anti-IgMb (MB86), anti-Sp6 Id (20.5) (14), anti-IgDb
(AF-3.33.3.2), PB493 (16), anti-CD21 (7G6), anti-CD23 (B3B4), anti-CD5
(53-7.3), and anti-CD11b (M1/70) mAb. Staining was performed in the
presence of saturating concentration of 2.4G2 anti-FcRII/III mAb.
Determination of hematocrits (Ht)
Blood samples were collected into heparinized microhematocrit tubes and
centrifuged in a microfuge, as described previously (17). Percentage of
packed RBC volume was directly measured after centrifugation.
Serological assays
Serum levels of total IgM were determined by ELISA as described previ-
ously (18). Serum levels of IgMa were determined by ELISA, in which
microtiter plates were coated with rabbit anti-mouse IgM Abs and devel-
oped with alkaline phosphatase-labeled rat anti-mouse IgMa (RS-3.1)
mAb. Results are expressed as micrograms per milliliter in reference to a
standard curve obtained with murine IgM. Serum levels of IgM anti-DNA,
anti-chromatin, and anti-DNP Abs in B6 mice were determined by ELISA
using alkaline phosphatase-labeled anti-IgM (LO-MM-9) mAb, and results
are expressed as titration units (units per milliliter) in reference to a stan-
dard curve established with a serum pool derived from B6 mice treated
with the polyclonal B cell activator LPS. Serum IgM anti-DNA activities
in Sp6 transgenic mice were quantified by ELISA using alkaline phos-
phatase-labeled anti-IgMa (RS-3.1) mAb, and results are expressed as units
per milliliter in reference to a standard curve established with a serum pool
from LPS-injected BALB/c mice. Serum levels of IgM Abs against bro-
melain-treated mouse RBC (BrMRBC) were determined by a flow cyto-
metric assay (19). Briefly, RBC from B6 mice were treated with 1 mg/ml
bromelain (Sigma-Aldrich) for 30 min at 37°C. After washing three times
with 1% BSA-PBS, 20 l of a 25% BrMRBC suspension was incubated
with 100 l of serum samples diluted 1/100 in 1% BSA-PBS for 1 h at 4°C.
Bound autoantibodies against BrMRBC were detected by staining with
biotinylated rat anti-mouse IgM mAb (LO-MM-9) followed by streptavi-
din-PE, and analyzed by FACS. Results are expressed as units per milliliter
in reference to a standard curve established with the median fluorescence
values obtained with serial dilutions of an IgM anti-BrMRBC mAb
(CP8B3D3) (20).
Cell culture
For spontaneous IgM secretion, cell suspensions were prepared from
spleen, MLN, and PeC of Yaa and non-Yaa B6 male mice. Spleen cell
suspensions were treated with Trizma-buffered lysis solution (150 mM
NH4Cl and 20 mM NH2C(CH2OH)3) to eliminate RBC. Triplicates of 106
cells were incubated in 200 l of DMEM containing 10% FCS at 37°C for
24 h. IgM levels in culture supernatants were determined by ELISA and are
expressed in nanograms per milliliter.
Enumeration of IgM-secreting cells by ELISPOT
The number of IgM-secreting cells was assessed by ELISPOT analysis as
previously described (21). MULTIscreen HA nitrocellulose-bottomed
plates (Millipore) were coated with 5 g/ml LO-MM-9 anti-IgM mAb
overnight at 37°C. After washing with PBS-0.1% Tween 20 and blocking
with DMEM containing 10% FCS, serial dilutions of spleen cell suspen-
sion, prepared as described for cell culture, were added to the plates and
incubated for 5 h at 37°C. After washing, plates were incubated with al-
kaline phosphatase-conjugated LO-MM-9 overnight at 4°C, washed, and
developed with 5-bromo-4-chloro-3-indolyl phosphate/NBT substrate
(Sigma-Aldrich). Frequencies of IgM-secreting cells were calculated by
counting wells containing between 20 and 100 spots with the use of a
binocular.
Immunohistochemistry and histopathology
Spleens from 8-wk-old B6 male mice of Yaa or non-Yaa genotype were
embedded in Tissue-Tek OCT compound (Miles) and snap-frozen in liquid
nitrogen. Plasma cells were stained using anti-CD138 (syndecan-1) mAb
(281-2; BD Pharmingen) followed by streptavidin-biotinylated HRP com-
plex (Amersham Biosciences). Binding of HRP complex was revealed with
3-amino-9-ethylcarbazo compound. The slides were further counterstained
with hematoxylin to easily distinguish follicles from red pulp. Frozen sec-
tions (10 m) were stained for follicular dendritic cells using purified anti-
CD35 (complement receptor 1) mAb (8C12; BD Pharmingen) followed by
FITC-coupled mouse anti-rat IgG (Jackson ImmunoResearch) and coun-
terstained with Texas Red-labeled goat anti-mouse IgM (Southern Bio-
technology Associates) in the presence of 2.4G2 anti-FcRII/III mAb, as
described previously (22). Major organs, including spleen and liver, were
obtained at autopsy, and histological sections were stained with H&E to
evaluate histopathological changes.
Depletion of CD4 T cells in vivo
B6 mice were treated from birth (during the first 24 h of life) to 4 wk of age
with rat anti-CD4 mAb (GK1.5), as previously described (23). The effi-
ciency of CD4 T cell depletion was evaluated weekly by flow cytometric
analysis of peripheral blood lymphocytes. As a control, mice were simi-
larly treated with polyclonal rat IgG purified from rat serum.
Statistical analysis
Statistical analysis was performed with the Mann-Whitney U test. Proba-
bility values 5% were considered insignificant.
Results
Early activation of 4C8 anti-RBC autoreactive B cells in B6
mice bearing the Yaa mutation
To determine the effect of the Yaa mutation on the development
and activation of autoreactive B cells, we crossed 4C8 transgenic
females with B6 male mice carrying the Yaa mutation (B6.Yaa) or
control male mice, and compared the development of anemia be-
tween Yaa and non-Yaa 4C8 transgenic mice. Among male off-
spring derived from crosses with Yaa-bearing progenitors, we
noted early mortality (before weaning) of a substantial number of
mice. At weaning, the cumulated number of female transgenic
mice was approximately three times higher than that of male trans-
genic littermates bearing the Yaa mutation. When mice found dead
during the first 4 wk of life were genotyped, virtually all of them
were Yaa males carrying the 4C8 transgene. Notably, such an in-
creased early mortality was observed neither in nontransgenic
B6.Yaa mice nor in non-Yaa 4C8 transgenic mice of either sex. To
confirm the early mortality of transgenic Yaa male mice, we geno-
typed mice alive at 3 wk of age, and followed their mortality rates.
As shown (Fig. 1A), essentially all transgenic Yaa male mice died
by 8 wk of age, whereas the mortality rates of transgenic mice
lacking the Yaa mutation and nontransgenic Yaa male mice were
10% during the first 8 wk of life.
At autopsy, we consistently observed massive agglutination of
RBC in spleen and, to a lesser extent, in liver from 4C8 transgenic
B6.Yaa mice that died early in life. These histological lesions were
similar to those observed in mice that died from acute anemia
following an injection of 200 g of 4C8 IgM mAb (17). In con-
trast, only a limited extent of agglutinated RBC was seen in
spleens from non-Yaa transgenic mice. In parallel to the early mor-
tality in transgenic B6.Yaa male mice, there was a decrease in Ht
values in these mice, compared with non-Yaa transgenic controls
( p  0.001; mean Ht values  1 SD: 4C8.Yaa, 26.6  9.4%;
4C8.B6, 39.8 6.7%; nontransgenic controls: 43.7 5.7%; Fig.
1B). These results indicated that the Yaa mutation enhanced 4C8
anti-RBC autoantibody production and caused a lethal anemia in
4C8 transgenic mice.
To determine whether the Yaa mutation could affect the devel-
opment and/or the differentiation of 4C8 transgenic B cells, we
analyzed by flow cytometry the presence of these cells in bone
marrow, spleen, MLN, PeC, and peripheral blood from transgenic
B6.Yaa and control male mice. Despite the development of a more
severe anemia in 4C8 B6.Yaa male mice, transgenic B cells were
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hardly detectable in any of the lymphoid tissues analyzed in these
mice, as in the case of non-Yaa transgenic mice (Fig. 2), in agree-
ment with the previous findings in 4C8 transgenic mice (13, 24,
25). Notably, 4C8 transgenic mice displayed only very limited
amounts of serum IgM, as determined for total IgM and transgenic
IgMa, even in the presence of the Yaa mutation (Table I). These
low concentrations of serum IgM were owed to a very small num-
ber of B cells and a rapid adsorption of 4C8 anti-RBC mAb to
circulating RBC, as previously observed in mice injected with 4C8
mAb (17). These results indicated that the Yaa mutation neither
inhibited clonal deletion of 4C8 anti-RBC autoreactive B cells in
the bone marrow nor promoted their clonal expansion in the
periphery.
Increased spontaneous IgM secretion in young B6 mice bearing
the Yaa mutation
The early mortality due to the development of severe anemia in
young 4C8 transgenic mice bearing the Yaa mutation suggested
that Yaa could induce the activation of B cells very early in life. To
test this possibility, we compared serum IgM levels between non-
transgenic B6.Yaa and non-Yaa male mice at 2, 3, 4, and 8 wk of
age. At 2 wk of age, serum levels of IgM in Yaa and non-Yaa
males were almost comparable (Fig. 3A). However, at 3 wk of age,
B6.Yaa male mice displayed significantly increased levels of IgM
FIGURE 1. Increased mortality in 4C8 IgM anti-RBC transgenic mice
carrying the Yaa mutation due to enhanced autoantibody production. A,
Male 4C8 transgenic (, ) and nontransgenic littermates (E, F) were
genotyped at 3 wk of age, and their mortality in the presence (, F) or
absence (, E) of the Yaa mutation was assessed. B, Ht of 4- to 6-wk-old
4C8.Yaa, 4C8 non-Yaa, and nontransgenic (non-Tg) control male mice.
FIGURE 2. Development of 4C8 transgenic B cells
in different lymphoid tissues of 4- to 6-wk-old
4C8.Yaa, 4C8 non-Yaa, and nontransgenic (non-Tg)
Yaa and non-Yaa male mice. Representative results ob-
tained from four to six mice in each group are shown.
Numbers indicate percentages based on total gated
mononuclear cells. In the bone marrow, 4C8 transgenic
mice both with and without the Yaa mutation showed a
predominant developmental block at the stage of imma-
ture (PB493B220int) B cells and consequently lacked
mature (PB493B220high) B cells. In the periphery, as
illustrated by spleen-cell staining, 4C8 mice hardly
bore any B220 B cells, neither of transgenic (IgMa)
nor of endogenous (IgMb) origin, independent of the
presence or absence of the Yaa mutation. Staining of
mononuclear PeC cells in non-Tg control mice with
mAb against CD5 and CD11b (Mac-1) separated B1a
(CD11bCD5) and B1b (CD11bCD5) cells from T
cells (CD11bCD5) and conventional B2 cells (dou-
ble-negative). All B cell subsets were hardly detectable
in the PeC of 4C8 transgenic mice with or without the
Yaa mutation.
Table I. Serum levels of total IgM and IgM(a) in 4C8 and Sp6
transgenic male mice with or without the Yaa mutation
Mice Transgene Yaa IgMa IgM(a)a
B6 4C8  4.1  2.5 3.2 1.8
B6 4C8  1.9  1.3 1.8 1.2
B6   210  111b NDc
B6   90  34b NDc
(BALB  B6)F1 Sp6  194  69 213 62
(BALB  B6)F1 Sp6  224  51 232 45
(BALB  B6)F1   438  142b 206  97b
(BALB  B6)F1   213  96b 97  32b
a Serum concentrations of total IgM and IgM(a) (a allotype) were determined at 4
wk of age for 4C8 transgenic mice and at 6 wk of age for Sp6 transgenic mice. Results
are expressed in micrograms per milliliter (means  1 SD of 8–12 mice in each
group).
b p  0.001.
c Not detectable.
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(mean  1 SD, 131  43 g/ml), compared with wild-type male
mice (58  24 g/ml; p  0.001), and the differences remained
significant until 8 wk of age (4 wk, p  0.001; 8 wk, p  0.05).
In contrast, serum levels of total IgG, measured at 8 wk of age,
were not different between Yaa and non-Yaa B6 male mice (Yaa,
11.2  3.3 mg/ml; non-Yaa, 10.1  4.9 mg/ml). Notably, when
B6.Yaa male mice were depleted of CD4 T cells by treatment
with GK1.5 anti-CD4 mAb from birth, they still displayed in-
creased serum levels of IgM, compared with similarly treated non-
Yaa B6 mice (means  1 SD at 4 wk of age: depleted B6.Yaa,
310 131 g/ml; depleted B6, 156 25 g/ml; p 0.05; control
B6.Yaa, 250  24 g/ml; control B6, 122  10 g/ml; p  0.05;
Fig. 3B).
To determine the site of increased IgM secretion in B6 mice
bearing the Yaa mutation, the spontaneous secretion of IgM was
measured by culturing mononuclear cells from spleen, MLN, and
PeC of 8-wk-old B6 male mice with or without the Yaa mutation.
Levels of IgM secreted by Yaa spleen cells during a 24-h culture
were markedly increased, compared with those by non-Yaa spleen
cells (means  1 SD: B6.Yaa, 350  187 ng/ml; B6, 169  92
ng/ml; p  0.001; Fig. 3C). In contrast, no increased secretion of
IgM was observed by MLN and PeC cells from B6.Yaa male mice
(MLN: B6.Yaa, 109 86 ng/ml; B6, 87 70 ng/ml; PeC: B6.Yaa,
295  201 ng/ml; B6, 276  170 ng/ml). Enhanced IgM secretion
by Yaa spleen cells was further confirmed by a 3- to 5-fold in-
crease in the frequency of IgM-secreting cells, as determined by
ELISPOT assay (Fig. 3D). Concordantly, immunohistochemical anal-
ysis of the spleen showed an increased accumulation in B6.Yaa mice
of CD138 plasma cells, located in the red pulp (Fig. 3E).
Because CD11b B1 cells have been considered to be the major
source of serum IgM (26), we determined whether an enhanced
IgM secretion in B6.Yaa male mice was related to a possible in-
crease in B1 cells in the periphery. However, the flow cytometry
analysis did not show any differences in the total number of B1
cells, including both B1 subsets (CD5 B1a and CD5 B1b), in
spleen and PeC between 8-wk-old B6.Yaa and control male mice
(data not shown). It should be stressed that the number of mature
follicular B cells was comparable between B6.Yaa and non-Yaa
male mice, even though the size of the MZ B cell compartment in
B6.Yaa male mice was substantially reduced, as described previ-
ously (11). Furthermore, we analyzed whether the Yaa mutation
promoted an accelerated development of mature B cells in the
spleen, which may predispose to an early activation of B cells.
However, flow cytometric analysis of splenic B cells for different
immature and mature B cell subsets, as well as immunohistochem-
ical analysis of the development of follicular dendritic cells did not
reveal significant differences between B6.Yaa and non-Yaa male
mice at 3 and 5 wk of age, respectively (data not shown).
To determine the specificity of IgM, the production of which
was enhanced by the presence of the Yaa mutation, we tested the
reactivity of serum IgM from 6-wk-old B6.Yaa male mice to dif-
ferent Ags, including DNA, chromatin, DNP, and BrMRBC (Fig.
FIGURE 3. Increase of spontaneous IgM secretion by spleen cells early
in life in B6 mice carrying the Yaa mutation, but without contribution of
CD4 T cells. A, Total serum IgM levels in 2- to 8-wk-old B6.Yaa (F) and
B6 control male mice (E) were determined by ELISA. B, CD4 T cells in
B6.Yaa (, ) and B6 male mice (F, E) were depleted by treatment with
GK1.5 mAb from birth (, F) or mice received polyclonal rat IgG as
control (, E). Total serum IgM levels were determined by ELISA at 4 wk
of age. C, Spleen, MLN, or PeC cells prepared from 8-wk-old B6.Yaa (F,
Œ, f) or B6 control male mice (E, ‚, ) were cultured for 24 h and
spontaneously secreted IgM was quantified by ELISA. A statistically sig-
nificant difference was found only for spleen cells. D, The frequency of
IgM-secreting cells among total spleen cells prepared from adult B6.Yaa or
B6 control male mice was determined by ELISPOT assay. In average,
B6.Yaa male mice contain 17 IgM-secreting cells per 105 total spleen cells,
whereas B6 male mice contain 5 IgM-secreting cells per 105 spleen cells. E,
Frozen sections of spleens from adult B6.Yaa or B6 control male mice were
stained with hematoxylin and anti-CD138 mAb for plasma cells (40).
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4). In parallel to increases in total IgM, sera from B6.Yaa male
mice exhibited significantly increased titers of IgM anti-chromatin,
anti-DNP, and anti-BrMRBC, compared with those from non-Yaa
male mice (means  1 SD: anti-chromatin: B6.Yaa, 14.0  10.5
U/ml vs B6, 4.4  2.7 U/ml; anti-DNP: 11.9  10.6 vs 1.5  1.1;
anti-BrMRBC: 3.8  1.1 vs 2.6  0.2; for all: p  0.001). In
contrast, IgM anti-DNA activities were hardly elevated in B6.Yaa
male mice (B6.Yaa, 5.4  4.0, vs B6, 4.4  1.3).
Lack of activation of Sp6 anti-DNA autoreactive B cells in B6
mice bearing the Yaa mutation
The analysis of the specificity of serum IgM in B6.Yaa and control
male mice suggested that enhanced IgM production occurring in
B6.Yaa mice did not simply reflect an increased polyclonal acti-
vation of B cells, but was possibly related to the specificity of the
BCR. To test this possibility, we determined the effect of the Yaa
mutation on the activation of B cells expressing a transgenic Sp6
IgMa anti-DNA Ab in (BALB.Sp6  B6)F1 mice. Serum levels of
Sp6 IgMa anti-DNA activities were comparable between trans-
genic Yaa and non-Yaa F1 male mice at 6 wk of age (means  1
SD: Yaa: 92.0  44.3 U/ml; non-Yaa: 110.2  74.2 U/ml),
whereas such activities were hardly detectable in sera from non-
transgenic F1 mice (2.5  0.7 U/ml; Fig. 5A). Notably, Sp6 anti-
DNA Abs did not show any significant binding to chromatin (data
not shown). These results were further confirmed by in vitro anal-
ysis for spontaneous secretion of transgenic Sp6 IgMa Abs by Yaa
and non-Yaa spleen cells, as assessed by ELISA and ELISPOT
assays (Fig. 5B). Moreover, no differences in serum levels of total
IgM and transgenic IgMa were found in Sp6 transgenic mice with
or without the Yaa mutation, whereas the potential of the Yaa
mutation to induce increased levels of serum IgM was confirmed
also in nontransgenic F1 controls (Table I).
Flow cytometric analysis on bone marrow and spleen cells
showed that the size of the immature and mature B cell compart-
ments in 8-wk-old Sp6 transgenic males bearing the Yaa mutation
was not different from that of transgenic non-Yaa males, and that
the majority of B cells in spleen expressed the transgenic Sp6 Id
(Fig. 6). However, it should be stressed that mature
PB493B220high, long-lived recirculating B cells were signifi-
cantly reduced in bone marrow from Sp6 transgenic mice, inde-
pendently of the Yaa genotype (means of three mice  1 SD: Yaa,
3.9  0.6%; non-Yaa, 4.7  0.6%), as compared with nontrans-
genic mice (Yaa, 9.5  0.6%; non-Yaa, 8.1  0.9%). This was
consistent with the finding that the percentage of B cells in pe-
ripheral blood was significantly reduced in Sp6 transgenic Yaa
(means of eight mice: 32.8  4.3%) and non-Yaa male mice
(means of nine mice: 28.1  5.1%), compared with nontransgenic
littermates (means of nine mice: Yaa, 58.3  7.5%; non-Yaa,
57.8  8.9%; p  0.001) (Fig. 6). Despite the reduction of the
recirculating B cells, the numbers of mature follicular and MZ B
cells in the spleen of Sp6 transgenic mice were not diminished
compared with those of nontransgenic littermates, as we have pre-
viously shown (11).
Discussion
In the present study, we have demonstrated that the expression of
the Yaa mutation induces a lethal form of autoimmune hemolytic
anemia in 4C8 IgM transgenic mice, likely as a result of an in-
creased activation of anti-RBC autoreactive B cells early in life.
This is consistent with the demonstration of high serum IgM levels
and an increased IgM secretion in spleen from nontransgenic B6
mice bearing the Yaa mutation. In contrast, the Yaa mutation fails
FIGURE 4. Autoreactive specificities of IgM autoantibodies in B6.Yaa
mice. Sera from 6-wk-old B6.Yaa (F) or B6 control male mice (E) were
analyzed by ELISA (anti-DNA, anti-chromatin, anti-DNP) or FACS (anti-
BrMRBC). Serum levels of IgM anti-chromatin, anti-DNP, and anti-
BrMRBC, but not anti-DNA, were significantly increased in B6.Yaa over
B6 mice.
FIGURE 5. No enhancement of the secretion of Sp6 transgenic IgMa
anti-DNA autoantibodies by the Yaa mutation in Sp6 transgenic mice. A,
Sera from 6-wk-old (BALB.Sp6  B6.Yaa)F1 or (BALB.Sp6  B6)F1
male mice, as well as from nontransgenic (non-Tg) controls (with or with-
out the Yaa mutation) were analyzed by ELISA for levels of IgMa anti-
DNA. No statistically significant difference was found between the two
transgenic strains. B, Transgenic IgMa secreted by spleen cells during 24 h
of culture and plasma cell frequencies were determined by ELISA and
ELISPOT, respectively, in (BALB.Sp6 B6)F1 male mice carrying or not
the Yaa mutation. Results from a representative experiment are shown
(three mice per group), and no statistically significant differences were
found.
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to induce activation of Sp6 IgM anti-DNA autoreactive B cells.
The differential effect of the Yaa mutation on these two types of
autoreactive B cells may be related to differences in the form and
nature of the autoantigens involved in stimulation of the respective
B cells.
It is striking to see that essentially all of the 4C8 transgenic mice
carrying the Yaa mutation spontaneously develop a lethal anemia
early in their lives (even before 4 wk of age). The development of
severe anemia in these mice was documented by decreases in Ht
values and histological findings (markedly agglutinated RBC in
red pulp of spleen). The pathogenesis of anemia in the 4C8 trans-
genic Yaa mice is in agreement with our previous finding that the
injection of 4C8 IgM mAb induces anemia as a result of massive
agglutination of RBC in spleen and liver, but is not due to com-
plement-mediated intravascular hemolysis (17).
It is clear that the development of lethal anemia in the context of
the Yaa mutation is not due to failure of clonal deletion of 4C8
anti-RBC autoreactive B cells in the bone marrow. However, we
did not find any sign of expansion of the 4C8 transgenic B cells in
any of the peripheral lymphoid tissues analyzed in Yaa mice. This
suggests that the development of lethal anemia early in life in
4C8 Yaa mice is likely to be a result of a transient activation of
mature 4C8 transgenic B cells. This idea is supported, although
indirectly, by the demonstration that nontransgenic B6.Yaa male
mice had increased serum levels of IgM from 3 wk of age, and
displayed enhanced levels of spontaneous IgM secretion, as well as
increased numbers of IgM-secreting cells in spleen. This is in
agreement with the earlier observation that spleen cells from BXSB.
Yaa male mice exhibit an increased IgM Ab production early in
their lives, compared with those from BXSB females (27).
In the 4C8 transgenic model, it has been repeatedly shown that
B1 cells are the major subset to become activated and secrete 4C8
anti-RBC autoantibodies (25, 28, 29). Because B1 cells largely
contribute to the production of serum IgM without T cell help, an
excessive activation of B1 cells could be partly responsible for an
increased IgM production in B6.Yaa mice. This is consistent with
the finding that B6.Yaa mice had higher serum levels of IgM anti-
BrMRBC Abs, the production of which is largely dependent on the
activation of B1 cells (30). However, we did not find any measur-
able increases in the number of B1 cells in PeC, spleen, and lymph
nodes of 4C8 transgenic Yaa mice developing severe anemia. In
addition, the analysis of nontransgenic Yaa mice failed to show an
expansion of B1 cells in PeC and an increased IgM production by
PeC B cells. Thus, our data rather argue against the idea that B1
cells are the target of Yaa.
We have shown that spleen is the major site for increased IgM
secretion in B6.Yaa mice, and that this process is largely indepen-
dent of the presence of CD4 T cells, because their depletion
FIGURE 6. Development of Sp6 transgenic B cells
in bone marrow (A), spleen (B), and peripheral blood
(C) of 8-wk-old (BALB/c B6)F1 mice. Representative
results obtained from three mice for bone marrow and
spleen cells, and from eight to nine mice for PBMC are
shown. Numbers indicate percentages based on total
gated mononuclear cells. Even though immature
(PB493B220int) B cells accumulated in the bone mar-
row of Sp6 transgenic mice, independently of the pres-
ence of the Yaa mutation, percentages of total B cells in
the spleen were comparable with those of nontransgenic
controls. In contrast, the percentages of B cells in pe-
ripheral blood were significantly reduced in Sp6 trans-
genic mice with or without the Yaa mutation, consistent
with the finding that recirculating (PB493B220high) B
cells were reduced in bone marrow of these mice. No-
tably, the vast majority of peripheral B cells from Sp6
mice expressed the transgenic Sp6 Id.
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failed to down-modulate hypersecretion of IgM in these mice. Be-
cause MZ B cells are the major subset to secrete IgM without T
cell help in spleen, Yaa may promote the activation of this partic-
ular B cell subset in a T cell-independent manner. However, our
previous analysis showed a markedly reduced number of MZ B
cells in B6.Yaa mice (11). MZ B cells are known to be very rapidly
activated upon stimulation, migrating into the red pulp and differ-
entiating into plasma cells (31, 32). Because we noted an accu-
mulation of plasma cells in the red pulp of Yaa spleens, one can
speculate that the reduction of MZ B cells in Yaa mice may be a
consequence of excessive and continuous activation of MZ B cells
by environmental T-independent Ags, and their migration into the
red pulp and differentiation into plasma cells. In this regard, it is
worth mentioning that we have recently observed an increased
level of IgM secretion in spleen, a diminished MZ B cell com-
partment, but normal numbers of B1 cells in B6 mice congenic for
the New Zealand autoimmunity 2 (Nba2) locus (33), which is a
major locus contributing to lupus susceptibility in NZB mice (34).
In agreement, our preliminary studies have shown that the intro-
duction of Nba2 induced an accelerated development of severe
anemia in the 4C8 transgenic mice. Furthermore, we have previ-
ously detected an increase, instead of a reduction, of the MZ B cell
compartment in Sp6 anti-DNA transgenic Yaa mice (11). This
could be due to the lack of spontaneous activation of these auto-
reactive B cells present in the MZ, and the subsequent failure of
migration into the red pulp, even in the presence of the Yaa mu-
tation. Consistently, our preliminary study has shown that anti-hen
egg lysozyme IgM transgenic mice bearing the Yaa mutation, in
which B cells lack antigenic stimulation, have an increased MZ B
cell compartment, as observed in Sp6 transgenic Yaa mice.
In contrast to 4C8 anti-RBC autoreactive B cells, it is striking to
observe that the Yaa mutation failed to activate Sp6 anti-DNA
autoreactive B cells, as judged by the lack of any increases in Sp6
IgMa anti-DNA Abs in sera and splenocyte culture supernatants.
Differential effect of Yaa cannot be explained by differences in the
functional states of 4C8 and Sp6 B cells, because 4C8 B cells
present in the periphery are expected to be more anergic than the
corresponding Sp6 B cells, because of a more pronounced deletion
of the former cells in the bone marrow. Notably, Sp6 transgenic
mice spontaneously produce substantial amounts of Sp6 anti-DNA
Abs. Because the recirculating pool of mature B cells was mark-
edly diminished in Sp6 transgenic mice, one cannot exclude the
possibility that Yaa differentially activates distinct B cell subpopu-
lations. Alternatively, it may be that the action of the Yaa mutation
is more dependent on BCR specificity, and does not simply reflect
a polyclonal activation of B cells. In fact, when the specificity of
serum IgM in nontransgenic B6.Yaa mice was analyzed, we ob-
served no increase in IgM anti-DNA activities, whereas IgM anti-
chromatin and anti-BrMRBC activities were substantially ele-
vated. As discussed above, Yaa may promote more efficiently the
activation of MZ B cells, which are readily stimulated by partic-
ulate forms of bloodborne Ags in a T cell-independent manner (35,
36). Thus, one can speculate that certain forms of autoantigens,
such as membrane-bound, high-density epitopes, could more effi-
ciently trigger the activation of Yaa-bearing B cells without T cell
help, as may be the case for 4C8 anti-RBC transgenic B cells. This
is in agreement with the observation in young B6.Yaa mice of
spontaneous production of IgM anti-BrMRBC autoantibodies, be-
cause the protease treatment possibly discloses repetitive autoan-
tigenic epitopes on the RBC surface. B cells specific for chromatin
autoantigens may also be more efficiently activated through con-
tact with apoptotic bodies that likely display suitable membrane-
bound autoantigenic determinants. In contrast, this may not be the
case for Sp6 anti-DNA B cells, which are unable to recognize
chromatin.
In the present study, we have shown that the Yaa mutation is
able to activate 4C8 anti-RBC autoreactive B cells, but not Sp6
anti-DNA autoreactive B cells. This suggests that Yaa can activate
autoreactive B cells without T cell help, but dependent on BCR
specificity, and thus likely related to the form and nature of au-
toantigens. However, it should be stressed that the Yaa mutation is
known to promote the production of various autoantibodies of IgG
class, including anti-DNA, in a CD4 T cell-dependent manner
(37). The level of activation induced in naturally occurring DNA-
specific B cells bearing the Yaa mutation upon contact with DNA
autoantigens may still be too weak to induce their differentiation
into IgM producers. However, the presence of Yaa in these B cells
may be sufficient to promote subsequent interaction with autore-
active Th cells. Thus, Yaa could reduce the threshold for B cell
activation following BCR engagement, which may result not only
in triggering a direct activation of B cells upon contact with ap-
propriate autoantigens but also in potentiating a weak interaction
with autoreactive Th cells. This idea is consistent with our previ-
ous observation that Yaa is able to potentiate IgG Ab responses
against foreign Ags only in mice that are genetically (H2-linked)
low-responding, but not high-responding (38). In addition, if Yaa
is indeed involved in the activation of MZ B cells, one can spec-
ulate that Yaa-bearing MZ B cells directly activated by particular
autoantigens may become efficient APCs, thereby promoting sub-
sequent T cell-dependent autoimmune responses. In this regard, it
is worth noting that a recent study has shown that a fraction of
activated MZ B cells can migrate into B cell follicles, and partic-
ipate in the germinal center formation in response to T-dependent
Ags (39). The understanding of the mechanism responsible for the
hyperreactive phenotype of Yaa B cells is of paramount impor-
tance for the elucidation of the molecular abnormality caused by
the Yaa mutation. Ultimately, advances in our understanding of the
nature of the Yaa defect should give important insights into the
development of lupus-like systemic autoimmune disease.
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The Yaa Mutation Promoting Murine Lupus Causes Defective
Development of Marginal Zone B Cells1
Hirofumi Amano,2* Eri Amano,2* Thomas Moll,* Dragan Marinkovic,† Nabila Ibnou-Zekri,*
Eduardo Martinez-Sorı´a,* Isabelle Semac,* Thomas Wirth,† Lars Nitschke,‡ and Shozo Izui3*
The accelerated development of systemic lupus erythematosus (SLE) in BXSB male mice is associated with the presence of an as
yet unidentified mutant gene, Yaa (Y-linked autoimmune acceleration). In view of a possible role of marginal zone (MZ) B cells
in murine SLE, we have explored whether the expression of the Yaa mutation affects the differentiation of MZ and follicular B
cells, thereby implicating the acceleration of the disease. In this study, we show that both BXSB and C57BL/6 Yaa mice, including
two different substrains of BXSB Yaa males that are protected from SLE, displayed an impaired development of MZ B cells early
in life. Studies in bone marrow chimeras revealed that the loss of MZ B cells resulted from a defect intrinsic to B cells expressing
the Yaa mutation. The lack of selective expansion of MZ B cells in diseased BXSB Yaa males strongly argues against a major role
of MZ B cells in the generation of pathogenic autoantibodies in the BXSB model of SLE. Furthermore, a comparative analysis with
mice deficient in CD22 or expressing an IgM anti-trinitrophenyl/DNA transgene suggests that the hyperreactive phenotype of Yaa
B cells, as judged by a markedly increased spontaneous IgM secretion, is likely to contribute to the enhanced maturation toward
follicular B cells and the block in the MZ B cell generation. The Journal of Immunology, 2003, 170: 2293–2301.
T he BXSB strain of mice spontaneously develops an auto-immune syndrome with features of systemic lupus ery-thematosus (SLE)4 that affects males much earlier than
females (1). This accelerated development of SLE in male BXSB
mice is due to the presence of an as yet unidentified mutant gene
located on the Y chromosome, designated Yaa (Y-linked autoim-
mune acceleration) (2). The Yaa gene by itself is unable to induce
significant autoimmune responses in mice without an apparent
SLE background, while it can induce and accelerate the develop-
ment of SLE in combination with autosomal susceptibility alleles
present in lupus-prone mice (3, 4). The selective production of
anti-DNA autoantibodies by B cells bearing the Yaa gene in Yaa
and non-Yaa double bone marrow chimeric mice revealed that the
Yaa defect is expressed in B cells (5, 6). Based on these results, it
can be speculated that the Yaa defect may decrease the threshold
for B cell Ag receptor (BCR)-mediated signaling, thereby trigger-
ing and excessively stimulating autoreactive B cells (7).
Newly generated B cells in the bone marrow emigrate to the
spleen, in which two types of transitional mature B cell precursors
(T1 and T2) exist (8). In the spleen, immature transitional B cells
can further differentiate into follicular or marginal zone (MZ) B
cells, which differ in their localization and cell surface markers.
Follicular, recirculating B cells are IgMintIgDhighCD21intCD23high
CD1lowCD9low, and resident MZ B cells located at the junction of
white and red pulps are IgMhighIgDlowCD21highCD23neg/lowCD1high
CD9high (9–11). Although follicular B cells respond to T-dependent
Ags, MZ B cells have recently been proposed to play a critical role in
host defense against T-independent blood-borne pathogens (12, 13).
In addition, several recent studies have claimed a potential role for
MZ B cells in the spontaneous development of autoantibodies in sys-
temic autoimmunity. CD1high B cells have been reported to produce
large amounts of IgM anti-DNA Abs in lupus-prone (NZB 
NZW)F1 mice (14), which apparently have an increased number of
MZ B cells (15). In addition, it has been shown that mice overex-
pressing B cell-activating factor of the TNF family (BAFF) sponta-
neously develop an SLE-like syndrome in association with a marked
increase in T2 and MZ B cells (16, 17). Because BAFF is apparently
a potent survival factor for immature T2 B cells, it can be speculated
that autoreactive T2 B cells could escape deletion and differentiate
into autoreactive MZ B cells in these mice. This is consistent with the
findings that autoreactive B cells are accumulated in the MZ (18, 19).
However, it still remains to be established that MZ B cells indeed
secrete pathogenic autoantibodies implicated in SLE.
Molecular mechanisms regulating the differentiation into MZ vs
follicular B cells have not been fully defined. However, studies on
several different genetically manipulated mice have suggested that
the impaired development of MZ B cells could be related to de-
fects in chemotactic migration to the MZ (20–22) and to hyper-
sensitive BCR signaling, favoring an accelerated maturation to-
ward follicular B cells (23–26). The latter hypothesis has further
been supported by the demonstration that the specificity and sur-
face density of BCR are the critical factors determining the lineage
commitment to different B cell subsets (27, 28). Because the Yaa
mutation may act by enhancing BCR signaling, it could bring
along a reduction of MZ B cell development. Alternatively, if the
accelerated development of SLE by the Yaa gene is associated
with an increased production of pathogenic autoantibodies by MZ
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B cells, the number of MZ B cells may rather be increased in mice
bearing the Yaa mutation. We show in this study that the devel-
opment of MZ B cells is markedly diminished in the presence of
the Yaa mutation and not expanded during the course of SLE in
BXSB mice, and discuss the possible mechanisms by which the
Yaa mutation leads to the MZ B cell defect and autoimmunity.
Materials and Methods
Mice
BXSB mice were purchased from The Jackson Laboratory (Bar Harbor,
ME). BXSB (H-2b) male, but not female mice develop an accelerated SLE,
which results in part from the action of the Yaa gene (1), and do not express
MHC class II I-E molecules because of a defect in the Ea gene encoding
the I-E -chain (29). BXSB mice lacking the Yaa gene or bearing the H-2d
haplotype (BXSB.H-2d), or an Ea transgene (BXSB.E), and C57BL/6
(B6) mice bearing the Yaa mutation have been previously described (4,
29–31). The B6.C20 strain carrying the IgHa allotype, instead of the IgHb
allotype, on the B6 background was kindly provided by M. Bosma (Phil-
adelphia, PA). CD22/ mice with a pure B6 background were developed
as described previously (32). BXSB mice expressing an Sp6 anti-
trinitrophenyl (TNP)/DNA IgM transgene (33) were created by backcross
procedures at the eighth generation. The analysis of transgenic IgMa and
endogenous IgMb expression in Sp6 transgenic mice showed that the ma-
jority (90%) of splenic B cells expressed the transgene.
Preparation of bone marrow chimeras
Three- to 4-mo-old BXSB.E Yaa or non-Yaa male recipients (I-E) were
irradiated at 850 rad and reconstituted with 5  106 bone marrow cells
from 3- to 4-mo-old BXSB Yaa or non-Yaa male donors (I-E), as de-
scribed previously (5). Two months later, chimerism in recipients was con-
trolled by the absence of I-E-positive circulating B cells by flow cytomeric
analysis. In some experiments, a mixture of donor bone marrow cells from
Yaa B6 male mice bearing the IgHb allotype and non-Yaa B6.C20 male
mice bearing the IgHa allotype was injected into irradiated B6 male mice.
As control, a mixture of bone marrow cells from IgHa and IgHb non-Yaa
male mice was injected into irradiated B6 male mice. Chimerism in recip-
ients was controlled by the presence of IgMa and IgMb allotype-positive
circulating B cells 2 mo after the reconstitution.
Flow cytometric analysis
Flow cytometry was performed using two- or three-color staining of spleen
cells, and analyzed with a FACSCalibur (BD Biosciences, Mountain View,
CA). The following Abs were used: anti-CD21 (7G6), anti-CD23 (B3B4),
anti-CD22 (CY34), anti-CD19 (1D3), anti-B220 (RA3-6B2), anti-IgMa
(RS-3.1), anti-IgMb (MB86), anti-IgD (AF6-122), anti-CD1d (1B1), anti-
CD9 (KMC8), anti-I-A (Y-3P), anti-I-E (Y-17), anti-LFA-1 -chain
(CD11a; H35.89.9), and anti-1 integrin (CD29; Ha2/5) mAb, and poly-
clonal goat anti-human IgG (BD PharMingen, San Diego, CA). Human
BAFF-human IgG Fc (BAFF-Fc) fusion protein was a kind gift of J.
Tschopp (Lausanne, Switzerland). Staining was performed in the presence
of saturating concentration of 2.4G2 anti-FcRII/III mAb.
Immunohistochemistry
Spleens from 2-mo-old BXSB mice of both Yaa and non-Yaa genotypes
were embedded in Tissue-Tek OCT compound and snap frozen in liquid
nitrogen. Frozen sections (4 m) were stained with PE-labeled anti-IgM
(1B4B1; Southern Biotechnology, Birmingham, AL), FITC-labeled anti-
IgD (11-26c.2a; PharMingen), and FITC-labeled MOMA-1 (Serotec, Ox-
ford, U.K.) mAb in the presence of 2.4G2 anti-FcRII/III mAb, as de-
scribed previously (26).
Immunizations and ELISA
Two-month-old B6 Yaa and non-Yaa male mice were immunized i.v. with
50 g of thymus-independent type 2 (TI-2) Ag, NIP-Ficoll (Biosearch
Technologies, San Francisco, CA), and bled on days 0 and 7. Serum levels
of IgM and IgG3 anti-(4-hydroxy-3-iodo-5-nitrophenyl)acetyl (NIP) Abs
were determined by ELISA, using alkaline phosphatase-labeled rat anti-
mouse IgM (LO-MM-9) and anti-mouse IgG3 (H139.61.1) mAb. Results
are expressed as U/ml in reference to a standard curve established by using
a pooled sera from B6 mice immunized with NIP-Ficoll. In addition, IgM
concentrations in culture supernatants were determined by IgM-specific
ELISA, as described previously (34).
Purification of splenic B cells and cell culture
B cells were purified from spleen by adherence of macrophages for 1 h at
37°C on plastic plates and subsequent treatment with IgM anti-Thy-1.2
(AT-83) mAb in the presence of rabbit complement (Cedarlane, Ontario,
Canada). The purity of B cells, as documented by flow cytometric analysis,
was superior to 95%. For spontaneous IgM secretion, 5  105 splenic B
cells purified from Yaa and non-Yaa B6 male mice were incubated in 0.2
ml of DMEM containing 10% FCS at 37°C for 24 h. For proliferative
responses of splenic B cells, 2  105 spleen cells were incubated with 1,
5, or 25 g/ml of B7-6 anti-IgM mAb in 0.2 ml of DMEM-10% FCS at
37°C, and cultures were pulsed with [3H]thymidine for the final 6 h of 3
days’ culture.
Western blot analysis
Total lysates of purified splenic B cells from 2-mo-old BXSB and B6 mice
of the Yaa and non-Yaa genotypes (three mice for each group) were sep-
arated on a 10% minigel and transferred to nitrocellulose (Hybond-C; Am-
ersham Pharmacia Biotech, Du¨bendorf, Switzerland) with a semidry blot-
ting apparatus (Bio-Rad, Glattbrugg, Switzerland). After 2 h of blocking at
room temperature in TTBS (10 mM Tris-HCl, pH 7.4, 100 mM NaCl, and
0.05% Tween 20) containing 5% low-fat, dry milk powder (TTBS-MP),
the filters were incubated with polyclonal rabbit anti-Lyn (amino-terminal)
Abs (Santa Cruz Biotechnology, Heidelberg, Germany) in TTBS-MP over-
night at 4°C. Thoroughly washed filters were incubated with alkaline-phos-
phatase-conjugated goat anti-rabbit IgG (Santa Cruz Biotechnology) for
1 h at room temperature. Chemiluminescence development was conducted
with the Immun-Star Pack reagents (Bio-Rad), and the filters were exposed
to X-OMAT Kodak films.
RT-PCR
Five micrograms of total RNA were prepared from purified splenic B cells
of 2-mo-old BXSB and B6 mice of both Yaa and non-Yaa genotype (three
mice for each group) by RNeasy Mini kit (Qiagen AG, Basel, Switzerland).
The first strand of cDNA (20 l) was synthesized with an oligo(dT) primer
and total RNA. For amplification with Taq DNA polymerase (Roche,
Basel, Switzerland), the following primers for Aiolos and SHP-1 genes
were used: Aiolos forward primer (5-GGCATCTTTTACTCAGAAAGG)
and reverse primer (5-TGGCTTGGTCCATCATCCG), and SHP-1 for-
ward primer (5-CCTGGACATTTCTTGTGCG) and reverse primer (5-
GTTCTCATCTGGACCTAGC). PCR products obtained following ampli-
fication of 5 l of cDNA diluted 1/50, 1/250, and 1/1250 were visualized
after electrophoresis through 2% agarose gels by staining with ethidium
bromide. The PCR products obtained with optimal cDNA concentration,
which gave an exponential phase of amplification, were quantified by den-
sitometric analysis. A reference control gene (GAPDH) was also amplified
with forward primer (5-TGAAGGTCGGTGTGAACGGATTTGG) and
reverse primer (5-ACGACATACTCAGCACCAGCATCAC) to standard-
ize amounts of RNA and to allow calculation of relative amounts of gene
expression. To ensure the absence of sample contamination, a reaction
mixture with no added cDNA was run in parallel with each PCR.
Measurement of intracellular Ca2 mobilization
A total of 107 spleen cells from B6 Yaa and non-Yaa male mice was loaded
with 4.5 M Indo-1 (Molecular Probes, Eugene, OR) and 0.04% pluronic
F-127 in RPMI (pH 7.4) with 1% FCS for 45 min at 37°C. After Indo-1
loading, cells were stained on ice with FITC-labeled anti-B220 mAb. Cells
were washed, and IgM on the B cell surface was cross-linked at 37°C with
10, 30, or 90 g/ml of B7-6 anti-IgM mAb. Increases of intracellular Ca2
in splenic B220 B cells were recorded in real time for 6 min with a
FACSVantage (BD Biosciences). The anti-B220 staining had no effect on
Ca2 flux, as was checked by comparison with unstained B cells.
Statistical analysis
Statistical analysis was performed with the Wilcoxon two-sample test. Val-
ues of p  5% were considered insignificant.
Results
Reduction of MZ B cells in BXSB and B6 mice bearing the Yaa
mutation
To investigate whether the Yaa mutation affected the size of the
MZ B cell compartment, flow cytometric analysis of spleen cells
from lupus-prone BXSB mice at 2 mo of age was performed. Anal-
ysis of cell surface expression of CD21 and CD23 on B220-pos-
itive population defines immature T1 B cells (CD21negCD23neg),
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follicular B cells (CD21intCD23high), and MZ B cells (CD21high
CD23neg/low). When compared with BXSB males or females lack-
ing the Yaa mutation, MZ B cells were substantially (4-fold)
diminished in BXSB Yaa male mice (Fig. 1, A and C). This phe-
notypic defect was further confirmed with the use of other markers,
including CD1d and CD9 (Fig. 1B). Histologically, spleens from
BXSB Yaa male mice showed normal anatomical structures. The
resident metallophilic, MOMA-1 MZ macrophages were cor-
rectly localized. However, in agreement with the flow cytometric
analysis, a characteristic rim of IgMIgD MZ B cells at the pe-
riphery of the follicles and separated by MOMA-1 macrophages
was poorly visible in the spleens of BXSB Yaa males, as compared
with non-Yaa BXSB males (Fig. 2).
The observed reduction of MZ B cells in BXSB Yaa male mice
could be secondary to the accelerated development of autoimmune
responses occurring in these mice, rather than a direct effect of the
Yaa gene defect on MZ B cell generation. To exclude this possi-
bility, we determined the size of the MZ B cell compartment in two
different substrains of BXSB male mice (BXSB.H-2d and
BXSB.E). These two substrains of BXSB male mice carry the
Yaa mutation, but fail to develop SLE during the first year of life,
because of the presence of the H-2d haplotype (30) or the transgene
encoding an I-E -chain (29), respectively. Despite the absence of
significant autoantibody production, the development of the
CD21highCD23neg/low MZ B cell compartment in these two BXSB
substrains was markedly limited, and indistinguishable from that
of conventional BXSB Yaa male mice (Fig. 1, A and C). The
association of the MZ B cell defect with the Yaa mutation was
further confirmed by analysis in 2-mo-old B6 Yaa male mice (Fig.
1, A and C), which lack significant autoantibody production. More
significantly, 6- to 8-mo-old conventional BXSB Yaa male mice
developing severe SLE did not shown any sign of selective ex-
pansion of MZ B cells (Fig. 1, A and C), arguing against a major
role of MZ B cells in the production of pathogenic lupus autoan-
tibodies in the BXSB model of SLE. Although we noted a slight
reduction of MZ B cells in 8-mo-old BXSB non-Yaa males, dif-
ferences between Yaa and non-Yaa males were still highly signif-
icant (data not shown).
Reduction of MZ B cells due to an intrinsic defect of B cells
expressing the Yaa mutation
To determine whether the impaired MZ B cell development in
mice bearing the Yaa mutation resulted from a defect in B cells
themselves or in the stromal microenvironment that supports the
FIGURE 1. Reduction of MZ B cells in BXSB and B6 mice bearing the
Yaa mutation. A, Spleen cells from BXSB, BXSB.E, and B6 male mice
of the Yaa or non-Yaa genotype at 2 and 8 mo of age were stained with a
combination of anti-B220, anti-CD21, and anti-CD23 mAb, and gated for
B220 cells. Mean percentages of MZ B cells (CD21highCD23neg/low) in
total spleen are indicated. Representative results from 8–20 mice in each
group are shown. B, Spleen cells from 2-mo-old BXSB mice were stained
with anti-CD21 and anti-CD1d mAb or with a combination of anti-IgM,
anti-IgD, and anti-CD9 mAb. Percentages of MZ B cells (CD21high
CD1dhigh) are indicated. Histograms show CD9 staining of the IgMhigh
IgDlow population of B cells enriched in MZ B cells. Percentages of
CD9high cells in the IgMhighIgDlow B cell population are indicated. Repre-
sentative results from five to seven mice are shown. C, Percentages of MZ
B cells (CD21highCD23neg/low) in spleen from BXSB, BXSB.H-2d,
BXSB.E, and B6 male mice of the Yaa or non-Yaa genotype at 2 and 6–8
mo of age. Means (SD) of each group are: 2-mo-old BXSB Yaa, 1.3 
0.8%; 6- to 8-mo-old BXSB Yaa, 0.8  0.4%; 2-mo-old BXSB.H-2d Yaa,
1.0  0.5%; 2-mo-old BXSB.E Yaa, 0.9  0.7%; 2-mo-old BXSB non-
Yaa, 4.7  0.7%; 2-mo-old B6 Yaa, 1.2  0.4%; 2-mo-old B6 non-Yaa,
4.8  1.1%. The results obtained with BXSB female mice were essentially
identical with those of non-Yaa BXSB male mice (means of 5 mice  SD:
4.8  1.0%).
FIGURE 2. Reduction of the MZ B cell compartment in BXSB Yaa
male mice. Spleen sections from 2-mo-old BXSB Yaa and non-Yaa male
mice were stained with PE-labeled anti-IgM (red) and FITC-labeled anti-
MOMA-1 (green) (A, Yaa and B, Non-Yaa) or PE-labeled anti-IgM (red)
and FITC-labeled anti-IgD (green) mAb (C, Yaa and D, Non-Yaa). Rep-
resentative results obtained from four mice in each group are shown.
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development of MZ B cells, we performed reciprocal bone marrow
cell reconstitution experiments between BXSB Yaa and non-Yaa
male mice. The transfer of bone marrow cells from BXSB non-Yaa
males into irradiated BXSB Yaa males efficiently reconstituted MZ
B cells (means of 7 mice  SD: 4.4  0.5%), as documented by
flow cytometric analysis (Fig. 3A). The extent of the MZ B cell
development observed in these mice was comparable to that ob-
served in non-Yaa mice reconstituted with non-Yaa bone marrow
cells (means of 4 mice SD: 4.6 1.1%). In contrast, MZ B cells
were poorly developed in irradiated BXSB non-Yaa males recon-
stituted with bone marrow cells from BXSB Yaa males (means of
5 mice  SD: 1.4  0.3%).
To confirm that the impaired development of MZ B cells in Yaa
mice resulted from a defect intrinsic to B cells bearing the Yaa
mutation, the development of MZ B cells was assessed in irradi-
ated B6 male mice reconstituted with a mixture of bone marrow
cells from Yaa B6 (IgHb) and non-Yaa B6.C20 (IgHa) male mice.
As control, irradiated B6 male mice were reconstituted with bone
marrow cells from both non-Yaa B6 and B6.C20 male mice. The
analysis of surface IgM allotypes revealed a selective accumula-
tion of IgMa-positive B cells of non-Yaa origin in the MZ, but not
in the follicular B cell compartment of Yaa/non-Yaa mixed chi-
meras, which contrasted with the comparable localization of B
cells bearing either IgM allotype in control chimeras (Fig. 3B).
Notably, the size of the MZ B cell compartment was somehow
lower in Yaa/non-Yaa mixed chimeras (means of 4 mice  SD:
3.3 1.5%) than that in control chimeras (means of 3 mice SD:
4.7  0.9%), most likely due to the defective development of MZ
B cells of Yaa origin.
Reduction of T2 B cells in BXSB and B6 mice bearing the Yaa
mutation
It has been considered that T2 B cells are the immediate precursors
differentiating into either MZ or follicular B cells (17, 24). Therefore,
the distribution of immature T1 (CD21negCD23negIgMhighIgDneg)
and T2 (CD21highCD23highIgMhighIgDhigh) B cells (8) was examined
in 2-mo-old BXSB and B6 male mice in relation to the Yaa mutation.
The proportion of newly formed T1 B cells appeared almost compa-
rable in both Yaa and non-Yaa males of either strain, while the size of
the T2 B cell compartment was substantially diminished in both
BXSB and B6 Yaa males (Fig. 4A), suggesting an accelerated matu-
ration of T2 B cells toward follicular B cells in Yaa male mice. No-
tably, a more pronounced decrease of T2 B cells than T1 B cells was
similarly observed in B6 mice deficient in the negative BCR regulator
CD22 (data not shown), which are also defective in the generation of
MZ B cells (26).
FIGURE 3. Impaired development of MZ B cells of Yaa origin in bone
marrow radiation chimeras. A, Irradiated Yaa or non-Yaa BXSB male mice
were reconstituted with bone marrow cells from BXSB Yaa or non-Yaa
males. Two months after reconstitution, spleen cells were stained with a
combination of anti-B220, anti-CD21, and anti-CD23 mAb, and gated for
B220 cells. Mean percentages of MZ B cells (CD21highCD23neg/low) in
spleen are indicated. Representative results from five to seven mice in each
group (Yaa3Non-Yaa and Non-Yaa3Yaa) are shown. B, Irradiated B6
mice were reconstituted with a mixture of bone marrow cells from Yaa B6
(IgHb) and non-Yaa B6.C20 (IgHa) male mice (Yaa  Non-Yaa) or from
non-Yaa B6 and B6.C20 male mice (control chimera). Two months after
reconstitution, spleen cells were stained with a combination of anti-CD21,
anti-CD23, and anti-IgM mAb. Histograms show non-Yaa-derived IgMa
staining of MZ (CD21highCD23neg/low) and follicular (FO; CD21intCD23high)
B cells in both mixed chimeras, and mean percentages (SD) of IgMa-positive
B cells in each compartment from three to four mice of each group are indi-
cated. Note a selective accumulation of IgMa-positive B cells of non-Yaa or-
igin in the MZ of Yaa/non-Yaa mixed chimeras. This was confirmed by IgMb
staining of Yaa B cells (data not shown).
FIGURE 4. Reduction of T2 B cells in 2-mo-old BXSB Yaa mice. A,
Spleen cells were stained with a combination of anti-IgM, anti-IgD, and
anti-CD21 mAb, in which percentages of T1 (CD21negIgMhigh) and T2
(IgMhighIgDhigh) B cells are indicated. B, Spleen cells were stained with a
combination of anti-IgM, anti-CD21, and anti-CD23 mAb. Within the
CD23 and CD23 cell gates, percentages of MZ (IgMhighCD21high
CD23–), T1 (IgMhighCD21negCD23), and T2 (IgMhighCD21highCD23) B
cells are indicated. Essentially identical results were obtained with B6 Yaa
male and CD22/ mice (data not shown). Representative results from
three to five mice are shown.
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It has been shown that BAFF secreted by dendritic cells, mono-
cytes/macrophages, and T cells (16, 35, 36) is apparently a potent
survival factor for T2 B cells, as overexpression of BAFF led to a
remarkable expansion of the T2 B cell population, accompanied by
an increase in MZ B cells (17). Thus, the reduction of T2 and MZ
B cells in Yaa male mice could be related to a lower expression of
BAFF-binding receptors. However, this possibility was excluded,
because the flow cytometric analysis using BAFF-Fc did not show
any significant differences in the binding of BAFF-Fc on T2, MZ,
and follicular B cells from Yaa and non-Yaa BXSB and B6 males
(data not shown).
A more recent study has demonstrated that an up-regulated ex-
pression of integrins, LFA-1 (L2) and 41, on MZ B cells and
the interaction with their respective ligands, ICAM-1 and
VCAM-1, expressed on resident stromal cells in the MZ is critical
for the localization and retention of MZ B cells (37). Staining with
anti-LFA-1 -chain (L) and anti-1 integrin mAb confirmed
higher levels of these two integrins in MZ B cells than in follicular
B cells in non-Yaa B6 male mice (Fig. 5). However, we did not
find any significant differences in the level of surface staining by
anti-L and anti-1 mAb on MZ and follicular B cells between Yaa
and non-Yaa mice. In addition, flow cytometric analysis failed to
show the appearance of the MZ-phenotype B cells in the peripheral
blood of Yaa mice, as opposed to mice treated with anti-L and
anti-4 mAb, causing the displacement of MZ B cells into the
blood (37).
Decreased levels of CD21 expression on follicular B cells from
BXSB and B6 mice bearing the Yaa mutation
It has recently been reported that the absence of MZ B cells in
Aiolos/ mice is accompanied by the enhanced maturation of
follicular B cells characterized by a lower level of CD21 expres-
sion (24). This was interpreted as a result of hypersensitive BCR
signaling in Aiolos-deficient B cells, favoring the maturation of T2
B cells toward follicular B cells. In fact, CD22-deficient follicular
B cells, which are hyperresponsive to BCR triggering, also exhib-
ited a down-regulation of CD21 expression (Fig. 6). Because the
Yaa defect may lead to an excessive activation of B cells, possibly
through lowering the threshold for BCR-mediated signaling, we
assessed whether the CD21 expression was similarly altered in
follicular B cells from BXSB or B6 male mice carrying the Yaa
mutation. The intensity of CD21 staining on follicular
CD21intCD23high B cells was significantly reduced in Yaa males,
as compared with non-Yaa males in both strains of mice ( p 
0.005; Fig. 6). Although the differences were relatively small, fol-
licular B cells from Yaa mice consistently showed lower levels of
CD21 in several independent analyses. Notably, we did not find
any measurable differences on splenic B cells between Yaa and
non-Yaa BXSB and B6 male mice in their expression levels of
different BCR coreceptors, CD22, CD19, and FcRIIB, and MHC
class II I-A, as determined by flow cytometric analysis. This was
also the case for Lyn, SHP-1, and Aiolos, all of which are known
to be implicated in BCR signaling and the MZ B cell development,
as assessed by Western blot or semiquantitative RT-PCR analysis
(data not shown).
Increased spontaneous secretion of IgM in Yaa B6 male mice,
but comparable responses to TI-2 Ag between Yaa and non-Yaa
B6 male mice
CD21 down-regulation in follicular B cells bearing the Yaa mu-
tation suggested that these B cells resemble lymphocytes that have
been constitutively activated, as the expression of CD21 is known
to be reduced following BCR-mediated activation of B cells (38,
39). If this is the case, one can expect an increased spontaneous
secretion of IgM Abs by splenic B cells bearing the Yaa mutation.
In fact, when 2-mo-old Yaa and non-Yaa B6 male mice were com-
pared, the amount of IgM spontaneously secreted during a 24-h
culture by splenic B cells bearing the Yaa mutation was 10-fold
higher than that of non-Yaa counterparts (Fig. 7A). However, Yaa
FIGURE 5. Lack of differences in expression levels of L- and 1-con-
taining integrins on MZ and follicular B cells between Yaa and non-Yaa B6
male mice. Spleen cells from 2-mo-old Yaa and non-Yaa B6 males were
stained with a combination of anti-CD21, anti-CD23, and anti-L or anti-
1 mAb. Histograms show L or 1 staining of MZ (CD21highCD23neg/low)
and follicular (FO; CD21intCD23high) B cells from Yaa and non-Yaa mice.
Mean fluorescence intensities (SD) of L and 1 from five B6 mice of the
Yaa or non-Yaa genotype are indicated.
FIGURE 6. Decreased expression of CD21 in follicular B cells from 2-mo-old CD22/ and Yaa mice. Spleen cells were stained with a combination
of anti-B220, anti-CD21, and anti-CD23 mAb. Within the B220 cell population, CD21intCD23high follicular B cells were gated, with maximal exclusion
of T2 (CD21highCD23high) cells. Histograms show CD21 staining of follicular B cells, in which the presence of contaminating T2 cells was too limited to
influence the value of peak fluorescence intensity of CD21. Mean fluorescence intensities (SD) of CD21 from five BXSB and B6 mice of the Yaa or
non-Yaa genotype and from two CD22/ and wild-type B6 mice are indicated. Differences in the fluorescence intensity of CD21 between Yaa and
CD22/ mice are due to the fact that these analyses were conducted in the laboratory of S. Izui and L. Nitschke, respectively, by using different batches
of mAb.
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B cells did not show any significant differences in Ca2 influx and
proliferative responses following BCR cross-linking with B7-6 anti-
IgM mAb at any dose tested (data not shown).
It has been shown that MZ B cells play a major role in humoral
responses against TI-2 Ags (20). To test whether the reduction of
MZ B cells in B6 Yaa mice affected their immune responses to
TI-2 Ags, 2-mo-old B6 mice were immunized i.v. with NIP-Ficoll.
NIP-specific IgM and IgG3 concentrations in B6 Yaa males during
the response to the TI-2 Ag were comparable to those of non-Yaa
counterparts (Fig. 7B).
Increased development of MZ B cells in BXSB Yaa male mice
expressing an Sp6 IgM anti-TNP/DNA transgene
To further define the possible mechanism responsible for the Yaa-
linked MZ B cell defect, we determined the effect of the Yaa mu-
tation on the development of MZ B cells expressing a transgene
encoding an Sp6 IgM anti-TNP/DNA Ab in BXSB mice. Studies
in several different Ig transgenic mice have shown that the pro-
portion of MZ B cells varies depending on the specificity of BCR,
and that partially autoreactive B cells tend to be more accumulated
in the MZ B cell compartment (19, 40). In agreement with results
obtained in mice expressing a VH81X H chain transgene confer-
ring self-reactivity (40), the flow cytometric analysis revealed that
the proportion of MZ B cells was significantly enlarged in 2-mo-
old non-Yaa BXSB Sp6 transgenic male mice (means of 5 mice 
SD: 9.4  2.1%), as compared with nontransgenic littermates
(means of 4 mice  SD: 4.6  1.3%) (Fig. 8A). In contrast to a
compromised development of MZ B cells in Yaa BXSB nontrans-
genic males (means of 4 mice  SD: 1.1  1.5%), the size of the
MZ B cell compartment in Sp6 transgenic BXSB Yaa males was
markedly increased (means of 5 mice  SD: 7.5  2.4%), reach-
ing a level almost comparable to that of non-Yaa BXSB transgenic
mice. These results suggest that MZ B precursors expressing the
Yaa mutation have the potential to migrate toward the MZ almost
as efficiently as those of non-Yaa origin. Notably, the levels of
CD21 expression on follicular B cells and of spontaneous IgM
secretion by splenic B cells did not significantly differ between Yaa
and non-Yaa Sp6 transgenic male mice (Fig. 8, B and C).
Discussion
In the present study, we have demonstrated that lupus-prone BXSB
and nonautoimmune B6 mice bearing the Yaa mutation display a
defect in the development of MZ B cells, as documented by flow
cytometric or histological analysis. This defect was similarly ob-
served in two BXSB Yaa substrains (BXSB.H-2d and BXSB.E),
which are protected from SLE (29, 30), indicating that the defect
in the MZ B cell generation is directly linked to the Yaa mutation,
and not secondary to the development of lupus-like autoimmune
responses. Studies in bone marrow chimeras revealed that the se-
lective loss of MZ B cells in Yaa mice results from a defect in-
trinsic to B cells expressing the Yaa mutation. In addition, the lack
FIGURE 7. Increased secretion of IgM by splenic B cells from B6 male
mice bearing the Yaa mutation, but comparable Ab responses to TI-2 Ag,
NIP-Ficoll. A, Spontaneous secretion of IgM in vitro after a 24-h incuba-
tion of splenic B cells from 2-mo-old B6 male mice of the Yaa or non-Yaa
genotype was determined by ELISA. IgM concentrations in supernatants
from three different mice (means  SD) are expressed as ng/ml of IgM. B,
Serum levels of IgM and IgG3 anti-NIP Abs were determined by ELISA 7
days after an i.v. injection of 50 g of NIP-Ficoll into 2-mo-old B6 mice.
Results are expressed as units per milliliter of anti-NIP Abs. Serum levels
of IgM and IgG3 anti-NIP Abs before the immunization were10 and 1
U/ml, respectively, in Yaa and non-Yaa B6 males.
FIGURE 8. Increased MZ B cell development, and lack of CD21 down-
modulation on follicular B cells and of increased spontaneous IgM secre-
tion by splenic B cells in BXSB Yaa male mice expressing an Sp6 IgM
anti-TNP/DNA transgene. A, Spleen cells from 2-mo-old Yaa and non-Yaa
BXSB Sp6 transgenic males and their nontransgenic littermates were
stained with a combination of anti-B220, anti-CD21, and anti-CD23 mAb,
and gated for B220 cells. Mean percentages of MZ B cells
(CD21highCD23neg/low) in spleen are indicated. Representative results from
four to five mice in each group are shown. B, Histograms show comparable
CD21 staining of follicular (CD21intCD23high) B cells between Yaa and
non-Yaa Sp6 transgenic male mice. Mean fluorescence intensity (SD) of
CD21 from five Sp6 transgenic male mice in each group is given. C, Spon-
taneous secretion of IgM in vitro after a 24-h incubation of splenic B cells
from 2-mo-old BXSB Sp6 transgenic male mice of the Yaa or non-Yaa
genotype was determined by ELISA. IgM concentrations in supernatants
from three different mice (means  SD) are expressed as nanograms per
milliliter of IgM.
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of preferential expansion of MZ B cells in aged BXSB Yaa males
developing severe SLE strongly argues against a major role of MZ
B cells in the generation of pathogenic autoantibodies in the BXSB
model of SLE.
Several recent studies have proposed a possible role for MZ B
cells in the spontaneous production of lupus autoantibodies in
mice. First, the size of the MZ B cell compartment has been re-
ported to be enlarged in lupus-prone (NZB  NZW)F1 mice (15),
and it was claimed to be linked to the Nba2 locus (41), which
provides the major contribution to lupus susceptibility in this
model of SLE (42). Second, CD1dhigh B cells, a phenotype of MZ
B cells, have been shown to produce more IgM autoantibodies than
follicular B cells in (NZB NZW)F1 mice (14). Third, mice over-
expressing BAFF developed a lupus-like autoimmune syndrome in
parallel to an expansion of MZ B cells (16). Finally, low affinity
autoreactive B cells could be positively selected into the MZ (18,
19, 40). However, as shown in the present study, a specific reduc-
tion, rather than an expansion, of MZ B cells in aged BXSB Yaa
males developing a lethal form of SLE suggests that the MZ B
cells are not critically involved in the Yaa-mediated accelerated
development of SLE in these mice. However, our results cannot
totally exclude the possibility that low numbers of MZ B cells in
BXSB Yaa male mice may in part be due to an increased activation
of autoreactive B cells in the MZ and their exit from this com-
partment. In fact, it has been reported that MZ B cells undergo
rapid migration to lymphoid follicles after exposure to blood-borne
bacterial products (43). Clearly, the experiment in lupus-prone
mice genetically deficient in the MZ B cell compartment would
provide a more definite conclusion to this issue.
It has been shown that MZ B cells are capable of differentiating
into plasma cells very rapidly upon stimulation with polyclonal B
cell activators (10). It may be possible that MZ B cells bearing low
affinity self-reactive BCR produce so-called natural autoantibodies
of the IgM isotype upon contact with blood-borne pathogens. These
natural IgM autoantibodies could play an important role in self toler-
ance, possibly by promoting the elimination of pathogenic self Ags or
maintaining central tolerance through opsonization of self Ags with
complement (44), as shown in mice deficient in secretory IgM, which
are predisposed to the production of IgG autoantibodies (45, 46). If
this is the case, the loss of MZ B cells occurring in mice bearing the
Yaa mutation could rather promote autoimmune responses, because of
a limited production of beneficial natural IgM autoantibodies. This
could partially explain the increased production of IgG autoantibodies
in CD22/ or Lyn/ mice having decreased MZ B cell compart-
ments (47–49). Furthermore, it is worth mentioning that, in contrast to
recent findings based on linkage analysis in (B6NZB)F2 mice (41),
the development of MZ B cells was substantially reduced in B6 mice
congenic for the Nba2 locus (unpublished data), which produce an-
tinuclear autoantibodies characteristic of SLE (42).
The mechanism by which the Yaa mutation affects the MZ B
cell development remains speculative, because the molecular de-
fect caused by the Yaa mutation has not yet been defined. Studies
in Aiolos/ mice, which are deficient in MZ B cells, revealed that
their B cells were more readily activated in response to BCR trig-
gering, and that the follicular B cells show hyperreactive pheno-
types (24). Therefore, it has been proposed that the strength of the
signal elicited via the BCR regulates the lineage commitment of
mature B cells into follicular vs MZ B cells, in which relatively
strong signals favor follicular B cell generation, while weaker sig-
nals induce differentiation into MZ B cells. This hypothesis is con-
sistent with the increased development of MZ B cells in Btk-de-
ficient mice, in which BCR signal strength is decreased (23, 24),
and the impaired MZ B cell generation in CD22/ mice, in which
BCR signaling is enhanced (26). Significantly, the present study
revealed that B cells bearing the Yaa mutation share the phenotype
of hyperreactive B cells, as shown by a decreased expression level
of CD21 and a markedly increased spontaneous production of IgM
Abs by splenic B cells in young B6 Yaa mice, which do not show
any sign of autoantibody production. In addition, it can be spec-
ulated that a pronounced decrease of T2 B cells in the Yaa mice,
as is the case in CD22/ and Aiolos/ mice (24), may be a
result of the accelerated and preferential differentiation of Yaa-
bearing T2 cells into follicular B cells. Thus, an attractive hypoth-
esis is that the Yaa mutation may act as a positive BCR regulator,
thereby modulating the maturation of MZ B cells. However, unlike
B cells deficient in Aiolos or CD22 (24), Yaa B cells did not show
an enhanced Ca2 release upon BCR stimulation by anti-IgM
mAb, although we cannot exclude the possibility that the effect of
the Yaa mutation on BCR signaling may be too subtle to be de-
tected under this experimental condition.
An alternative possibility is that a signal derived from surround-
ing cells may play an additional role in the activation, differenti-
ation, or survival of mature B cells in spleen, in which the Yaa
mutation is implicated, thereby affecting the development of MZ B
cells. It has been reported that the development of MZ B cells is
markedly reduced in CD19-deficient mice (23, 50), despite the fact
that CD19 functions as a positive BCR regulator through the for-
mation of the BCR coreceptor complex with CD21 (51). However,
because of the presence of CD19 in excess of CD21 on the cell
surface, it has been speculated that CD19 may act as a receptor for
unidentified ligands (51), thereby regulating the generation or sur-
vival of MZ B cells in a BCR-independent manner. In addition, we
have recently observed that mice deficient in CD40 or CD40 li-
gand have an increased proportion of MZ B cells (unpublished
data). Although the expression levels of CD19 and CD40 are not
altered in splenic B cells from Yaa mice, it might be worth inves-
tigating whether the Yaa mutation can modulate the CD19 or
CD40 signaling pathway.
It is also possible that the Yaa mutation leads to defects in the
motility and responsiveness to chemokines critical for the migra-
tion of MZ B precursors to the appropriate site. This hypothesis
has been used to explain the loss of MZ B cells in mice lacking
Pyk-2 tyrosine kinase, Lsc (the murine homologue of human p115
Rho GTP exchange factor), or DOCK-2 (a hemopoietic cell-spe-
cific CDM family protein) (20–22). In addition, a more recent
study has demonstrated a critical role of integrins, LFA-1 and
41, in the localization and retention of MZ B cells (37). How-
ever, the expression levels of these integrins on MZ and follicular
B cells in Yaa mice were not different from those in non-Yaa mice.
Furthermore, we observed that BXSB Yaa male mice expressing
the Sp6 anti-TNP/DNA transgene developed a MZ B cell com-
partment almost comparable to that of non-Yaa counterparts.
Therefore, we consider a migration defect to the MZ or a local-
ization and retention defect within the MZ as a less likely expla-
nation for the loss of MZ B cells in Yaa mice. In addition, the
experiment with the Sp6 transgenic mice further supports the de-
pendence on BCR specificity and signaling in maturation and sur-
vival of MZ B cells. The increase of MZ B cell compartment in the
Sp6 transgenic mice is consistent with the finding that low affinity
self-reactive B cells tend to be accumulated in the MZ (19, 40). It
has been speculated that self Ags may very weakly trigger such
autoreactive B cells, thereby favoring the differentiation into MZ B
cells (23, 24, 40). In this regard, it is of interest to note that the
follicular B cells bearing the Sp6 transgene and Yaa mutation no
longer showed hyperreactive phenotypes, consistent with the nor-
mal development of the MZ B cell compartment in the Sp6 trans-
genic Yaa mice. One possible explanation for this is that these
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autoreactive B cells could become partially anergic, thus counter-
acting the action of the Yaa mutation. This possibility warrants
further investigation by using different Ig transgenic mice bearing
the Yaa mutation.
It is significant that follicular B cells in Yaa mice exhibit hy-
perreactive phenotypes, as judged by an increased spontaneous
secretion of IgM in vitro. This was further supported by serological
analysis, showing increased levels of serum IgM in 5- to 6-wk-old
young B6 and BXSB Yaa males, as compared with non-Yaa males
(unpublished data). This is in agreement with the earlier observa-
tion that spleen cells from BXSB Yaa males exhibit an increased
polyclonal IgM Ab production early in their life, as compared with
those from BXSB female mice (52). This would also explain why
Ab responses against TI-2 Ags were not diminished in the Yaa
mice (31), in contrast to lower Ab responses against TI-2 Ags in
several, but not all, mice deficient in the MZ B cell development
(13, 20, 26, 53). It has been reported that mice overexpressing
CD19 or deficient in CD22 or Lyn, in which B cells become ab-
normally hyperresponsive to antigenic stimulation, spontaneously
produced increased levels of autoantibodies (48, 49, 54, 55).
Therefore, it is reasonable to assume that the hyperreactive phe-
notype of Yaa B cells is implicated in the Yaa-mediated acceler-
ation of autoantibody production in lupus-prone mice.
In conclusion, we have shown in the present study that the Yaa
mutation causes an impaired development of MZ B cells, and that
the lack of selective expansion of MZ B cells in diseased BXSB
Yaa male mice argues against a critical role of MZ B cells in the
generation of pathogenic autoantibodies in this SLE model. It can
be hypothesized that in the presence of the Yaa mutation, B cells
may be more readily activated by putative natural in vivo ligand(s),
thereby contributing not only to the enhanced maturation into fol-
licular B cells and the block of MZ B cell generation, but also to
the accelerated development of SLE. The understanding of the
mechanism responsible for the Yaa-associated MZ B cell defect
and the hyperreactive phenotype of Yaa B cells is of paramount
importance for the elucidation of the molecular abnormality
caused by the Yaa mutation, and hence the development of lupus-
like systemic autoimmune disease.
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A Critical Role for FcRIIB in the Induction of Rheumatoid
Factors1
Thomas Moll,* Lars Nitschke,† Michael Carroll,‡ Jeffrey V. Ravetch,§ and Shozo Izui2*
Rheumatoid factors (RF) are autoantibodies with specificity for the Fc portion of IgG, and IgG-containing immune complexes are
likely to be the major source of RF autoantigens. Therefore, the activation of RF-producing B cells could be controlled specifically
through recognition of IgG immune complexes by the low-affinity IgG FcR, FcRIIB, a potent negative regulator of the BCR. To
test this possibility, we determined the development of RF in C57BL/6 (B6) mice lacking FcRIIB, in relation to the H2 haplotype,
complement C3, and the Y-linked autoimmune acceleration (Yaa) mutation. FcRIIB-null B6 mice displayed substantial anti-
IgG2a RF activities in their sera, in addition to anti-DNA autoantibodies. Their RF and anti-DNA responses were linked to the
H2b haplotype, but were suppressed almost completely by the H2d haplotype. Strikingly, the absence of C3 failed to modulate RF
production, but strongly inhibited anti-DNA production. Furthermore, we observed that partial FcRIIB deficiency (i.e., het-
erozygous level of FcRIIB expression) was sufficient to induce the production of RF and anti-DNA autoantibodies in the presence
of the Yaa mutation. In contrast to FcRIIB, the deficiency in another BCR negative regulator, CD22, was unable to promote RF
and anti-DNA autoimmune responses in B6 mice. Our results indicate that RF autoimmune responses are critically controlled by
FcRIIB, together with the H2b and Yaa gene, while C3 regulates positively and specifically anti-DNA, but not RF autoimmune
responses. The Journal of Immunology, 2004, 173: 4724–4728.
R heumatoid factors (RF)3 are defined as autoantibodieswith specificity for the Fc portion of IgG. The presenceof RF is a characteristic feature of patients with rheuma-
toid arthritis, and RF-containing immune complexes (IC) could
contribute to several pathological manifestations, such as necro-
tizing arteritis and arthritis, in these patients. The development of
similar lesions in lupus-prone MRL-lpr/lpr mice deficient in the
Fas apoptosis receptor (1–3) is likely related to the fact that these
mice spontaneously produce high titers of RF (4–6).
The activation of RF-specific B cells results from BCR-depen-
dent uptake of IC, presentation of antigenic peptides derived from
IC, and interaction with Ag-specific T cells. However, this process
is likely to be tightly controlled, because RF activities are hardly
detectable in sera from nonautoimmune mice, and the spontaneous
production of RF is not a common feature of systemic lupus ery-
thematosus. It has been shown that the only murine strains that
spontaneously produce high titers of RF are deficient in Fas-me-
diated apoptosis (5, 6). The absence of substantial RF production
in mice is likely to be related to the unique feature of the autoan-
tigens involved in RF autoimmune responses; high-affinity RF-
producing B cells, generated during the germinal center response
from low-affinity RF-specific B cells activated by IC, should be
eliminated efficiently by apoptosis through interaction with excess
amounts of monomeric IgG. Notably, activated B cells in the ger-
minal center are particularly sensitive to apoptosis because of their
down-regulated Bcl-2 and up-regulated Fas expression (7). This is
consistent with our recent finding that autoimmune-prone mice
overexpressing a Bcl-2 transgene in B cells are able to produce
substantial titers of RF (8).
In addition, the activation of RF-producing B cells can be in-
hibited through the interaction of RF autoantigens (i.e., IgG
present in IC) with the low-affinity IgG FcR, FcRIIB. FcRIIB is
an inhibitory receptor containing an ITIM motif and, upon its co-
ligation to the BCR, recruits the inositol polyphosphate phospha-
tase. This leads to the hydrolysis of phosphatidylinositol 3,4,5-
triphosphate and prevents further activation of BCR signaling (9).
Thus, FcRIIB sets thresholds for the IC-mediated activation of B
cells. Consequently, FcRIIB could efficiently down-regulate the
development of RF autoimmune responses more selectively than
other autoimmune responses, such as anti-DNA.
Since mice deficient in FcRIIB can spontaneously develop anti-
DNA autoimmune responses on a C57BL/6 (B6) background (10),
in the present study we have explored whether an absent or defi-
cient expression of FcRIIB in B cells could also lead to the spon-
taneous production of RF. In addition, our previous study has
shown that the Y-linked autoimmune acceleration (Yaa) mutation
enhanced anti-DNA production, but failed to promote RF re-
sponses in mice overexpressing Bcl-2 in B cells (8). Therefore, the
effect of the Yaa mutation on the induction of RF production was
also investigated in mice partially deficient in FcRIIB. In addition
to FcRIIB, the roles of C3 and another BCR negative regulator,
CD22, in the induction of RF were evaluated, in comparison to
anti-DNA autoantibody production. In the present study, we show
that FcRIIB plays a critical role in the development of RF, and
that this autoimmune response is modulated by the H2 haplotype
and the Yaa mutation, but not by C3 and CD22.
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Materials and Methods
Mice
B6 (H2b) and B10.D2 (H2d) mice were purchased from The Jackson Lab-
oratory (Bar Harbor, ME). The production of FcRIIB- and C3-deficient
mice was previously described (11, 12). FcRIIB- and C3-deficient mice
were backcrossed for eight generations with B6 mice. B6 mice bearing the
Yaa gene were developed by backcross procedures, and established at the
12th backcross generation as described (13). CD22/ mice with a pure B6
background were developed as described previously (14). FcRIIB/ B6
mice carrying the H2d haplotype or the C3 null mutation were obtained
through intercross between FcRIIB/ and B10.D2 mice and between
FcRIIB/ and C3/ B6 mice, respectively. Mice deficient in FcRIIB
and bearing the H2d haplotype were identified by flow cytometric analysis
of circulating B cells using 2.4G2 anti-FcRII/III and anti-I-A (Y-3P anti-
I-Ab and MKD6 anti-I-Ad) mAb. The C3/ genotype was determined by
the absence of serum C3, as determined by ELISA (15).
Serological assays
Serum levels of anti-IgG2a RF were determined by ELISA as described
previously (16). Briefly, microtiter plates were initially coated with (4-
hydroxy-3-iodo-5-nitrophenyl)acetyl (NIP)-conjugated BSA, followed by
an incubation with murine IgG2ab,1 (S43-10) anti-NIP mAb. Then, plates
were incubated with 1/2000 diluted sera, and the assay was developed with
alkaline phosphatase-conjugated rat anti-mouse -chain (H139.52.1). As
control, serum samples were incubated with plates coated only with NIP-
BSA. Results are expressed as OD405 obtained with NIP-BSA-anti-NIP
coated plates after subtracting OD values of control plates coated only with
NIP-BSA. Serum levels of IgG anti-DNA autoantibodies were determined
by ELISA, and results are expressed as titration units (units per milliliter),
as described previously (17).
Flow cytometric analysis
Flow cytometry was performed using two-color staining of spleen cells or
peripheral blood lymphocytes, and analyzed with a FACSCaliber (BD Bio-
sciences, Mountain View, CA), as described previously. The following
Abs were used: anti-FcRII/III (2.4G2), anti-I-Ab (Y-3P), anti-I-Ad
(MKD6), and anti-B220 (RA3-6B2) mAb. To determine the interaction of
LO-MM-9 and b7-6 anti-IgM mAb with FcRIIB on B cells, peripheral
blood B cells from B6 mice were first incubated with 10 g of LO-MM-9
or b7-6 mAb for 45 min at 4°C and then stained with biotinylated 2.4G2
anti-FcRII/III and PE-labeled anti-B220 mAb, followed by
streptavidin-CyChrome.
Spleen cell culture
B cell proliferative responses were determined by incubating 2  105
spleen cells from B6 mice with different concentrations of rat anti-IgM
(LO-MM-9 or b7-6) mAb in a total volume of 200 l of DMEM containing
10% FCS. Cultures were pulsed with 1 Ci of [3H]thymidine for the final
6 h of a 3-day culture, harvested, and counted for radioactivity.
Statistical analysis
Statistical analysis was performed with the Mann-Whitney U test. Proba-
bility values 5% were considered insignificant.
Results
H2 control of RF and anti-DNA autoantibody production in
mice deficient in FcRIIB
To assess the possible role of FcRIIB in the down-regulation of
RF autoimmune responses, we determined whether the lack of
FcRIIB expression could promote the spontaneous production of
RF in B6 mice. As reported previously (10), FcRIIB/ B6 fe-
male mice spontaneously developed substantial titers of IgG anti-
DNA autoantibodies at 6 mo of age (Fig. 1A). Serum levels of
anti-IgG2a RF activities were also elevated in FcRIIB/ B6
mice (Fig. 1B).
It has previously been shown that BALB/c (H2d) mice deficient
in FcRIIB failed to develop IgG anti-DNA autoantibodies, and
that the lack of this response is apparently regulated by gene(s)
within or closely linked to the MHC (18). Therefore, we generated
FcRIIB/ B6 mice bearing the H2d haplotype by backcross pro-
cedure. As shown in Fig. 1, spontaneous production of RF and IgG
anti-DNA autoantibodies was markedly limited in H2d mice, as
compared with that in H2b mice ( p  0.0001 for both RF and
anti-DNA). In fact, their levels were almost comparable to the
baseline levels obtained in wild-type B6 mice.
Inhibition of anti-DNA, but not RF autoantibody production in
FcRIIB and C3 double-deficient B6 mice
We next explored the possible role of C3 in the induction of RF
and anti-DNA autoantibody production in FcRIIB/ B6 mice,
since the binding of C3 fragments to nuclear autoantigens or IgG
IC could promote the activation of autoreactive B cells through
amplified positive signaling via the CD21-CD19 pathway. When
serum levels of RF and IgG anti-DNA autoantibodies in FcRIIB
and C3 double-deficient (FcRIIB/C3/) B6 mice were com-
pared with those of FcRIIB/ B6 mice at 6 mo of age, the
absence of C3 didn’t affect the spontaneous development of RF
(Fig. 2). In contrast, serum levels of IgG anti-DNA autoantibodies
were markedly reduced in FcRIIB/C3/ B6 mice, as compared
with FcRIIB/ mice ( p  0.0001).
Induction of RF and anti-DNA production in FcRIIB
haploinsufficient mice bearing the Yaa mutation
We have recently shown that the Yaa mutation promotes the pro-
duction of IgG anti-DNA autoantibodies, but hardly that of RF in
B6 mice (8). In view of a possible key role for FcRIIB in RF
autoimmune responses, we determined whether the Yaa mutation
is able to promote RF production in B6 mice if their expression of
FcRIIB is diminished to a heterozygous level. Mature B cells in
FIGURE 1. Serum levels of anti-DNA and anti-IgG2a RF in 6-mo-old FcRIIB-deficient (F) or FcRIIB/ control (E) B6 female mice bearing the
H2b or H2d haplotype. A, Serum IgG anti-DNA activities were determined by incubating 1/100 diluted serum samples in microtiter plates coated with calf
thymus DNA, and the assay was developed with alkaline phosphatase-conjugated goat anti-mouse IgG-specific polyclonal Ab. Results are expressed as
units per milliliter. B, Serum anti-IgG2a RF activities were determined by incubating 1/2000 diluted serum samples in microtiter plates coated with
NIP-BSA and anti-NIP (S43-10, IgG2ab,1) mAb, and the assay was developed with alkaline phosphatase-labeled anti--chain mAb. Results are expressed
as OD405 after subtracting OD values obtained with control plates coated only with NIP-BSA.
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FcRIIB/ B6 mice displayed reduced levels of FcRIIB, as
compared with wild-type B cells, and these expression levels were
unchanged by the presence of the Yaa mutation (data not shown).
FcRIIB/ heterozygous male mice without the Yaa gene hardly
exhibited significant anti-IgG2a RF and anti-DNA activities in
their sera (Fig. 3). However, increased levels of RF as well as
anti-DNA autoantibodies were observed in FcRIIB/ haploin-
sufficient mice bearing the Yaa gene, as compared with FcRIIB-
sufficient B6 Yaa male mice ( p  0.05 and p  0.001,
respectively).
It has been speculated that the Yaa defect may decrease the
threshold of BCR signaling, thereby triggering autoreactive B
cells. More precisely, the Yaa mutation might down-modulate a
negative signaling pathway triggered through coligation of BCR
with FcRIIB. To test this possibility, we compared the inhibitory
effect of FcRIIB on anti-IgM-induced proliferative responses of
splenic B cells from FcRIIB/ B6 mice with or without the Yaa
mutation. We chose two different anti-IgM mAb, LO-MM-9 and
b7-6, which have markedly different capacities to interact with
FcRIIB. This was documented by a competitive binding assay, in
which the binding of 2.4G2 anti-FcRII/III mAb to splenic B cells
from B6 mice was substantially blocked by preincubation with
LO-MM-9, but only slightly with b7-6 anti-IgM mAb (Fig. 4A).
Furthermore, proliferative responses of FcRIIB-sufficient B cells
after stimulation with LO-MM-9 mAb were strongly inhibited, as
compared with FcRIIB-deficient B cells ( p  0.05), while stim-
ulation with b7-6 mAb induced robust responses in both types of
B cells, although still statistically different ( p  0.05; Fig. 4B).
Importantly, combined analysis with LO-MM-9 and b7-6 mAb
demonstrated that the Yaa mutation was unable to up-regulate LO-
MM-9 anti-IgM-induced proliferative responses of FcRIIB/ B
cells. These results suggest that the Yaa mutation is unlikely to be
involved in the modulation of a negative signaling pathway trig-
gered through FcRIIB after its coligation with BCR by IC in
RF-specific B cells.
Lack of RF and anti-DNA induction in B6 mice deficient
in CD22
CD22 acts as a negative regulator of BCR signaling, through rec-
ognition of 2,6-linked sialic acid-bearing glycans (19). Interval
mapping analysis for lupus susceptibility loci suggested that the
defective Cd22a gene expressed in lupus-prone NZW mice is a
possible candidate gene contributing to lupus susceptibility (20,
21). Therefore, we tested the development of IgG anti-DNA au-
toantibodies and RF in 8 mo-old CD22/ B6 female mice. In
contrast to FcRIIB/ mice, CD22/ B6 female mice failed to
display significant anti-DNA and anti-IgG2a RF activities in their
sera, as compared with wild-type B6 mice (means of anti-DNA 
SD of 12 mice, CD22/, 20.4  7.3 U/ml; CD22/, 22.7  9.6
U/ml; mean OD values for RF, CD22/, 0.031  0.033;
CD22/, 0.086  0.034). This further suggested a more specific
role for FcRIIB in the induction of RF autoimmune responses.
FIGURE 2. Serum levels of anti-DNA and anti-IgG2a RF in 6-mo-old FcRIIB-deficient and FcRIIB/C3/ B6 female mice (F) compared with
FcRIIB/ controls (E). A, Serum IgG anti-DNA activities were determined by incubating 1/100 diluted serum samples in microtiter plates coated with
calf thymus DNA, and the assay was developed with alkaline phosphatase-conjugated goat anti-mouse IgG-specific polyclonal Ab. Results are expressed
as units per milliliter. B, Serum anti-IgG2a RF activities were determined by incubating 1/2000 diluted serum samples in microtiter plates coated with
NIP-BSA and anti-NIP mAb, and the assay was developed with alkaline phosphatase-labeled anti--chain mAb. Results are expressed as OD405 after
subtracting OD values obtained with control plates coated only with NIP-BSA.
FIGURE 3. Serum levels of anti-DNA and anti-IgG2a RF in 6-mo-old FcRIIB / haploinsufficient B6 male mice with or without the Yaa mutation
(F), compared with FcRIIB/ controls (E). A, Serum IgG anti-DNA activities were determined by incubating 1/100 diluted serum samples in microtiter
plates coated with calf thymus DNA, and the assay was developed with alkaline phosphatase-conjugated goat anti-mouse IgG-specific polyclonal antibody.
Results are expressed as units per milliliter. B, Serum anti-IgG2a RF activities were determined by incubating 1/2000 diluted serum samples in microtiter
plates coated with NIP-BSA and anti-NIP mAb, and the assay was developed with alkaline phosphatase-labeled anti--chain mAb. Results are expressed
as OD405 after subtracting OD values obtained with control plates coated only with NIP-BSA.
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Discussion
In the present study, we explored the role of a negative regulator
of BCR, FcRIIB, in the production of RF. Our analysis has dem-
onstrated spontaneous production of RF in FcRIIB-deficient B6
mice and these RF responses were modulated by the gene(s) within
or closely linked to the MHC and by the Yaa mutation, but unaf-
fected by the absence of C3. The lack of involvement of C3 in RF
autoimmune response markedly contrasted with the finding that
anti-DNA autoantibody production in FcRIIB/ B6 mice was
strongly inhibited by the absence of C3. This further supports the
notion that RF and anti-DNA autoimmune responses are differen-
tially regulated, which is related to the different nature of the au-
toantigens involved in either autoimmune response.
Our demonstration that FcRIIB-deficient B6 mice spontane-
ously produce substantial levels of RF strongly supports the hy-
pothesis that IC are the major source of autoantigens for RF re-
sponses, and that the triggering of RF-producing B cells is
specifically inhibited as a result of corecognition of IC by FcRIIB
and BCR. Thus, FcRIIB down-regulates the excessive activation
by IC of low-affinity RF-specific B cells, which cannot be effi-
ciently eliminated by monomeric IgG, unlike high-affinity RF-spe-
cific B cells. Furthermore, FcRIIB expressed on follicular den-
dritic cells may also contribute to the elimination of RF-specific B
cells generated during the germinal center reaction, as it has been
proposed that preferential interaction of IC present on follicular
dendritic cells with FcRIIB over BCR could result in B cell ap-
optosis (22). This is consistent with our recent observation that an
abnormality in B cell apoptosis plays an important role in the in-
duction of RF autoimmune responses (8).
Studies in FcRIIB-deficient B6 and BALB/c mice have shown
that spontaneous production of autoantibodies, such as anti-DNA,
was markedly limited in BALB/c mice, as compared with B6 mice
(10). The genetic analysis revealed that one of the loci that control
autoantibody production in this model is linked to the MHC (18).
Our analysis of FcRIIB/ B6 mice bearing the H2d haplotype
(B6 and BALB/c mice carry H2b and H2d, respectively) has clearly
shown that the presence of the H2d haplotype provides a strong
protection from the development of RF and anti-DNA autoimmune
responses. These results are consistent with the previous demon-
stration that lupus-prone mice bearing the H2b haplotype are more
susceptible to the development of lupus-like autoimmune syn-
drome, as compared with those bearing the H2d haplotype (23–26).
However, it should be stressed that FcRIIB/ BALB/c mice
bearing the H2b haplotype failed to develop significant autoim-
mune responses (18). This suggests that the H2b haplotype by itself
is not sufficient to trigger autoimmune responses in FcRIIB-de-
ficient BALB/c mice, indicating the lack of additional genetic fac-
tor(s) promoting autoimmune responses in BALB/c mice.
It is significant that the lack of C3 hardly modulated the pro-
duction of RF, but markedly inhibited anti-DNA autoimmune re-
sponses in FcRIIB-deficient B6 mice. This suggests that, in con-
trast to RF autoimmune responses, C3 deposition on nuclear
autoantigens plays an important role in the amplification of anti-
DNA autoantibody production through the interaction with CD21-
CD19 complexes. The lack of C3 involvement in RF responses
may be explained as follows: C3 deposition on nuclear autoanti-
gens would be more intense than on IgG-containing IC, which is
likely related to the fact that the early components of the classical
complement pathway exhibit a strong interaction with apoptotic
bodies implicated in anti-DNA autoimmune responses (27, 28).
Thus, our data suggest that complement is not only involved in the
elimination of potential autoantigens through the binding to apo-
ptotic bodies, but also plays a critical role by activating autoreac-
tive B cells through CD21-CD19 complexes. Because C3 is less
efficient for the interaction and subsequent elimination of apoptotic
bodies as compared with C1q, C2, and C4 (28), it appears that C3
rather acts as a positive regulator of anti-DNA autoantibody pro-
duction. In contrast, C1q, C2, and C4 are protective against the
development of anti-DNA autoantibody responses; this is consis-
tent with the findings that C1q- or C4-deficiency promotes the
spontaneous production of anti-DNA autoantibodies in mice (27,
29, 30). All these results are in agreement with the strong associ-
ation of systemic lupus erythematosus with C1q, C2, and C4 de-
ficiency, but not with C3 deficiency (31).
We have recently shown a synergistic interaction between the
Yaa mutation and Bcl-2 overexpression on IgG anti-DNA produc-
tion, but not on RF production (8). We interpreted these results as
FIGURE 4. Interaction of LO-MM-9 and b7-6 anti-IgM mAb with
FcRIIB and splenic B cell proliferative responses after stimulation with
LO-MM-9 and b7-6 mAb. A, Spleen B cells from B6 mice were stained
with 2.4G2 anti-FcRII/III mAb after preincubation with either LO-MM-9
(dotted line) or b7-6 mAb (light black line). Fluorescence intensities of
2.4G2 staining on B220 B cells are shown. The shaded histogram rep-
resents the absence of 2.4G2 staining on FcRIIB/ control B cells. Rep-
resentative results obtained from three individual mice are shown. B,
Splenic B cell proliferative responses following stimulation with 25 g/ml
LO-MM-9 (u) or b7-6 (f) mAb in FcRIIB /, /, or / B6 mice
with or without the Yaa mutation. Results are expressed as cpm of [3H]thy-
midine incorporation (means of four to six mice per group  SD), and the
white segments represent background proliferation without addition of
mAb.
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follows: unlike anti-DNA-specific B cells, the activation of RF-spe-
cific B cells is negatively regulated through corecognition of IC by
FcRIIB, and the Yaa mutation may be unable to counteract the po-
tent negative signal triggered by FcRIIB engagement in B cells ex-
pressing normal levels of FcRIIB. Nevertheless, our present study
has shown that the Yaa mutation is able to promote RF responses in
FcRIIB/ haploinsufficient mice, indicating that the Yaa mutation
can counteract FcRIIB-mediated negative signaling, if the latter is
partially deficient. However, we observed that the presence of the Yaa
mutation is unable to up-modulate B cell proliferative responses in the
presence of LO-MM-9 anti-IgM mAb, which interacts efficiently with
FcRIIB, thereby down-regulating B cell proliferation. This strongly
suggests that, even if Yaa acts as a positive regulator of BCR signal-
ing, it may not directly impede the negative signaling pathway trig-
gered by FcRIIB upon coligation with BCR.
Another B cell coreceptor that is potentially involved in the
inhibition of autoantibody production is CD22, which—-like
FcRIIB—acts as a negative regulator of BCR signaling (32). It
has been suggested that recognition of 2,6-linked sialic acid-bear-
ing glycans on autoantigens by CD22 on B cells may be a mech-
anism to prevent activation of potentially autoreactive B cells (33).
However, despite the development of IgG anti-DNA autoantibod-
ies reported in CD22/ mice bearing a mixed genetic background
of 129 and B6 strains (34, 35), the CD22/ mice with a pure B6
background used in the present study failed to develop RF as well
as anti-DNA autoantibodies. Differences in the genetic background
of CD22-deficient mice likely account for this discrepancy. Nev-
ertheless, the lack of RF autoimmune responses in CD22/ B6
mice further indicates a more specific role for FcRIIB in the
control of RF autoimmune responses.
Our previous and current studies have demonstrated that an ab-
normality in B cell apoptosis and FcRIIB is critical for the in-
duction of RF autoimmune responses. This is likely related to the
unique feature of the autoantigens involved in these responses. The
abundance of monomeric IgG in the circulating blood efficiently
induces peripheral tolerance of high-affinity RF-specific B cells,
which can potentially be generated in the germinal centers during
the course of immune responses against self and foreign Ags. In
addition, corecognition of RF autoantigens (i.e., IC) by BCR and
FcRIIB inhibits the priming and maturation of low-affinity RF-
specific B cells. In this regard, it would be of interest to determine
whether the development of RF in patients with rheumatoid ar-
thritis is associated with unique genetic abnormalities, such as
functional defects in B cell apoptosis and/or FcRIIB.
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OBJECTIVES: 
The presence of rheumatoid factors (RF) is a characteristic feature of patients with 
rheumatoid arthritis, but not SLE. Among murine lupus models, only apoptosis-deficient 
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The presence of rheumatoid factors (RF) is a characteristic feature of patients with rheuma-
toid arthritis, but not systemic lupus erythematosus. In this study, we have explored the role
of the anti-apoptotic Bcl-2 protein and the Y-linked autoimmune acceleration (Yaa) mutation
in the production of IgG RF in comparison with IgG anti-DNA autoimmune responses. Analy-
sis in C57BL/6 mice, in their F1 hybrids with lupus-prone NZW mice, and in bone marrow
chimeras containing mixtures of C57BL/6 bcl-2-transgenic and BXSB non-transgenic cells
demonstrated that an enforced Bcl-2 expression in B cells promoted the induction of IgG
anti-DNA production in these mice, while significant IgG RF responses were observed only
in mice developing high levels of gp70-anti-gp70 immune complexes and lethal glomerulo-
nephritis. Moreover, in contrast to a synergistic interaction between the Yaa mutation and
Bcl-2 overexpression on IgG anti-DNA production, the Yaa mutation failed to enhance the
production of IgG RF induced in bcl-2-transgenic mice. Our results reveal that defects in the
regulation of B cell apoptosis play a critical role in the production of IgG RF, and that the Yaa
mutation differentially modulates RF and anti-DNA autoimmune responses, likely related to
the nature of autoantigens involved in each autoimmune response.
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Abbreviations: RF: Rheumatoid factor IC: Immune com-
plex Yaa: Y-linked autoimmune acceleration BCR: B cell
antigen receptor Tg: Transgenic B6: C57BL/6 B6.bcl-2:
B6 bearing the human bcl-2 transgene BMC: Bone marrow
cells NIP: (4-Hydroxy-3-iodo-5-nitrophenyl)acetyl
1 Introduction
Rheumatoid factors (RF) are defined as autoantibodies
which have specificity to the Fc portion of IgG, and their
presence is a characteristic feature of patients with rheu-
matoid arthritis. It has been demonstrated that IgM RF
can be formed spontaneously [1] and following mito-
genic or antigenic stimulation in non-autoimmune strains
of mice [2–4]. RF formed in non-autoimmune mice are
nearly always restricted to the IgM class, while lupus-
prone MRL-lpr/lpr mice deficient in the Fas apoptosis
receptor spontaneously produce high titers of IgG RF as
well as IgM RF [5–7]. Circulating intermediate-sized
immune complexes (IC) consisting of IgG RF [8, 9], simi-
lar to those found in sera or synovial fluids from patients
with rheumatoid arthritis [10], could contribute to several
pathological manifestations, such as necrotizing arteritis
and arthritis, uniquely observed in MRL-lpr/lpr mice
[11–13]. Moreover, studies with mouse monoclonal RF
reveal that RF of the IgG3 subclass are highly patho-
genic, inducing glomerulonephritis and necrotizing vas-
culitis [14, 15].
The spontaneous production of IgG RF is not a common
feature of SLE. It has been shown that the only mouse
strains which spontaneously produce IgG RF are those
deficient in Fas-mediated apoptosis [6, 7]. In contrast to
Fas (lpr) or FasL (gld) mutation, the Y-linked autoimmune
acceleration (Yaa) mutation, which promotes the produc-
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Fig. 1. Serum levels of IgG anti-DNA and anti-IgG2a RF in
B6 and (NZW×B6)F1 male mice bearing the bcl-2 transgene
and/or the Yaa mutation at 4 months of age. WT: wild type.
(A) Serum IgG anti-DNA activities were determined by incu-
bating 1:100 diluted serum samples with microtiter plates
coated with calf thymus DNA, and the assay was developed
with alkaline phosphatase-conjugated goat anti-mouse IgG-
specific antibodies. Results are expressed as U/ml. (B)
Serum anti-IgG2a RF activities were determined by incubat-
ing 1:2,000 diluted serum samples with microtiter plates
coated with NIP-BSA and anti-NIP (NIP-23, IgG2aa, Q 1) mAb,
and the assay was developed with alkaline phosphatase-
labeled anti- ‹ -chain mAb. Results are expressed as OD val-
ues at 405 nm after subtracting OD values obtained with
control plates coated only with NIP-BSA.
tion of several autoantibodies, including anti-DNA, fails
to induce IgG RF production in lupus-prone BXSB and
MRL mice [7, 16]. Previous studies have suggested that
the Yaa defect may decrease the threshold for B cell
antigen receptor (BCR)-mediated signaling, thereby trig-
gering and excessively stimulating autoreactive B cells,
but is likely to be unrelated to the process of B cell apop-
tosis [17]. Consequently, the expansion of IgG RF-
specific B cell clones may be critically dependent on
defects in lymphocyte apoptosis, while this is not always
the case for anti-DNA-specific B cells. In fact, studies in
several genetically manipulated mice revealed that the
production of IgG anti-DNA autoantibodies can result
from abnormal BCR hyperresponsiveness to antigenic
stimulation without apparent defects in B cell apoptosis
[18–21].
Since mice overexpressing a human bcl-2 transgene
within the B cell compartment can spontaneously
develop anti-DNA autoimmune responses [21, 22], we
have explored whether an enforced transgenic (Tg)
expression of the anti-apoptotic Bcl-2 protein in B cells
could also lead to the spontaneous production of IgG RF.
Furthermore, in view of the possible role of the Yaa muta-
tion as a positive BCR regulator, we have determined
whether the Yaa mutation is able to enhance RF and anti-
DNA autoimmune responses in bcl-2-Tg mice. We here
demonstrate that Bcl-2 overexpression in B cells results
in the spontaneous production of IgG RF, in addition to
anti-DNA autoantibodies, in mice bearing an appropriate
autoimmune genetic background, and that the Yaa
mutation increases anti-DNA, but not RF autoimmune
responses in this model, indicating a differential regula-
tion of these two autoimmune responses by the Yaa
mutation.
2 Results
2.1 Additive action of the bcl-2 and Yaa genes on
IgG anti-DNA production in C57BL/6 and
(NZW×B6)F1 mice
Using a previously described line of Tg C57BL/6 (B6)
mice which overexpresses the human bcl-2 gene
(B6.bcl-2) in B cells [22], we first determined whether
alterations in the regulation of B cell apoptosis could
promote the spontaneous production of IgG anti-DNA
autoantibodies in B6 mice with or without the Yaa muta-
tion. As observed in the original human bcl-2-Tg mice
with a mixed genetic background of B6 and SJL strains
[22], B6.bcl-2 Tg male mice lacking the Yaa mutation
produced significant titers of IgG anti-DNA autoanti-
bodies at 4 months of age, as compared with control
non-Tg males (p X 0.001; Fig. 1A). The serum levels of
IgG anti-DNA antibodies were further elevated by the
presence of the Yaa mutation (p X 0.005), indicating an
additive action of the bcl-2 and Yaa genes on the pro-
duction of IgG anti-DNA autoantibodies in B6 mice.
Notably, B6.Yaa male mice displayed increased produc-
tion of IgG anti-DNA antibodies at levels comparable to
those of B6.bcl-2 Tg male mice lacking the Yaa mutation.
When sera from 4-month-old (NZW×B6)F1 hybrid mice
were assessed, levels of IgG anti-DNA autoantibodies in
bcl-2-Tg F1 males bearing the Yaa mutation were again
greater than those of F1 males bearing either the bcl-2
transgene or the Yaa mutation alone (p X 0.001; Fig. 1A),
confirming the additive effect of the bcl-2 and Yaa genes
on this autoimmune response. Like B6 mice, non-Tg Yaa
F1 males developed IgG anti-DNA antibodies at levels
comparable to those of non-Yaa, bcl-2-Tg F1 males, but
significantly greater than those of non-Yaa, non-Tg F1
male mice (p X 0.01).
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Fig. 2. IgG subclass analysis of anti-IgG2a RF in 4-month-
old (NZW×B6)F1 bcl-2-Tg male mice. IgG subclasses of
anti-IgG2a RF were quantified by incubating 1:2,000 diluted
serum samples with microtiter plates coated with NIP-BSA
and anti-NIP (NIP-23, IgG2aa, Q 1) mAb, and the assay was
developed with alkaline phosphatase-labeled anti-IgG1
(D5002B5), anti-IgG2ab (C506FS), anti-IgG2ae (PV1.2) or
anti-IgG3 (H139.61.1) mAb. Results are expressed as OD
values at 405 nm after subtracting OD values obtained with
control plates coated only with NIP-BSA. OD values
obtained with non-Tg littermates for each IgG subclass-
specific RF assay were X 0.1.
2.2 Induction of RF in bcl-2-Tg (NZW×B6)F1 but
not B6 mice, and lack of an additive effect of
the Yaa mutation
We next explored the possible induction of RF in B6 and
(NZW×B6)F1 mice overexpressing the human bcl-2 gene
with or without the Yaa mutation. Despite significant IgG
anti-DNA autoantibody production in B6.bcl-2 Tg and
B6.Yaa male mice, anti-IgG2a RF activities were rarely
detectable in sera from 4-month-old B6.bcl-2 Tg male
mice, even in the presence of the Yaa mutation (Fig. 1B).
In contrast, the majority of 4-month-old (NZW×B6)F1
bcl-2-Tg male mice had substantial titers of anti-IgG2a
RF, as compared with non-Tg littermates (p X 0.001).
These serum RF activities were owed to IgG RF, as no
measurable levels of IgM RF activities were detected in
sera from (NZW×B6)F1 bcl-2-Tg male mice (data not
shown). Significantly, the presence of the Yaa mutation
failed to enhance RF production occurring in bcl-2-Tg F1
hybrids, and only 3 of 18 non-Tg F1 mice bearing the Yaa
mutation displayed significant titers of anti-IgG2a RF.
When RF activities specific for IgG1 were similarly
assessed, essentially identical results were obtained
with these B6 and (NZW×B6)F1 mice (data not shown).
Little induction of anti-IgG2a RF in B6.bcl-2 Tg mice was
not related to the fact that B6 mice bear the IgG2ab allo-
type, while the target autoantigen used in the RF assay
was the IgG2aa allotype of anti-(4-hydroxy-3-iodo-5-
nitrophenyl)acetyl (NIP) mAb (NIP-23). In fact, when the
IgG2ab allotype of anti-NIP mAb (S43–10) was used as
the target autoantigen, RF activities were again hardly
detectable in sera from B6.bcl-2 Tg mice [mean optical
density (OD) values ± SD: Tg, 0.19±0.14; non-Tg,
0.14±0.05], while substantial RF activities were observed
in sera from (NZW×B6)F1 bcl-2-Tg mice (Tg, 1.02±0.44;
non-Tg, 0.16±0.07; p X 0.001).
To determine which IgG subclasses of RF were induced
in (NZW×B6)F1 bcl-2-Tg mice, serum levels of IgG1,
IgG2a and IgG3 anti-IgG2a RF were determined by IgG
subclass-specific RF assay. Since the IgG2a allotypes of
NZW and B6 mice are IgG2ae and IgG2ab, respectively,
RF assays were developed with either anti-IgG2ae
(PV1.2) or anti-IgG2ab (C506FS) allotype-specific mAb,
each of which does not cross-react with the IgG2aa allo-
type of anti-NIP mAb (NIP-23) used as the target autoan-
tigen.
Sera exhibiting high RF activities, as measured with anti-
‹ -chain mAb, from 4-month-old F1 mice carrying the
bcl-2 transgene displayed increased titers of IgG2ae and/
or IgG2ab anti-IgG2a RF. In contrast, only a fraction (2 of
17) or none of them were positive for IgG3 and IgG1 anti-
IgG2a RF, respectively (Fig. 2). This was also the case for
anti-DNA autoantibodies in these sera, which displayed
increases in IgG2a (means ± SD: bcl-2-Tg, 74±37 U/ml;
non-Tg, 6±2 U/ml), but neither IgG1 (bcl-2-Tg, 10±4 U/
ml; non-Tg, 10±5 U/ml) nor IgG3 ( X 5 U/ml for both bcl-
2-Tg and non-Tg mice) anti-DNA activities. Notably, the
complete inhibition of RF and IgG anti-DNA induction in
(NZW×B6)F1 bcl-2-Tg mice depleted of CD4+ T cells
indicated a critical involvement of CD4+ T cells in the
development of both RF (mean OD values ± SD of 12
mice: anti-CD4-treated, X 0.1; control, 0.97±0.32) and
anti-DNA autoantibodies (anti-CD4-treated, 14±5 U/ml;
control, 115±87 U/ml).
2.3 Induction of RF by B6.bcl-2 Tg B cells in
bone marrow chimeras containing mixtures
of B6.bcl-2 Tg and BXSB non-Tg cells
The activation of RF-specific B cells is likely to result
from BCR-dependent uptake of IC, presentation of anti-
genic peptides derived from IC, and interaction with
antigen-specific T cells. If so, the markedly limited RF
formation in B6.bcl-2 Tg mice with or without the Yaa
mutation can be related to poor production of
autoantigen-autoantibody IC, as compared with their F1
hybrids with NZW mice bearing several dominant lupus
susceptibility genes [23]. In fact, non-Yaa and Yaa
B6.bcl-2 Tg males displayed neither measurable levels
of gp70-anti-gp70 IC ( X 0.1 ? g/ml), implicated in mouse
Eur. J. Immunol. 2004. 34: 1077–1084 B cell apoptosis and RF 1079
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Fig. 3. Serum levels of anti-IgG2a RF in different groups of
BMC chimeras (4 months after reconstitution). Group I,
B6.bcl-2 + BXSB; group II, B6.bcl-2.Yaa + BXSB; group III, B6
+ BXSB. (A) Serum anti-IgG2a RF activities were determined
by incubating 1:2,000 diluted serum samples with microtiter
plates coated with NIP-BSA and anti-NIP (NIP-23, IgG2a, Q 1)
mAb, and the assay was developed with alkaline phospha-
tase-labeled anti- ‹ -chain mAb. Results are expressed as OD
values at 405 nm after subtracting OD values obtained with
control plates coated only with NIP-BSA. (B) The IgG2ab allo-
type of anti-IgG2a RF ( Æ ; B6 origin) was quantified by incu-
bating serum samples with plates coated with NIP-BSA and
anti-NIP (NIP-23, IgG2aa, Q 1) mAb, and the assay was devel-
oped with alkaline phosphatase-labeled anti-mouse IgG2ab-
specific (C506FS) mAb. The IgG2aa allotype of anti-IgG2a RF
( 1 ; BXSB origin) was quantified by incubating serum samples
with plates coated with NIP-BSA and anti-NIP (S43–10,
IgG2ab, Q 1) mAb, and the assay was developed with alkaline
phosphatase-labeled anti-mouse IgG2aa,e-specific (H106.77.1)
mAb. Results are expressed as OD values at 405 nm after sub-
tracting OD values obtained with control plates coated only
with NIP-BSA. OD values obtained with a serum pool from 4-
month-old (NZW×B6)F1 bcl-2-Tg mice (IgG2ae/b), used as con-
trols, were comparable in both allotype-specific anti-IgG2a RF
assays (IgG2ae anti-IgG2a: 1.568; IgG2ab anti-IgG2a: 1.379).
lupus nephritis [24, 25], nor significant glomerular
lesions. In contrast, (NZW×B6)F1 bcl-2-Tg mice devel-
oped severe glomerulonephritis with a 50% mortality
rate at 13 months, which was associated with high
serum levels of gp70-anti-gp70 IC (means ± SD of
15 mice at 4 months of age: bcl-2-Tg, 4.0±3.2 ? g/ml;
non-Tg, 0.2±0.2 ? g/ml; p X 0.001).
To address the role of IC production in RF autoimmune
responses, we investigated whether B6.bcl-2 Tg B cells
are able to develop RF responses in the presence of sub-
stantial amounts of autoantigen-autoantibody IC. For
this purpose, we constructed radiation-mixed bone mar-
row cell (BMC) chimeras containing mixtures of non-Yaa,
B6.bcl-2 Tg (Ighb) cells and non-Yaa BXSB (Igha) cells
(group I), as described in Table 1. As expected, the IgM
allotype analysis of circulating B cells showed the domi-
nance of IgMb-bearing B cells of B6.bcl-2 origin over
IgMa-positive B cells of BXSB origin in recipient mice
(Table 1). Nevertheless, more than one third of B cells
were still derived from BXSB mice. These chimeras
developed severe glomerulonephritis with a 50% mortal-
ity rate at 11 months, and had significant titers of circu-
lating gp70-anti-gp70 IC 4 months after reconstitution
(means ± SD of nine mice: 2.1±1.3 ? g/ml). However,
control BMC chimeras containing mixtures of non-Tg B6
and non-Yaa BXSB mice (group III) failed to develop glo-
merulonephritis at least until 12 months after reconstitu-
tion, and their serum levels of gp70-anti-gp70 IC were
hardly detectable ( X 0.1 ? g/ml).
Notably, unlike the group-I chimeras, B cells of BXSB
origin became dominant over those of B6 origin in recipi-
ent mice (Table 1), which is probably due to an intrinsic
genetic defect of B cells from lupus-prone BXSB mice.
When serum levels of RF were determined 4 months
after reconstitution, high titers of RF were generated in
mixed BMC chimeras containing B6.bcl-2 Tg B cells
Table 1. BMC chimeric micea)
Group BMC donor IgMb IgMa
I B6bcl-2 (Ighb) + BXSB.Igha 46.4±4.0 26.9±6.8
II B6bcl-2.Yaa (Ighb) +
BXSB.Igha
45.6±3.8 28.2±7.5
III B6 (Ighb) + BXSB.Igha 22.5±4.0 35.6±6.1
a) All the BMC were derived from male mice. BXSB.Igha
mice used in the experiment lack the Yaa mutation.
Irradiated (BXSB×B6)F1 male mice were used as
recipients. The percentage of IgMb and IgMa allotype-
positive B cells in peripheral blood mononuclear cells
(means of six mice ± SD) were determined 4 months after
reconstitution.
(group I), but not in control group III chimeras (p X 0.001;
Fig. 3A). The analysis of the IgG2a allotype of anti-IgG2a
RF confirmed that RF was exclusively produced by
B6.bcl-2 Tg B cells in mixed BMC chimeras (Fig. 3B).
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Fig. 4. Serum levels of IgG anti-DNA autoantibodies in differ-
ent BMC chimeras (4 months after reconstitution). Group I,
B6.bcl-2 + BXSB; group II, B6.bcl-2.Yaa + BXSB; group III,
B6 + BXSB. (A) Serum IgG anti-DNA activities were deter-
mined by developing the assay with alkaline phosphatase-
conjugated goat anti-mouse IgG-specific antibodies, and
results are expressed as U/ml. (B) The IgG2ab ( Æ ; B6 origin)
and IgG2aa allotypes ( 1 ; BXSB origin) of anti-DNA anti-
bodies were quantified by developing the assay with alkaline
phosphatase-conjugated anti-mouse IgG2ab-specific
(C506FS) or anti-mouse IgG2aa,e-specific (H106.77.1) mAb,
and results are expressed as U/ml.
When RF autoimmune responses were assessed in
mixed BMC chimeras containing mixtures of B6.bcl-2 Tg
cells bearing the Yaa mutation and non-Yaa BXSB cells
(group II), we observed that the levels of RF produced by
Yaa-bearing B6.bcl-2 Tg B cells were comparable to
those produced by B6.bcl-2 Tg B cells lacking the Yaa
mutation in group I (Fig. 3), confirming the lack of addi-
tive action of the bcl-2 and Yaa genes on RF autoimmune
responses. In contrast, the presence of the Yaa mutation
in B6.bcl-2 Tg B cells significantly enhanced the produc-
tion of IgG anti-DNA autoantibodies in these mixed BMC
chimeras (p X 0.005; Fig. 4A). The IgG2a allotype analysis
of anti-DNA antibodies in the mixed BMC chimeras
showed a selective production of anti-DNA antibodies by
B6.bcl-2 Tg B cells, and further confirmed a higher level
of anti-DNA induction in these cells by the presence of
the Yaa mutation (p X 0.01; Fig. 4B).
3 Discussion
In the present study, we explored the role of the anti-
apoptotic Bcl-2 protein and the autoimmune accelerator
Yaa in the production of IgG RF in comparison with IgG
anti-DNA autoantibody responses. Our analysis in B6
mice and their F1 hybrids with lupus-prone NZW mice
has demonstrated that the inhibition of B cell apoptosis
promotes the induction of IgG anti-DNA production in
both B6 and (NZW×B6)F1 hybrid mice, while IgG RF pro-
duction was only induced in (NZW×B6)F1 mice develop-
ing IC-mediated glomerulonephritis. Moreover, we
observed that the Yaa mutation is unable to enhance IgG
RF production occurring in (NZW×B6)F1 bcl-2-Tg mice,
which contrasts with an additive effect of the Yaa muta-
tion and Bcl-2 overexpression on IgG anti-DNA autoanti-
body production in both B6 and (NZW×B6)F1 mice. Our
results indicate a critical role of B cell apoptosis in IgG
RF autoimmune responses and reveal a differential regu-
lation by the Yaa mutation of RF and anti-DNA autoim-
mune responses.
Our demonstration that overexpression of Bcl-2 in
B cells results in the spontaneous development of IgG
RF in (NZW×B6)F1 mice is consistent with the previous
finding that lupus-prone MRL-lpr/lpr mice deficient in
Fas-mediated apoptosis spontaneously produce sub-
stantial titers of IgG RF [6, 7]. It has previously been
shown that the IgM RF production can be induced fol-
lowing antigenic stimulation, likely through the activation
of low-affinity RF-specific B cells by IC [3, 4]. High-
affinity RF-specific B cells of the IgG isotype generated
during the germinal center response are likely to be effi-
ciently eliminated by apoptosis through interaction with
excess amounts of monomeric IgG. B cells in the germi-
nal center are particularly sensitive to apoptosis because
of their down-regulated Bcl-2 and up-regulated Fas
expression [26]. In addition, even low-affinity RF-specific
B cells may be susceptible to apoptosis in the germinal
center, as it has been proposed that preferential interac-
tion of IC present on follicular dendritic cells with Fc + RIIB
over BCR could result in B cell apoptosis [27].
In the bcl-2-Tg mice used in the present study, the Bcl-2
protein is expressed in B cells of the germinal center [28],
and these Tg B cells are thus protected, though not
completely, from apoptotic death following high-affinity
interaction with their corresponding antigen [29]. It has
also been shown that autoreactive anti-DNA B cells gen-
erated through somatic hypermutations are rescued as a
result of the overexpression of the bcl-2 transgene [30].
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Thus, the results obtained in both bcl-2-Tg and Fas-
deficient mice strongly support a critical role for B cell
apoptosis in the germinal center for the elimination of
RF-specific B cells.
The induction of IgG RF production in (NZW×B6)F1 bcl-
2-Tg mice, but not in B6.bcl-2 Tg mice, clearly indicates
that the defect in B cell apoptosis is by itself not suffi-
cient for the development of this particular autoimmune
response, as opposed to the significant production of
IgG anti-DNA autoantibodies in B6.bcl-2 Tg mice. Since
the activation of RF-specific B cells is likely to be depen-
dent on the presence of sufficient concentrations of IC,
the level of overall autoantibody production and IC for-
mation occurring in B6.bcl-2 Tg mice, as compared to
(NZW×B6)F1 Tg mice, may be too limited to trigger the
activation of RF-specific B cells. This is consistent with
the finding that B cells from B6.bcl-2 Tg mice are capa-
ble of producing high titers of IgG RF in the B6.bcl-2 Tg/
BXSB mixed BMC chimeras, which developed increased
levels of circulating gp70-anti-gp70 IC and severe glo-
merulonephritis.
In addition, a recent study has demonstrated that RF-
specific B cells can be activated through the cross-
linking of BCR and Toll-like receptor 9 (TLR9) by DNA-
containing IC in vitro [31]. However, it should be noted
that the DNA sequences containing non-methylated
CpG motifs that can trigger TLR9 are characteristic of
bacterial DNA but uncommon in mammalian DNA [32],
which apparently constitutes the major source of DNA
autoantigens [33, 34]. Nevertheless, it is possible that
TLR9 plays an additional role for RF autoimmune
responses in association with bacterial infection, since
anti-DNA autoantibodies efficiently interact with both
mammalian and bacterial DNA.
Our current analysis in B6 and (NZW×B6)F1 mice in the
context of Yaa and bcl-2 transgene expression reveals
that the Yaa gene displays an epistatic interaction with
the bcl-2 gene, thereby promoting IgG anti-DNA produc-
tion. The observed additive effect of the Yaa and bcl-2
genes on anti-DNA responses is compatible with the
idea that the Yaa mutation may be functionally associ-
ated with the BCR signaling pathway, but not with the
process of B cell apoptosis [17, 35]. Therefore, it is
somehow unexpected to see that the Yaa mutation fails
to enhance IgG RF responses occurring in (NZW×B6)F1
bcl-2-Tg mice and in B6.bcl-2 Tg/BXSB mixed BMC chi-
meras. This may be related to the unique feature of auto-
antigens involved in RF autoimmune responses.
Unlike anti-DNA-specific B cells, the activation of RF-
specific B cells is negatively regulated through co-
recognition of IC by Fc + RIIB. Thus, one can speculate
that the effect of the Yaa mutation may not be strong
enough to counteract the potent negative signal trig-
gered by Fc + RIIB engagement in RF-specific B cells
expressing normal levels of Fc + RIIB. This idea is in
agreement with our preliminary observation that the Yaa
mutation is able to promote IgG RF production in
Fc + RIIB+/– haploinsufficient mice. In contrast to RF
responses, Fc + RIIB may play only a limited inhibitory
role, if any, in the initial triggering of anti-DNA-specific
B cells, since the major source of nuclear autoantigens is
unlikely to be in a form of DNA complexed with IgG anti-
DNA autoantibodies. Thus, the Yaa mutation could
enhance the activation of anti-DNA-specific B cells more
efficiently than RF-specific B cells. Increased sustained
production of IgG anti-DNA autoantibodies occurring in
Fc + RIIB-deficient mice [21] is probably related to the
lack of negative regulation of this autoimmune response
after the interaction with DNA-anti-DNA IC. In addition,
one cannot exclude the possibility that the Fc + RIIB defi-
ciency and ensuing defective apoptosis may favor the
selection of anti-DNA autoreactive B cells generated
during the germinal center response [27].
In conclusion, we have shown, first, that an abnormality
in B cell apoptosis is critical for the induction of IgG RF
autoimmune responses, and second, that the Yaa muta-
tion is unable to promote RF responses developing in
mice overexpressing Bcl-2 in B cells. This latter finding
contrasts with the synergistic action of the Yaa and bcl-2
genes on IgG anti-DNA autoantibody production, indi-
cating a differential regulation of RF and anti-DNA auto-
immune responses by the Yaa mutation. Clearly, elucida-
tion of regulatory mechanisms responsible for anti-DNA
and RF production should help to identify the molecular
mechanism of the Yaa mutation, which plays a critical
role in the development of lupus-like autoimmune dis-
ease.
4 Materials and methods
4.1 Mice
B6.bcl-2 (IgG2ab) Tg mice [22] and NZW (IgG2ae) mice were
purchased from The Jackson Laboratory (Bar Harbor, ME).
B6.Yaa mice (IgG2ab) bearing the Yaa gene and BXSB.Igha
mice bearing the Igha allotype (IgG2aa), but lacking the Yaa
mutation, were developed by backcross procedures, and
established at the 12th backcross generations as described
[36, 37]. The (NZW×B6)F1 hybrids used in this study were
obtained in our animal facilities. The presence of the human
bcl-2 transgene in F1 mice was determined by PCR using
the following primers: forward primer 5’-AAGC-
CGGCGACGACTTCT and reverse primer 5’-TTGGGGC-
AGGCATGTTGA.
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4.2 Depletion of CD4+ T cells in vivo
(NZW×B6)F1 mice were treated from birth (during the first
24 h of life) to 4 months of age with rat anti-CD4 mAb (GK-
1.5), as described previously [38]. The efficiency of CD4+
T cell depletion was evaluated monthly by flow cytometry
analysis of peripheral blood lymphocytes. As a control, mice
were similarly treated with polyclonal rat IgG purified from
rat serum.
4.3 Preparation of bone marrow chimeras
Male (BXSB×B6)F1 mice, 3–4 months old, were irradiated at
800 rad and reconstituted with a mixture of BMC from 4–5-
month-old B6 (Ighb) and BXSB.Igha male mice (a mixture of
equal numbers of each donor). A mixture of 5×106 viable
BMC treated with anti-Thy-1.2 (AT-83) mAb and rabbit com-
plement was injected into irradiated recipients as detailed in
Table 1. The level of reconstitution was controlled by stain-
ing peripheral blood B cells with anti-IgMa (RS-3.1) and anti-
IgMb (MB86) mAb, as described previously [39].
4.4 Serological assays
Serum levels of RF specific for IgG2a or IgG1 were deter-
mined by ELISA as described previously [14]. Briefly, micro-
titer plates were initially coated with NIP-conjugated BSA,
followed by incubation with either mouse IgG2aa, Q 1 (NIP-
23), IgG2ab, Q 1 (S43–10) or IgG1, Q 1 (18.1.16) anti-NIP mAb.
Then, plates were incubated with 1:2,000 diluted sera, and
the assay was developed with different mAb coupled with
alkaline phosphatase. Alkaline phosphatase-conjugated
mAb used were rat anti-mouse ‹ -chain (H139.52.1), rat anti-
mouse ? -chain (LO-MM-9), rat anti-mouse IgG1 (D5002B5),
rat anti-mouse IgG2aa,e (H106.77.1), mouse anti-mouse
IgG2ab (C506FS), mouse anti-mouse IgG2ae (PV1.2) and rat
anti-mouse IgG3 (H139.61.1). As control, serum samples
were incubated with plates coated only with NIP-BSA.
Results are expressed as OD values at 405 nm obtained
with NIP-BSA/anti-NIP-coated plates after subtracting
those of control plates coated only with NIP-BSA.
Serum levels of IgG, IgG subclasses and IgG2a allotypes of
anti-DNA autoantibodies were determined by ELISA, and
results are expressed as titration units (U/ml), as described
previously [39–41]. Serum levels of gp70-anti-gp70 IC were
quantified by ELISA combined with the precipitation of sera
with polyethylene glycol (average molecular weight 6,000),
and results are expressed as ? g/ml of gp70 complexed with
anti-gp70 autoantibodies, as described previously [42].
4.5 Histopathology
Samples of all major organs were obtained at autopsy when
mice were moribund, and histological sections were stained
with either the periodic acid-Schiff reagent or hematoxylin/
eosin. Glomerulonephritis was scored on a 0–4 scale based
on the intensity and extent of histopathological changes, as
described previously [36, 37]. Glomerulonephritis of
grades 3 and 4 was considered significant contributor to
clinical disease or death.
4.6 Statistical analysis
Statistical analysis was performed with the Wilcoxon two-
sample test; p values G 0.05 were considered insignificant.
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OBJECTIVES: 
CD22 is a B-cell restricted transmembrane protein endowed with two distinctive 
functional properties: adhesion (binding of glycoproteins) and signal transduction (regulation 
of BCR signaling). B cells bearing the Cd22a allele may express aberrant forms of CD22 with 
alterations in the ligand-binding site due to polymorphic variations. In this study, we explored 
this possibility by using two different mAb, which recognize distinct epitopes of CD22. 
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 Abstract 
 
 The Cd22 gene encodes a B cell-restricted adhesion molecule, which binds 
α2,6-linked sialic acids, and functions primarily as a negative regulator of B-cell 
receptor signaling. B cells bearing the Cd22a allele may express aberrant forms of 
CD22, which differ in the N-terminal sequences constituting the ligand-binding site, 
due to the synthesis of abnormally processed Cd22 mRNA, resulting from a short 
interspersed nucleotide element insertion. In this study, we explored this possibility 
by using two different mAb, which recognize distinct epitopes of CD22. The staining 
pattern of splenic B cells obtained with CY34 mAb, which was expected to bind 
poorly to the aberrant CD22, was highly heterogeneous in Cd22a mice, as compared 
with Cd22b mice. In addition, the presence of two distinct subsets (CY34hi and 
CY34lo) of B cells became more evident after activation of splenic B cells from lupus-
prone Cd22a NZB mice with LPS. On B cells from Cd22a mice, a larger proportion of 
CD22 was not bound by cis ligands, i.e. "unmasked", than on B cells from Cd22b 
mice, as determined by the binding to a synthetic ligand. Moreover, B cells from 
Cd22a mice exhibited a prolonged Ca2+ mobilization compared to Cd22b mice. Our 
demonstration that Cd22a B cells express aberrant forms of CD22, which can 
deregulate B-cell signaling, provides further support for Cd22a as a potential 
candidate allele for murine systemic lupus erythematosus. 
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  CD22 is a B cell-specific member of the Ig superfamily with seven Ig-like 
domains, which functions as an adhesion receptor recognizing α2,6-linked sialic acid-
bearing glycans on target cells, and as a coreceptor for the B-cell receptor (BCR) (1). 
Upon BCR cross-linking, CD22 is rapidly tyrosine-phosphorylated on its cytoplasmic 
tail, which results in recruitment and activation of phosphotyrosine phosphatase SHP-
1, thereby negatively regulating BCR signaling (2). Furthermore, the finding that 
CD22-deficient B cells exhibit a greatly enhanced and prolonged Ca2+ signal after 
BCR stimulation (3-6) indicated that CD22 functions primarily as a negative regulator 
of BCR signaling by controlling the threshold of BCR-mediated signal transduction. 
Recently, the mechanism by which CD22 regulates the Ca2+ level in B cells has been 
largely solved. CD22 augments calcium efflux by activating a plasma membrane 
calcium-ATPase (PMCA4), the activation of which requires tyrosine phosphorylation 
of CD22 and SHP-1 (7). 
CD22 is a member of the Siglec (Sialic-acid binding immunoglobulin-like 
lectin) family of adhesion receptors, which bind specifically to sialic acids in 
characteristic linkages (8). CD22 has a specificity for α2,6-linked sialic acids (2,6Sia), 
a common structure on N-linked glycans, which is abundantly expressed on the 
surface of many cells (9, 10). CD22 binds to 2,6Sia with its first V-set Ig domain (11, 
12). It has been shown that CD22 is constitutively bound to ligands in cis, i.e. to 
ligands on the same cellular surface, on the majority of both human and mouse B 
cells (13-15). These cis interactions seem to regulate the inhibitory signaling function 
of CD22, because when they were impaired, lower tyrosine phosphorylation and 
higher Ca2+ signaling after BCR activation were observed (16, 17). The affinity of 
CD22 for sialic acids is very low and does not differ greatly for several sialylated 
proteins, suggesting that it is just the presence and density of the carbohydrate, but 
not the protein backbone, that determines ligand binding (18). 
 The CD22a protein carries a 6 amino-acid deletion and 8 amino-acid 
substitutions in the first Ig-like domain, as compared to CD22b (19). In addition, we 
have demonstrated that the Cd22a gene contains a short interspersed nucleotide 
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 element insertion in the second intron (20). As a consequence, Cd22a B cells 
synthesize abnormally processed Cd22 mRNA, which contains insertions of ~20-120 
nucleotides between exons 2 and 3, and/or deletions of ~100-190 nucleotides in 
exon 4 encoding the first Ig-like domain of CD22. Thus, it has been speculated that 
Cd22a B cells could express aberrant forms of CD22, which differ in the N-terminal 
sequences constituting the ligand-binding site (16, 17, 21). We explored this 
possibility by assessing the binding to B cells of two different anti-CD22 mAb, CY34 
and NIM-R6, which apparently recognize an epitope present in the first or fourth Ig-
like domain, respectively (21, 22). Moreover, we determined the binding capacity of B 
cells from different mouse strains for a synthetic ligand containing α2,6-linked sialic 
acids. Finally, the induction of Ca2+ mobilization upon BCR cross-linking was 
compared between Cd22a and Cd22b B cells. 
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 Materials and Methods 
Mice 
C57BL/6 (B6; Cd22b), BALB/c (Cd22b), DBA/2 (Cd22a), NZB (Cd22a) and 
NZW (Cd22a) mice were purchased from the Jackson Laboratories, Bar Harbor, ME. 
CD22-/- mice with a pure B6 background were developed as described previously (6). 
 
Cell culture 
2 x 106 spleen cells from a pool of 2 month-old B6, DBA/2 or NZB mice were 
incubated in 1 ml of DMEM containing 10% FCS in Falcon 24-well plates in the 
presence of 25 µg/ml LPS for 24 or 48 h. Then, the expression of CD22 on B cells 
was determined by flow cytometric analysis. 
 
Flow cytometric analysis 
Flow cytometry was performed using two-color staining of lymphocytes, and 
analyzed with a FACSCalibur (BD Biosciences, San Jose, CA). The following 
antibodies and reagents were used: FITC-labeled NIM-R6 rat anti-CD22 (19), FITC-
labeled CY34 rat anti-CD22 (23), FITC-labeled rat IgG, FITC-labeled M1/70 rat anti-
Mac-1, PE-labeled RA3-6B2 rat anti-B220 and PE-labeled 53-7.3 rat anti-CD5 
(except for anti-CD22 mAb, all from PharMingen, San Diego, CA). 
 
Staining of cells with N-glycolylneuramic acid - galactose - N-acetylglucosamine - 
streptavidin-alkaline phosphatase (NeuGcα2,6-SAAP) 
Preparation and use of the probe NeuGcα2,6Gal-SAAP have been described 
in detail elsewhere (15). NeuGcα2,6Gal-SAAP consists of the sialoside 
NeuGcα2,6Galβ1,4GlcNAc-biotin, bound to streptavidin-alkaline phosphatase, which 
is then FITC-labeled. The probe used for the experiments here is a new preparation 
which gives a higher degree of background staining with CD22-/- B cells, than 
previously (15). For staining, single-cell suspensions were prepared from total 
spleen. Prior to FACS analysis, all cells were depleted of erythrocytes by lysis with 
hypotonic Gey's solution. Sialidase treatment was performed with 0.2 U/ml 
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 neuraminidase of A. ureafaciens (Roche Applied Science, Mannheim, Germany) for 1 
hour at 37 ºC in PBS-0.1% BSA. 1-2 x 105 erythrocyte-depleted splenic cells were 
first stained with anti-B220 mAb. Staining with FITC-labeled NeuGcα2,6Gal-SAAP 
was performed by incubating the cells with the probe for 45 min on ice. Flow 
cytometry was performed as described above. 
 
Ca2+ mobilization measurements 
Splenocytes were loaded with Indo-1, as described (17) and stained with 
FITC-labeled anti-Mac-1 and PE-labeled anti-CD5. Splenocytes were then stimulated 
with polyclonal goat anti-kappa antibodies at 37 ºC, and increases in intracellular free 
Ca2+ in B cells were measured in real time with the use of a FACSvantage (BD 
Biosciences) by gating on Mac-1- and CD5-negative B cells. The recorded files were 
transferred to FlowJo software (Tree Star, Ashland, OR), and the median of each 
sample was calculated. 
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 Results 
Heterogeneous staining pattern of Cd22a B cells with CY34, but homogeneous 
staining pattern with NIM-R6 
 When splenic B cells from 2 month-old DBA/2 (Cd22a), NZB (Cd22a), NZW 
(Cd22a) and B6 (Cd22b) mice were stained with FITC-labeled CY34 mAb, the 
intensity of surface staining on Cd22a B220+ B cells, gated using PE-labeled anti-
B220 mAb, was lower than that of Cd22b B cells (Fig. 1). Moreover, it was striking to 
see that the staining pattern of B cells with the CY34 mAb was very heterogeneous in 
the three strains of mice bearing the Cd22a allele, as compared with that of Cd22b B6 
mice (Fig. 1). In contrast, splenic B cells from the three different Cd22a strains 
exhibited a homogeneous staining pattern by FITC-labeled NIM-R6 mAb, almost 
similar to that observed in Cd22b mice. Notably, the staining patterns of CD22 by the 
CY34 and NIM-R6 mAb in another Cd22b strain of mice, BALB/c, were essentially 
identical to those in B6 mice (data not shown). These results suggested that, unlike 
CD22 molecules expressed by mice carrying the Cd22b allele, CD22 on B cells from 
mice bearing the Cd22a allele were highly heterogeneous because of differences in 
their N-terminal region. This is consistent with the finding that Cd22a B cells express 
multiple forms of Cd22 mRNA transcripts having highly variable N-terminal 
sequences coding for the first Ig-like domain. In addition, we noted that the intensity 
of NIM-R6 staining on Cd22b B cells was consistently higher than that observed on 
Cd22a B cells, although the differences were relatively small. This may be due to the 
non-expression at the cell surface of truncated CD22 proteins generated as a result 
of aberrant mRNA splicing in Cd22a B cells (20). 
 
Limited up-regulation of CD22 bearing the CY34 epitope in Cd22a B cells stimulated 
with LPS 
 We have previously observed, by staining with NIM-R6 mAb, that B cells of 
NZW (Cd22a) mice upregulated CD22 less efficiently after activation with LPS in the 
presence of IL-4 than those of B6 (Cd22b) mice (20). To further define the expression 
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 of aberrant and intact CD22 in Cd22a B cells, we compared the level of CD22 
molecules detectable by CY34 and NIM-R6 mAb after incubation of spleen cells with 
LPS. Spleen cells from both DBA/2 (Cd22a) and B6 (Cd22b) mice displayed almost 
comparable increases in CD22 levels detectable by NIM-R6 mAb after 48 h of LPS 
stimulation (Fig. 2A), indicating that total CD22 expression at the B-cell surface was 
equally augmented in mice of either allotype. In contrast, the level of CD22 
recognized by CY34 mAb was barely increased in DBA/2 mice, as compared with B6 
mice, probably due to the presence of CD22 molecules with an aberrant first Ig-like 
domain that were poorly detected by CY34 mAb. Thus, our data not only support the 
expression of aberrant forms of CD22 on the surface of Cd22a B cells, but also 
indicate that a substantial portion of CD22 molecules newly generated after LPS 
stimulation in Cd22a B cells could represent such abnormal CD22. 
 As observed in DBA/2 mice, LPS stimulation of spleen cells from NZB (Cd22a) 
mice uniformly up-regulated the expression level of CD22 recognized by NIM-R6 
mAb, but hardly that of CD22 detectable by CY34 mAb (Fig. 2B). More significantly, 
after stimulation with LPS, we observed a marked increase in the number of B cells 
expressing aberrant CD22, which was very poorly recognized by the CY34 mAb. 
Thus, the presence of two distinct subpopulations of B cells, CY34hi and CY34lo, 
became more evident in NZB mice. It should be mentioned that the CY34lo subset 
did not express CD5 at a significant level (data not shown), indicating that these were 
not B-1 cells present in high numbers in NZB mice (24). Since an expansion of the 
CY34lo subset was not observed in LPS-stimulated spleen cells from non-
autoimmune DBA/2 mice, this finding is likely related to the particular genetic 
background of autoimmune-prone NZB mice. 
 
Increased binding by Cd22a B cells to a synthetic CD22 ligand 
Since the CD22a protein carries mutations in exon 4 coding for the ligand-
binding first Ig-like domain (19), we tested whether sialic-acid binding is affected by 
these mutations. To examine the ligand-binding capacity of CD22a in situ on the 
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 surface of B cells, we used a synthetic probe (NeuGcα2,6Gal-SAAP) which carries 
α2,6-linked sialic acids coupled as an oligomer to streptavidin (15). Most CD22 on 
the surface of B cells of B6 mice (Cd22b) was "masked" by binding to endogenous 
ligands in cis and therefore could not be stained by the probe NeuGcα2,6Gal-SAAP 
(Fig. 3A). However, there was a subpopulation (16 %) of B cells with "unmasked" 
CD22, which can be stained with NeuGcα2,6Gal-SAAP, as described previously 
(15). Not all probe-binding was CD22-specific, as can be seen by staining of B cells 
from CD22-deficient mice. Residual binding of NeuGcα2,6Gal-SAAP to CD22-/- B 
cells could be due to other Siglecs expressed, or could be unspecific. In comparison 
to B6 mice, DBA/2 or NZB mice, which express CD22a, had significantly more B cells 
with unmasked CD22. This higher level of unmasking was also reflected in a shift of 
the total B cell population in NeuGcα2,6Gal-SAAP binding, as demonstrated by 
histograms (Fig. 3A). The sialic-acid binding capacity of CD22a on B cells of DBA/2 
and NZB mice was heterogeneous. However, the overall ligand-binding capacity was 
increased on B cells carrying CD22a, as compared to B cells carrying CD22b. In 
addition, splenic B cells from BALB/c mice (Cd22b) also had a similar proportion (16 
%) of unmasked CD22, as Cd22b B6 mice (data not shown). 
Next, we tested the capacity of CD22a and CD22b to bind the synthetic probe 
after removal of cis ligands from the surface of B cells by sialidase treatment. After 
this treatment, all B cells from CD22-sufficient mice bound the synthetic ligand at 
comparable levels (Fig. 3B). However, the majority of CD22-/- B cells still failed to 
bind the probe after this treatment. This indicated that CD22a and CD22b can bind 
the synthetic 2,6Sia-containing CD22 ligand equally well, if not blocked by 
endogenous ligands on the cellular surface. 
 
Enhancement of Ca2+ responses in Cd22a B cells 
Since ligand binding by CD22 on the cellular surface has been shown to inhibit 
Ca2+ signaling after BCR activation (16, 17), we compared Ca2+ mobilization of B 
cells from Cd22a and Cd22b mice. We noted differences in Ca2+ responses between 
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 mouse strains expressing different IgM allotypes, but the same Cd22 allotype (such 
as B6 and BALB/c), when stimulated with both monoclonal or polyclonal anti-IgM 
antibodies (data not shown). Therefore, various concentrations of polyclonal anti-
kappa antibodies were used to stimulate splenic B cells from mouse strains with 
CD22b (B6 and BALB/c) or CD22a (DBA/2 and NZB). As a comparison, CD22-/- B 
cells were included in this analysis. Anti-kappa antibodies at concentrations of 5 and 
1.7 µg/ml triggered prolonged and higher Ca2+ responses in CD22a-expressing B 
cells (Fig. 4). Similar differences were also seen at lower antibody concentrations 
(data not shown). Since B cells from both mouse strains expressing CD22a displayed 
higher and prolonged responses as compared to CD22b B cells, we conclude that 
this result can likely be attributed to the difference in CD22 allotypes. 
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 Discussion 
 Our data support the notion that Cd22a B cells express, in addition to intact 
CD22, aberrant forms of this molecule that differ in the N-terminal region constituting 
the ligand-binding site. Furthermore, up-regulation of intact CD22 molecules in 
response to LPS is limited in Cd22a mice, as compared with Cd22b mice. We also 
showed that CD22 protein from Cd22a mice is less bound to endogenous ligands on 
the B cell surface than their counterpart from Cd22b strains. However, the capacity of 
both CD22a and CD22b proteins to bind to 2,6Sia is similar after removal of 
endogenous ligands from the cellular surface by sialidase treatment. Finally, B cells 
carrying the Cd22a allele display a prolonged Ca2+ flux, compared to B cells from 
Cd22b mice. 
The full-length CD22a protein carries a 6 amino-acid deletion plus several 
point mutations in the first Ig-like domain, in comparison to the CD22b protein. An N-
linked glycosylation site of CD22 is affected by the deletion (22). These mutations 
map to the C' and C'' β-strands of one beta-sheet, as can be deduced from the 
protein structure of sialoadhesin (25) and alignment of CD22 sequence with the 
known sialoadhesin structure (26). The C' and C'' β-strands are far away from the 
sialic-acid binding pocket of the Siglecs, which is formed by β-strands A, F and G 
(25). Therefore, the mutations present in the such “normal” CD22a protein are 
unlikely to affect the sialic-acid binding site. 
Due to abnormal splicing of Cd22a mRNAs, aberrant CD22 molecules are 
most likely expressed on Cd22a B cells with substantial deletions and/or insertions in 
the first Ig-like domain which constitutes the ligand-binding site (20). Expression of 
these aberrant forms impairs binding of the anti-CD22 CY34 mAb. The epitope for 
CY34 binding has been mapped to Arg at position 120 in the first Ig-like domain, in 
close vicinity to Arg at position 130, which is highly conserved within the Siglec family 
and required for sialic-acid binding (26). Therefore, the ligand-binding capacity of the 
aberrant forms of CD22a is likely to be affected. This could explain the higher degree 
of unmasked CD22 on the surface of B cells from Cd22a mice. However, sialidase-
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 treated B cells show a normal binding of the sialylated probe to CD22a. This indicates 
that, at least with the help of this artificial ligand, a difference between the ligand-
binding capacity of CD22a and CD22b proteins cannot be detected. 
Alternatively, expression of CD22a might affect homodimerization of CD22. 
Indeed, an N-terminal N-linked glycosylation site is missing in the first Ig-like domain 
of CD22a, due to the 6 amino-acid deletion present in the Cd22a gene (22). In the 
CD22b molecule, this glycosylation site most likely carries carbohydrates, including 
α2,6-linked sialic acids, and should be sterically well accessible to the sialic-acid 
binding domain, also present in the first Ig-like domain. Indirect evidence for such a 
model of homodimerization comes from experiments in which sialylation of CD22 
protein prevented CD22-mediated adhesion (27). Defective homodimerization would 
explain why less CD22 is bound in cis on Cd22a B cells and also why the ligand-
binding capacity is normal after sialidase treatment. More experiments are needed to 
test this possibility. Furthermore, we have recently shown that in spleen of B6 mice a 
higher proportion of transitional and marginal zone (MZ) B cells than follicular B cells 
carries unmasked CD22 (15). Since ratios of transitional, MZ and follicular B cells in 
DBA/2 and NZB mice are comparable to those of B6 mice (data not shown), 
imbalance in these B cell subsets can be excluded to account for the higher 
unmasking of CD22 in Cd22a mice. 
Impaired ligand binding by CD22 in cis on the B-cell surface has previously 
been shown to affect BCR signaling. When CD22 ligand binding was prevented by a 
genetic or pharmacological approach, anti-IgM stimulated B cells showed less 
tyrosine phosphorylation of CD22, less SHP-1 recruitment, and a higher Ca2+ 
mobilization (16, 17). Direct sialic-acid dependent binding of CD22 to membrane IgM 
has been suggested in order to explain these findings. Accordingly, unmasking of 
CD22 has been implicated in increased BCR signaling, although this has not been 
demonstrated experimentally (15). Therefore, it is significant that in the present study 
we could demonstrate both higher unmasked CD22 and, in parallel, increased and 
prolonged Ca2+ signaling in B cells from Cd22a mice, compared to Cd22b mice. The 
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 more pronounced “shoulder” of the Ca2+ peak, i.e. prolonged Ca2+ mobilization, could 
be due to inhibited Ca2+ efflux by insufficient activation of the Ca2+ ATPase, PMCA4, 
by CD22 (7). Whatever glycoprotein is involved as cis binding partner for CD22, 
these results are consistent with the idea that ligand binding contributes to the 
inhibition of Ca2+ signaling by CD22. 
The expression of aberrant CD22 molecules in Cd22a mice may have 
significant consequences for B-cell responses to antigen, and in particular for the 
spontaneous production of autoantibodies. In agreement with our demonstration of 
enhanced BCR-mediated Ca2+ responses in NZB and DBA/2 mice, the WEHI-231 B-
cell line bearing the Cd22a allele also shows enhanced Ca2+ responses, as 
compared with the wild-type cell line bearing the Cd22b allele (28). In addition, a 
recent study suggested that simultaneous interactions between B cells and target 
cells via BCR:autoantigen and CD22:CD22-ligand could be a mechanism to prevent 
activation of potentially autoreactive B cells (29). Thus, in Cd22a mice, lower basal 
expression levels and defective up-regulation of CD22 on potentially autoreactive B 
cells may favor the production of autoantibodies by reducing the BCR signaling 
threshold. In agreement, deficiency in CD22 expression, even at a heterozygous 
level, was able to promote the production of IgG anti-DNA autoantibodies in B6 mice 
(3, 20, 30). Interval mapping analysis for lupus susceptibility loci revealed that an 
NZW locus that peaked in the vicinity of the Cd22a gene was strongly linked with 
autoantibody production and lupus-like glomerulonephritis (31-33). More recent 
genetic analysis of B6 x (NZB x B6)F1 backcross mice also showed a strong linkage 
of autoantibody production with an interval encompassing the Cd22a gene (Kikuchi et 
al., manuscript in preparation). Clearly, further assessment of the functional 
capacities of the different allelic forms of CD22 and of the regulation of CD22 
expression will help to better understand the role of CD22 polymorphism in the 
development of B-cell mediated autoimmune diseases. 
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 Figure Legends 
 
FIGURE 1. Heterogeneous staining pattern of Cd22a B cells with CY34 mAb, but 
homogeneous staining pattern with NIM-R6 mAb. Spleen cells from 2 month-old 
DBA/2 (Cd22a), NZB (Cd22a), NZW (Cd22a) and B6 (Cd22b) mice were stained with 
either FITC-labeled CY34 or NIM-R6 anti-CD22 mAb. Histograms show 
representative results of CY34 and NIM-R6 staining on B220+ B cells obtained from 
three individual mice. Shaded histograms indicate the background staining of B cells 
with FITC-labeled control rat IgG conjugates, except for B6 mice, where shaded 
histograms indicate the staining of B cells from CD22-/- B6 mice with FITC-labeled 
CY34 or NIM-R6 anti-CD22 mAb. 
 
FIGURE 2. Altered activation-induced upregulation of surface CD22 on splenic B 
cells from Cd22a and Cd22b mice. 
(A) Limited up-regulation of CD22 recognized by CY34 mAb in LPS-stimulated B 
cells from Cd22a mice, as compared with Cd22b mice. Spleen cells from 2 month-old 
non-autoimmune DBA/2 (Cd22a) and B6 (Cd22b) mice were incubated with 25 µg/ml 
of LPS for 48 h, and the expression levels of CD22 were assessed using FITC-
labeled CY34 and NIM-R6 anti-CD22 mAb. Fluorescence intensities on stimulated 
(dark lines) and unstimulated (shaded) B220+ B cells are shown. Note that LPS 
stimulation failed to upregulate the expression level of CD22 detectable by CY34 
mAb on B cells from DBA/2 mice. Representative results of three independent 
experiments are shown. 
(B) CY34hi and CY34lo B-cell subsets in LPS-stimulated spleen cells from 
autoimmune-prone NZB (Cd22a) mice. Spleen cells from 2 month-old NZB mice were 
incubated with 25 µg/ml of LPS for 24 or 48 h, and expression levels of CD22 were 
assessed by using FITC-labeled CY34 and NIM-R6 anti-CD22 mAb. Fluorescence 
intensities on stimulated (dark lines) and unstimulated (shaded) B220+ B cells are 
shown. Note a marked expansion of the CY34lo B-cell population 48 h after 
stimulation with LPS. Representative results of three independent experiments are 
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 shown. 
 
FIGURE 3. Higher proportion of B cells bearing unmasked CD22 in Cd22a DBA/2 
and NZB mice than in Cd22b B6 mice. 
(A) Untreated splenocytes of the indicated mice were stained with PE-labeled anti-
B220 and FITC-labeled NeuGcα2,6Gal-SAAP. This probe detects unmasked CD22, 
which are not bound by endogenous ligands. On the right, histogram overlays of 
B220+ B cells for NeuGcα2,6Gal-SAAP staining are shown. Percentages represent 
the proportion of B220+ B cells which bind NeuGcα2,6Gal-SAAP (± 1SD). 
Significance by Student’s t-test: DBA/2 vs B6, p<0.05; NZB vs B6, p<0.001. 
(B) Splenocytes were pre-treated with sialidase to remove sialic acids from the 
cellular surface and then stained. While untreated cells of DBA/2 and NZB mice show 
a higher proportion of unmasked CD22 (both an increased population with high 
probe-binding, as well as more probe-binding to the entire B cell population), 
sialidase-treated cells of all 3 wild-type strains bind the NeuGcα2,6Gal-SAAP probe 
equally well. One typical out of three independent experiments is shown. 
 
FIGURE 4. Increased and prolonged Ca2+ mobilization in Cd22a B cells from DBA/2 
and NZB mice, compared to Cd22b B cells from B6 and BALB/c mice. Splenocytes of 
the indicated mice were stimulated with different concentrations of goat anti-kappa 
antibodies at the time point indicated by arrows. B cells were gated and the ratio of 
bound to unbound Indo-I, which is proportional to the intracellular Ca2+ concentration, 
was determined. Medians of all gated B cells are shown in the overlays. One typical 
out of three independent experiments is shown. 
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OBJECTIVES: 
Given the role of CD22 as a negative regulator of BCR signaling, its regulated 
expression is likely to determine thresholds for B cell responses to foreign and self antigens. 
Therefore, in the present study, we have conducted a systematic analysis of CD22 expression 
in both B1 and B2 cells in response to different activation stimuli, including anti-IgM mAb, 
anti-CD40 mAb, LPS and IL-4. 
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Differentially Regulated Expression and Function of CD22 in
Activated B-1 and B-2 Lymphocytes1
Fre´de´ric Lajaunias,* Lars Nitschke,† Thomas Moll,* Eduardo Martinez-Soria,*
Isabelle Semac,* Yves Chicheportiche,‡ R. Michael E. Parkhouse,§ and Shozo Izui2*
CD22 is a B cell-restricted transmembrane protein that apparently controls signal transduction thresholds initiated through the
B cell Ag receptor (BCR) in response to Ag. However, it is still poorly understood how the expression of CD22 is regulated in B
cells after their activation. Here we show that the expression levels of CD22 in conventional B-2 cells are markedly down-regulated
after cross-linking of BCR with anti-IgM mAb but are up-regulated after stimulation with LPS, anti-CD40 mAb, or IL-4. In
contrast, treatment with anti-IgM mAb barely modulated the expression levels of CD22 in CD5 B-1 cells, consistent with a weak
Ca2 response in anti-IgM-treated CD5 B-1 cells. Moreover, in CD22-deficient mice, anti-IgM treatment did not trigger en-
hanced Ca2 influx in CD5 B-1 cells, unlike CD22-deficient splenic B-2 cells, suggesting a relatively limited role of CD22 in BCR
signaling in B-1 cells. In contrast, CD22 levels were markedly down-regulated on wild-type B-1 cells in response to LPS or
unmethylated CpG-containing oligodeoxynucleotides. These data indicate that the expression and function of CD22 are differ-
entially regulated in B-1 and conventional B-2 cells, which are apparently implicated in innate and adaptive immunity,
respectively. The Journal of Immunology, 2002, 168: 6078–6083.
C D22, a B cell-specific member of the Ig superfamily withseven Ig-like domains, functions as a coreceptor for the Bcell Ag receptor (BCR)3 (1, 2) and is also an adhesion
receptor recognizing 2,6-linked sialic acid-bearing glycans on
target cells (3–5). First appearing on the surface of pre-B cells,
CD22 is fully expressed by mature IgMIgD B cells and finally
lost on terminally differentiated plasma cells (6, 7). Upon BCR
cross-linking, the cytoplasmic domain of CD22 is rapidly tyrosine-
phosphorylated, resulting in recruitment of a number of signaling
molecules, including tyrosine kinases (Lyn and Syk), phospho-
lipase C-1, and phosphatidylinositol 3-kinase (8, 9). However,
tyrosine-phosphorylated CD22 recruits and activates SH2 domain-
containing protein tyrosine phosphatase (SHP-1) (10), which neg-
atively regulates BCR signaling (11), and CD22-deficient splenic
B cells exhibit a greatly enhanced and prolonged Ca2 signal after
BCR stimulation (6, 12–14). These findings suggest that CD22
functions primarily as a negative regulator of BCR signaling by
controlling signal transduction threshold initiated through BCR in
B cells in response to Ag (1, 2).
B-1 cells differ from conventional peripheral B cells (B-2) by
their anatomical location, Ag specificity, surface markers, and their
potential for self-renewal (15). B-1 cells are the predominant B cell
population in the peritoneal cavity, but rare in spleen and lymph
nodes of adult mice (16). Abs secreted by B-1 cells are primarily
polyreactive IgM of low affinity and cross-react with a variety of
self Ags (17–20). Ab production by B-1 cells was induced by
multivalent T cell-independent bacterial polysaccharide Ags (18,
21, 22), whereas B-2 cells recognize a wide variety of Ags with
high affinity. B-1 cells are also distinguished from B-2 cells by
their unique surface markers such as CD5, Mac-1, and lower B220
expression. It has recently been shown that CD5 plays the role of
a negative regulator in BCR-mediated proliferation of B-1 cells
(23), likely by recruiting SHP-1 (24), but it is still not well defined
how CD22 is implicated in the activation of B-1 cells upon their
stimulation.
In view of the primary role of CD22 as a negative regulator of
BCR signaling, its regulated expression is likely to determine sig-
nal transduction thresholds initiated through BCR, and thus in turn
B cell responses to foreign Ags and self Ags. Although LPS or
CD40 ligation in the presence of IL-4 up-regulates the expression
of CD22 (7, 25), the control of CD22 expression in response to
BCR cross-linking is still poorly understood. Therefore, in the
present study, we have conducted a systematic analysis of CD22
expression in both B-1 and B-2 cells in response to different ac-
tivation stimuli. In addition, we compared the influence of CD22
on Ca2 signaling between these two subsets of B cells.
Materials and Methods
Mice
C57BL/6 (B6) mice were purchased from The Jackson Laboratory (Bar
Harbor, ME). CD22/ mice with a pure B6 background were developed
as described previously (6, 7). B6 mice deficient in FcRII (26) or bearing
the X-linked immunodeficiency (Xid) mutation (deficient in the Btk kinase)
(27) were respectively provided by Dr. J. Ravetch (Rockefeller University,
New York, NY) and Dr. A. Hugins (Geneva, Switzerland).
Cell culture
Spleen or peritoneal cavity cells (1–2  106) from a pool of three to five
mice at 2–4 mo of age were incubated in 1 ml of DMEM containing 10%
FCS in Falcon 24-well plates (BD Labware, Franklin Lakes, NJ) in the
presence of LPS, b7-6 rat anti-IgM (28), Bet-2 rat anti-IgM (29), F(ab)2
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goat anti-IgM (Jackson ImmunoResearch Laboratories, Hamburg, Germa-
ny), FGK45 rat anti-CD40 mAb (a gift from Dr. J. Andersson, Basel In-
stitute for Immunology, Basel, Switzerland), different cytokines or unmeth-
ylated CpG-containing oligodeoxynucleotides (CpG-ODN; 5-TCCATGA
CGTTCCTGACGTT-3; Microsynth, Balgach, Switzerland) for 24, 48, or
72 h. Optimal concentrations of each stimulator were predetermined by the
measurement of proliferative responses or up-regulation of MHC class II
molecules on B cells. Then, the expression of CD22, MHC class II, and
CD86 molecules on B cells was determined by flow cytometric analysis.
Polyclonal rat IgG purified from pooled rat serum by protein G column
chromatography was used as control. For some experiments, B cells from
peritoneal lavage cells were purified by complement-mediated T cell lysis
with anti-CD4 and anti-CD8 mAb and the removal of adherent macro-
phages by an overnight incubation on tissue culture plastic wells. After this
procedure, the remaining cells were 95% B lineage cells, as determined
by flow cytometric analysis. These cells were then stimulated with either
b7-6 anti-IgM mAb (25 g/ml) or F(ab)2 goat anti-IgM (10 g/ml).
Flow cytometric analysis
Flow cytometry was performed using two-color staining of lymphocytes
and analyzed with a FACSCalibur (BD Biosciences). The following Abs
and reagents were used: FITC-labeled NIM-R6 rat anti-CD22 (30); FITC-
or PE-conjugated RA3-6B2 rat anti-B220 (BD PharMingen, San Diego,
CA); FITC- or biotin-labeled Y-3P rat anti-I-A (BD PharMingen); FITC-
labeled anti-CD86 (BD PharMingen); PE- or biotin-labeled 53-7.3 rat anti-
CD5 (BD PharMingen); PE-labeled goat anti-IgM (BD PharMingen); and
PE-labeled streptavidin (BD PharMingen).
Northern blot analysis
Total RNA was prepared from spleen cells by RNeasy Mini kit (Qiagen,
Basel, Switzerland). RNA (5 g) was electrophoresed on a 1% agarose gel,
transferred to nylon membrane, and hybridized with a 32P-labeled murine
CD22 cDNA (30). The CD22 mRNA levels were quantified by determin-
ing the ratios of the intensities of CD22 mRNA bands and methylene
blue-stained 18S rRNA bands by densitometric analysis.
Measurement of intracellular Ca2 mobilization
Spleen or peritoneal cavity cells (107) from a pool of three to five CD22/
and wild-type B6 mice were loaded with 4.5 M Indo-1 (Molecular
Probes, Eugene, OR) and 0.003% pluronic F-127 in RPMI (pH 7.4) with
1% FCS for 45 min at 37°C. After Indo-1 loading, cells were stained on ice
with FITC-labeled anti-B220 and PE-labeled anti-CD5 mAb. Cells were
washed and IgM on the B cell surface was cross-linked at 37°C with 30
g/ml b7-6 anti-IgM mAb. Increases of intracellular Ca2 in splenic B-2
cells (gated B220CD5) or peritoneal B-1 cells (gated B220CD5)
were recorded in real time for 8 min with the use of a FACSVantage (BD
Biosciences). The anti-B220 or anti-CD5 pretreatment on ice had no effect
on Ca2 flux, as was checked by comparison to unstained B cells.
Results
Increased CD22 expression on splenic B cells after stimulation
with LPS, anti-CD40 mAb, or IL-4 but decreased expression on
B cells after activation with anti-IgM mAb
It has been previously shown that CD22 levels were increased after
stimulation of splenic B cells with LPS or CD40 ligand in the
presence of IL-4 (7, 25). To confirm this observation, splenic B
cells from 2-mo-old B6 mice were stimulated with either LPS or
anti-CD40 mAb at optimal concentrations of each stimulator (25
g/ml). Intensities of surface CD22 staining on B cells, as assessed
by flow cytometry using NIM-R6 anti-CD22 mAb, were signifi-
cantly increased on B220 B cells at 24 h and remained at high
levels after 48 and 72 h of stimulation with either LPS or rat
anti-CD40 mAb (Fig. 1 and 2), but not with polyclonal rat IgG
(data not shown). CD22 expression levels were also up-regulated
after the stimulation with IL-4 (500 U/ml) but were unchanged
after the treatment with IFN-, IL-1, IL-6, or TNF at any dose
tested (data not shown).
We next examined whether CD22 expression levels can be sim-
ilarly up-regulated after the activation of B cells by cross-linking
of BCR with anti-IgM mAb. When different concentrations (1, 5,
or 25 g/ml) of b7-6 anti-IgM mAb were tested, CD22 surface
expression was substantially diminished at 48 h and further down-
regulated at 72 h in a dose-dependent manner (Fig. 3A). At 72 h,
mean fluorescence intensity of CD22 in B cells stimulated with 25
g/ml anti-IgM mAb became 40% of that of control unstimu-
lated B cells (Fig. 2). The down-regulated expression of CD22 in
B cells stimulated with anti-IgM mAb contrasted markedly with an
up-regulated expression of I-A molecules on the same B cells (Fig.
3B). Essentially identical results were obtained with another anti-
IgM mAb, Bet-2, or F(ab)2 goat anti-IgM polyclonal Abs (data
not shown). An inhibitory role of FcRII for the expression of
CD22 after BCR cross-linking by anti-IgM mAb, possibly coen-
gaging FcRII, was excluded, because CD22 on FcRII-deficient
B cells was similarly down-regulated after the activation with anti-
IgM mAb (Fig. 2). To determine the possible role of BCR-medi-
ated CD22 internalization after anti-IgM treatment, the extent of
CD22 down-modulation was assessed on spleen B cells bearing
the Xid mutation, which are known to be defective in certain BCR-
triggered events, such as proliferation (31). Xid B cells internalized
BCR as efficiently as wild-type B cells, as judged by decreased
surface staining with polyclonal goat anti-IgM conjugates 1, 3, and
6 h after the incubation with anti-IgM mAb (data not shown). In
FIGURE 2. Modulation of CD22 surface expression on B-2 cells after
stimulation with LPS, anti- (-)CD40, or anti-IgM mAb. Spleen cells from
2-mo-old B6, FcRII-deficient B6 or Xid B6 mice were incubated with 25
g/ml LPS, anti-CD40, or b7-6 anti-IgM mAb for 72 h, and the expression
levels of CD22 were assessed by incubation with FITC-labeled rat anti-
CD22 mAb (NIM-R6) and PE-conjugated anti-B220 mAb. Results from
three to five individual mice, expressed as mean fluorescence intensities of
CD22 on B220 B cells, are shown. Background fluorescence intensity on
B220 cells was 3.0.
FIGURE 1. Increased surface expression of CD22 on B-2 cells after
stimulation with LPS or anti- (-)CD40 mAb. Spleen cells from 2-mo-old
B6 mice were incubated with 25 g/ml LPS or anti-CD40 mAb for 24, 48,
and 72 h, and the expression levels of CD22 were assessed by incubation
with FITC-labeled rat anti-CD22 mAb (NIM-R6) and PE-conjugated anti-
B220 mAb. Fluorescence intensities of CD22 on stimulated (dark lines)
and unstimulated (shaded) B220 B cells are shown.
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contrast, the level of CD22 was only poorly down-regulated in
anti-IgM-treated Xid B cells, as compared with wild-type B cells
(Fig. 2).
To determine whether the increased or decreased levels of CD22
on differently activated B cells were paralleled by the modulation
of CD22 mRNA abundance, the levels of mRNA coding for CD22
were assessed by Northern blot analysis on spleen cells after the
stimulation with either LPS, anti-CD40 or anti-IgM mAb. The
treatment with either LPS or anti-CD40 mAb led to an increase of
CD22 mRNA levels at 24 and 48 h, whereas anti-IgM mAb treat-
ment markedly down-regulated the level of CD22 mRNA at 24 h,
as compared with control cultures (Fig. 4).
Lack of CD22 modulation on B-1 cells treated with anti-IgM
mAb and failure to enhance Ca2 response in CD22-deficient
B-1 cells treated with anti-IgM mAb
Because it has been described that CD5 B-1 cells express CD22
at levels comparable with those of conventional B-2 cells (7, 32),
we determined whether CD22 expression can be modulated on B-1
cells following the stimulation with anti-IgM mAb in a way similar
to that of B-2 cells. When the expression levels of CD22 on peri-
toneal lavage cells from 3- to 4-mo-old B6 mice were analyzed
after 48 h of stimulation with anti-IgM mAb, no down-regulation
of CD22 expression was observed in CD5 B-1 cells (Fig. 5A). In
contrast, the stimulation with anti-IgM mAb substantially reduced
the levels of CD22 on the CD5 population of peritoneal B cells.
To determine whether other BCR-mediated signaling events are
blocked in B-1 cells, additional studies were conducted to evaluate
the expression of I-A and costimulatory CD86 molecules. As
shown in Fig. 5B, the treatment with anti-IgM mAb led to an
up-regulated expression of I-A and CD86 molecules in the CD5
population, but not in CD5 B-1 cells (Fig. 5B). Notably, essen-
tially identical results were obtained with F(ab)2 goat anti-IgM
polyclonal Abs (data not shown).
The lack of down-regulation of CD22 within the CD5 B-1
population after anti-IgM stimulation suggested a different role of
CD22, as compared with splenic B-2 cells. To address whether the
BCR signal on B-1 cells is indeed negatively regulated by CD22,
we stimulated peritoneal B-1 cells and splenic B-2 cells from
CD22-deficient and wild-type B6 mice with ant-IgM mAb and
measured intracellular Ca2 mobilization. Peritoneal wild-type
CD5 B-1 cells showed a weaker Ca2 response than splenic B-2
cells (Fig. 6), consistent with the lack of down-modulation of
CD22 and the lack of up-regulation of I-A and CD86 in this pop-
ulation. Significantly, the CD5 B-1 cells from CD22-deficient
mice only gave a weak Ca2 response, not higher than that seen in
the B-1 cells of wild-type mice. In contrast, a strongly enhanced
Ca2 response was observed in CD22-deficient B cells from the
spleen, as expected (6, 7).
Marked down-regulation of CD22 expression on peritoneal B-1
cells after stimulation with LPS or CpG-ODN
Because CD5 B-1 cells failed to modulate CD22 upon BCR
cross-linking by anti-IgM mAb, we determined whether LPS stim-
ulation could up-regulate CD22 expression, as observed in splenic
B cells. When peritoneal lavage cells of B6 mice were stimulated
with LPS, we observed a marked reduction of CD22 expression in
the majority of CD5 B-1 cells and no up-regulation in the rest of
the B-1 cells (Fig. 7). This was in contrasted with an increased
expression of CD22 on the CD5 population of peritoneal B cells
similar to that observed with splenic B cells.
A marked down-regulation of CD22 upon LPS stimulation
could be a unique feature of B-1 cells in response to nonspecific B
cell activators of microbial origin to promote immune responses
against bacterial Ags. This is in agreement with the fact that B-1
cells are involved in T-independent Ab responses against bacterial
polysaccharide Ags (22, 33). Therefore, we also tested the effect of
an immunostimulatory oligodeoxynucleotide containing an un-
methylated CpG motif present in bacterial, but not vertebrate DNA
FIGURE 3. Reduced surface expression of CD22 and enhanced expres-
sion of I-A on B-2 cells after stimulation with anti-IgM mAb. Spleen cells
from 2-mo-old B6 mice were incubated with 1, 5, or 25 g/ml of b7-6
anti-IgM mAb for 24, 48 and 72 h, and the expression levels of CD22 were
assessed by incubation with FITC-labeled rat anti-CD22 (NIM-R6) or
FITC-labeled rat anti-I-A (Y-3P) and PE-conjugated anti-B220 mAb. A,
Fluorescence intensities of CD22 on stimulated (dark lines) and unstimu-
lated (shaded) B220 B cells 24, 48, and 72 h after the incubation with the
indicated concentrations of anti-IgM mAb. B, Fluorescence intensities of
I-A on stimulated (dark lines) and unstimulated (shaded) B220 B cells
after 24 h of incubation with anti-IgM mAb.
FIGURE 4. Northern blot analysis of CD22 mRNA from B6 spleen
cells stimulated with LPS, anti- (-)CD40, or b7-6 anti-IgM mAb. At in-
dicated time points, cultures were harvested, and total RNA was isolated
and analyzed by Northern blotting. Positions of 18S and 28S rRNA are
indicated. The CD22 mRNA levels were quantified by determining the
ratios of the intensities of CD22 mRNA bands and methylene blue-stained
18S bands by densitometric analysis.
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(34) on the expression of CD22 on peritoneal B-1 cells and con-
ventional splenic B-2 cells. As for LPS stimulation, CD22 levels
were markedly reduced on nearly all CD5 B-1 cells after activa-
tion with CpG-ODN (Fig. 7). In addition, we observed a significant
down-regulation of CD5 on B-1 cells after the activation with
CpG-ODN, but not LPS (data not shown). In contrast, CpG-ODN
stimulation did not induce substantial changes in CD22 expression
levels on CD5 peritoneal and splenic B cells, although the levels
of CD22 expression became somehow more heterogeneous in
splenic B cells (Fig. 7).
Discussion
In the present study, we have assessed the modulation of CD22 in
activated B cells in relation to the B-1 and B-2 phenotypes. Our
results revealed several important points. First, the expression lev-
els of CD22 in conventional splenic B-2 cells were markedly
down-regulated after activation via the BCR by anti-IgM mAb, in
contrast to an up-regulated CD22 expression after activation with
LPS, anti-CD40 mAb, or IL-4. Second, CD22 expression was dif-
ferently regulated in CD5 B-1 cells after the activation with LPS
or anti-IgM mAb; their CD22 levels were hardly modulated after
stimulation with anti-IgM mAb but markedly down-regulated in
response to LPS. Strikingly, a similar down-regulation of CD22
was also observed in CD5 B-1 cells after stimulation with im-
munostimulatory CpG-ODN. Finally, anti-IgM treatment did not
trigger enhanced Ca2 influx in CD5 B-1 cells from CD22-de-
ficient mice, in contrast to a strongly increased Ca2 response of
CD22-deficient B-2 cells from the spleen compared with wild-type
B-2 cells. Our results thus demonstrate that the expression and
function of CD22 is differentially regulated in B-1 and conven-
tional B-2 cells.
The first significant observation in the present study is the
marked down-regulation of CD22 in conventional B-2 cells after
cross-linking of BCR with anti-IgM mAb. This is somehow sur-
prising because other B cell stimulators, such as LPS, anti-CD40
mAb, or IL-4, uniformly up-regulated the expression levels of
CD22 in these cells. This difference apparently resulted from a
differential regulation of the expression levels of CD22 mRNA
after BCR-mediated and -independent stimulation of B-2 cells. A
rapid loss of CD22 mRNA, peaking at 24 h after anti-IgM treat-
ment, likely accounts for the down-modulation of CD22 expres-
sion on B-2 cells. The down-regulation of CD22 in anti-IgM mAb-
treated B-2 cells could in part be related to the cointernalization of
CD22 with BCR during culture, because endocytosed CD22 ap-
pears to be rapidly degraded (35). However, it should be stressed
that only a small fraction (5%) of total CD22 apparently asso-
ciates with BCR (36, 37). Moreover, we observed limited CD22
down-modulation on anti-IgM-treated Xid B cells defective in cer-
tain BCR-triggered signaling, but not BCR internalization, which
strongly argues against the idea that BCR-mediated CD22 coint-
ernalization plays a major role in anti-IgM-induced CD22 down-
regulation on B-2 cells.
The observed specific and selective down-regulation of CD22
expression in B-2 cells after cross-linking of the BCR may be
relevant for the development and regulation of immune responses
to foreign Ags and self Ags. It is now well established that CD22
FIGURE 5. Lack of modulation of CD22, I-A, and CD86 on CD5 B-1
cells after stimulation with anti-IgM mAb. A, Peritoneal lavage cells from
3- to 4 mo-old B6 mice were incubated with 25 g/ml b7-6 anti-IgM mAb
for 48 h, and the expression levels of CD22 were assessed by FITC-labeled
rat anti-CD22 mAb (NIM-R6) and biotinylated anti-CD5 mAb. Fluores-
cence intensities of CD22 on stimulated (dark lines) and unstimulated
(shaded) CD5 and CD5 B cells are shown. Representative results of
three separate experiments are shown. B, Peritoneal B cells purified from
3- to 4-mo-old B6 mice were incubated with 25 g/ml b7-6 anti-IgM mAb
for 24 h, and the expression levels of I-A and CD86 were assessed by using
biotinylated anti-CD5 mAb and FITC-labeled anti-I-A or anti-CD86 mAb.
Fluorescence intensities of I-A and CD86 on stimulated (dark lines) and
unstimulated (shaded) CD5 and CD5 B cells, representative of two sep-
arate experiments, are shown. The analysis of CD22 in these experiments
using purified B cells also confirmed the lack of CD22 modulation on
CD5 B-1 cells treated with anti-IgM mAb (data not shown).
FIGURE 6. Lack of enhancement of Ca2 response in CD22-deficient
B-1 cells treated with anti-IgM mAb. Cells from spleen or peritoneal cavity
were stimulated with 30 g/ml b7-6 anti-IgM mAb for 8 min. Intracellular
Ca2 concentrations are represented as the ratio of bound to unbound
Indo-1. Color density blots indicate the percentage of cells with certain
Ca2 concentrations at a given time point. The shown diagrams are for
B220 cells in the spleen and for CD5B220 B-1 cells in the peritoneal
cavity (PC B-1). Pretreatment with anti-CD5 and anti-B220 Abs on ice had
no effect on Ca2, as controlled with unstained cells. Arrows, Addition of
anti-IgM mAb. CD5 B-1 cells of CD22-deficient mice showed no en-
hanced Ca2 flux after anti-IgM stimulation, in contrast to the enhanced
Ca2 response in CD22 -deficient splenic B-2 cells.
6081The Journal of Immunology
113
becomes rapidly tyrosine phosphorylated on its cytoplasmic tail
upon cross-linking of BCR and recruits SHP-1, thereby negatively
regulating BCR signaling (1, 2). Thus, it is conceivable that the
down-regulation of CD22 in B-2 cells after BCR cross-linking
could result in a diminished number of CD22 molecules associated
with recycled or newly generated BCR. Consequently, BCR-me-
diated signaling and hence B cell responses to Ag could be pro-
moted. In contrast, the up-regulated expression of CD22 in B cells
activated by BCR-independent stimulators, such as LPS, anti-
CD40 mAb or IL-4, may help prevent unwanted activation of B
cells bearing BCR with low affinity binding or with autoreactivity,
emerging as a result of somatic hypermutations during immune
responses. Thus, dysregulated expression of CD22 could lead to
excessive activation of B cells and autoantibody production, as in
the case of mice deficient in CD22 (12, 25, 38). Genome wide
mapping analysis for lupus susceptibility loci in autoimmune-
prone New Zealand White (NZW) mice revealed that an interval
containing the Cd22 gene on chromosome 7 is linked with auto-
antibody production and lupus-like glomerulonephritis (39–41).
More recently, after the activation of B cells with LPS in the pres-
ence of IL-4, CD22 expression was less up-regulated in NZW mice
bearing the Cd22a allele, as compared with B6 mice bearing the
Cd22b allele (25). This is apparently related to the synthesis of
abnormally processed CD22 mRNA, in addition to the wild-type
transcripts, as a result of a short interspersed nucleotide element
insertion in the second intron of the Cd22a gene. Thus, defective
up-regulation of CD22 on potentially autoreactive B cells stimu-
lated nonspecifically during immune responses may favor the pro-
duction of autoantibodies in lupus-prone mice bearing the Cd22a
allele, such as (New Zealand Black  NZW)F1 hybrid mice.
In contrast to conventional B-2 cells, the expression of CD22 is
controlled differently in CD5 B-1 cells, which are involved in the
production of natural and pathogenic autoantibodies (18–20, 42)
and in the T cell-independent Ab responses against bacterial poly-
saccharide Ags (22, 33). The stimulation with anti-IgM mAb
barely modulated CD22 expression levels in B-1 cells. This may in
part be related to the expression of CD5 on these cells, which
negatively controls BCR-mediated signaling (23), likely by re-
cruitment of SHP-1 (24, 43). This is consistent with the finding
that the anti-IgM treatment led to weak Ca2 mobilization and
failed to up-regulate the expression level of I-A and CD86 in B-1
cells. In addition, we observed that the early BCR signaling ap-
pears to be poorly regulated by CD22 in B-1 cells, because CD5
B-1 cells lacking CD22 failed to exhibit enhanced Ca2 flux re-
sponses, unlike conventional splenic B-2 cells. This markedly con-
trasted with the finding that B-1 cells of CD5-deficient mice ex-
hibited a more sustained Ca2 flux and were able to undergo
proliferation after IgM stimulation, compared with control B-1
cells (23). These data suggest that CD5 functions as the major
negative regulator of BCR signaling in B-1 cells.
Furthermore, we observed an expansion of the majority of
CD5 B-1 cells with markedly down-regulated CD22 expression
after the stimulation with LPS. Interestingly, immunostimulatory
CpG-ODN, the sequence of which is specifically present in bac-
terial DNA, also markedly reduced the expression levels of CD22
on nearly the entire population of CD5 B-1 cells. Because we
have not performed the experiments with purified B-1 cells, it re-
mains to be determined whether the down-regulation of CD22 was
due to a direct effect of LPS or CpG-ODN on B-1 cells or sec-
ondary to cytokines secreted by macrophages activated with LPS
or CpG-ODN. Although the negative role of CD22 for BCR sig-
naling in CD5 B-1 cells is apparently less prominent than in
conventional B-2 cells, one cannot exclude the possibility that the
observed marked down-regulation of CD22 by LPS or CpG-ODN
could be a mechanism to reduce BCR signaling thresholds in B-1
cells expressing CD5. In this regard, it should be stressed that the
level of CD5 was also significantly down-regulated in B-1 cells
treated with CpG-ODN, thereby further promoting the activation
of B-1 cells specific for bacterial Ags.
In conclusion, we have demonstrated that the expression of
CD22 is differentially regulated after BCR-mediated and -indepen-
dent activation in B-1 and B-2 cells, which are apparently impli-
cated in innate and adaptive immunity, respectively (17, 44). In
addition, our data suggest that CD5 is a more potent negative reg-
ulator of BCR signaling than CD22 in B-1 cells, contrary to con-
ventional B-2 cells. In view of the potential role of CD22 in the
development of lupus-like autoimmune diseases (12, 25, 38, 41),
further assessment of the regulation of CD22 expression in mice
bearing different allelic forms of CD22 should help understand a pos-
sible role of CD22 polymorphism in the development of autoimmune
and other diseases in which B cell function is dysregulated.
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FIGURE 7. Differential regulation of CD22 on CD5 B-1 and CD5 B
cells after stimulation with LPS or immunostimulatory CpG-ODN. Peri-
toneal lavage and spleen cells from 3- to 4-mo-old B6 mice were incubated
with 25 g/ml LPS or 3 g/ml CpG-ODN for 48 h, and the expression
levels of CD22 were assessed by FITC-labeled rat anti-CD22 mAb (NIM-
R6), followed by biotinylated anti-CD5 mAb and PE-streptavidin. Fluo-
rescence intensities of CD22 on CpG-ODN-stimulated (thick lines), LPS-
stimulated (thin lines) and unstimulated (shaded) CD5 and CD5 B cells
in the peritoneal cavity (PC) and conventional B-2 cells from spleen (SPC),
representative of three separate experiments, are shown.
6082 MODULATION OF CD22 IN ACTIVATED B LYMPHOCYTES
114
References
1. Cyster, J. G., and C. C. Goodnow. 1997. Tuning antigen receptor signaling by
CD22: integrating cues from antigens and the microenvironment. Immunity
6:509.
2. Tedder, T. F., J. Tuscano, S. Sato, and J. H. Kehrl. 1997. CD22, a B lymphocyte-
specific adhesion molecule that regulates antigen receptor signaling. Annu. Rev.
Immunol. 15:481.
3. Stamenkovic, I., D. Sgroi, A. Aruffo, S. M. Sy, and T. Anderson. 1991. The B
lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen
CD45RO on T cells and 2–6 sialyltransferase, CD75, on B cells. Cell 66:1133.
4. Law, C. L., A. Aruffo, K. A. Chandran, R. T. Doty, and E. A. Clark. 1995. Ig
domains 1 and 2 of murine CD22 constitute the ligand-binding domain and bind
multiple sialylated ligands expressed on B and T cells. J. Immunol. 155:3368.
5. Van der Merwe, P. A., P. R. Crocker, M. Vinson, A. N. Barclay, R. Schauer, and
S. Kelm. 1996. Localization of the putative sialic acid-binding site on the im-
munoglobulin superfamily cell-surface molecule CD22. J. Biol. Chem. 271:9273.
6. Nitschke, L., R. Carsetti, B. Ocker, G. Ko¨hler, and M. C. Lamers. 1997. CD22 is
a negative regulator of B-cell receptor signaling. Curr. Biol. 7:133.
7. Erickson, L. D., L. T. Tygrett, S. K. Bhatia, K. H. Grabstein, and
T. J. Waldschmidt. 1996. Differential expression of CD22 (Lyb8) on murine B
cells. Int. Immunol. 8:1121.
8. Law, C. L., S. P. Sidorenko, K. A. Chandran, Z. Zhao, S. H. Shen, E. H. Fischer,
and E. A. Clark. 1996. CD22 associates with protein tyrosine phosphatase 1C,
Syk and phospholipase C-1 upon B cell activation. J. Exp. Med. 183:547.
9. Tuscano, J. M., P. Engel, T. F. Tedder, A. Agarwal, and J. H. Kehrl. 1996.
Involvement of p72syk, p53/56lyn kinase and phosphatidyl inositol-3 kinase in
signal transduction via human B lymphocyte antigen CD22. Eur. J. Immunol.
26:1246.
10. Doody, G. M., L. B. Justement, C. C. Delibrias, R. J. Matthews, J. Lin,
M. L. Thomas, and D. T. Fearon. 1995. A role in B cell activation for CD22 and
the protein tyrosine phosphatase SHP. Science 269:242.
11. Cyster, J. G., and C. C. Goodnow. 1995. Protein tyrosine phosphatase 1C neg-
atively regulates antigen receptor signaling in B lymphocytes and determines
thresholds for negative selection. Immunity 2:13.
12. O’Keefe, T. L., G. T. Williams, S. L. Davies, and M. S. Neuberger. 1996. Hy-
perresponsive B cells in CD22-deficient mice. Science 274:798.
13. Sato, S., A. S. Miller, M. Inaoki, C. B. Bock, P. J. Jansen, M. L. K. Tang, and
T. F. Tedder. 1996. CD22 is both a positive and negative regulator of B lym-
phocyte antigen receptor signal transduction: altered signaling in CD22-deficient
mice. Immunity 5:551.
14. Otipoby, K. L., K. B. Andersson, K. E. Dravest, S. J. Klaus, A. G. Farr,
J. D. Kerner, R. M. Perlmutter, C. L. Law, and E. A. Clark. 1996. CD22 regulates
thymus-independent responses and the lifespan of B cells. Nature 384:634.
15. Hayakawa, K., R. R. Hardy, D. R. Parks, and L. A. Herzenberg. 1983. The “LY-1
B” cell subpopulation in normal, immunodefective, and autoimmune mice.
J. Exp. Med. 157:202.
16. Hayakawa, K., R. R. Hardy, and L. A. Herzenberg. 1986. Peritoneal Ly-1 B cells:
genetic control, autoantibody production, increased  light chain expression. Eur.
J. Immunol. 16:450.
17. Baumgarth, N., O. C. Herman, G. C. Jager, L. A. Herzenberg, and
L. A. Herzenberg. 1999. Innate and acquired immunities to influenza virus are
provided by distinct B cells. Proc. Natl. Acad. Sci. USA 96:2250.
18. Hayakawa, K., R. R. Hardy, M. Honda, L. A. Herzenberg, and A. D. Steinberg.
1984. Ly-1 B cells: functionally distinct lymphocytes that secrete IgM autoanti-
bodies. Proc. Natl. Acad. Sci. USA 81:2494.
19. Hardy, R. R., K. Hayakawa, M. Shimizu, K. Yamasaki, and T. Kishimoto. 1987.
Rheumatoid factor secretion from human Leu-1 B cells. Science 236:81.
20. Casali, P., S. E. Barastero, M. Nakamura, G. Inghirami, and A. L. Notkins. 1987.
Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to
Leu-1 B cell subset. Science 236:77.
21. Fo¨rster, I., and K. Rajewsky. 1987. Expansion and functional activity of Ly-1
B cells upon transfer of peritoneal cells into allotype-congenic, newborn mice.
Eur. J. Immunol. 17:521.
22. Su, S. D., M. W. Ward, M. A. Apicella, and R. E. Ward. 1991. The primary B
cell response to the O/core region of bacterial lipopolysaccharide is restricted to
the Ly-1 lineage. J. Immunol. 146:327.
23. Bikah, G., J. Carey, J. R. Ciallella, A. Tarakhovsky, and S. Bondada. 1996.
CD5-mediated negative regulation of antigen receptor-induced growth signals in
B-1 B cells. Science 274:1906.
24. Sen, G., G. Bikah, C. Venkataraman, and S. Bondada. 1999. Negative regulation
of antigen receptor-mediated signaling by constitutive association of CD5 with
the SHP-1 protein tyrosine phosphatase in B-1 cells. Eur. J. Immunol. 29:3319.
25. Mary, C., C. Laporte, D. Parzy, M. L. Santiago, F. Stefani, F. Lajaunias,
R. M. E. Parkhouse, T. L. O’Keefe, M. S. Neuberger, S. Izui, and L. Reninger.
2000. Dysregulated expression of the Cd22 gene as a result of a short interspersed
nucleotide element insertion in Cd22a lupus-prone mice. J. Immunol. 165:2987.
26. Bolland, S., and J. V. Ravetch. 2000. Spontaneous autoimmune disease in
FcRIIB-deficient mice results from strain-specific epistasis. Immunity 13:277.
27. Thomas, J. D., P. Sideras, C. I. E. Smith, I. Vorechovsky, V. Chapman, and
W. E. Paul. 1993. Colocalization of X-linked agammaglobulinemia and X-linked
immunodeficiency genes. Science 261:355.
28. Julius, M. H., C. H. Heusser, and K. U. Hartmann. 1984. Induction of resting B
cells to DNA synthesis by soluble monoclonal anti-immunoglobulin. Eur. J. Im-
munol. 14:753.
29. Kung, J. T., S. O. Sharrow, D. G. Sieckmann, R. Lieberman, and W. E. Paul.
1981. A mouse IgM allotype determinant (Igh-6.5) recognized by a monoclonal
rat antibody. J. Immunol. 127:873.
30. Torres, R. M., C. L. Law, L. Santos-Argumedo, P. A. Kirkham, K. Grabstein,
R. M. E. Parkhouse, and E. A. Clark. 1992. Identification and characterization of
the murine homologue of CD22, a B lymphocyte-restricted adhesion molecule.
J. Immunol. 149:2641.
31. Rigley, K. P., M. M. Harnett, R. J. Phillips, and G. B. Klaus. 1989. Analysis of
signaling via surface immunoglobulin receptors on B cells from CBA/N mice.
Eur. J. Immunol. 19:2081.
32. Andersson, K. B., K. E. Draves, D. M. Magaletti, S. Fujioka, K. L. Holmes,
C. L. Law, and E. A. Clark. 1996. Charcterization of the expression and gene
promoter of CD22 in murine B cells. Eur. J. Immunol. 26:3170.
33. Pecquet, S. S., C. Ehrat, and P. B. Ernst. 1992. Enhancement of mucosal antibody
responses to Salmonella typhimurium and the microbial hapten phosphorylcho-
line in mice with X-linked immunodeficiency by B-cell precursors from the peri-
toneal cavity. Infect. Immun. 60:503.
34. Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale,
G. A. Koretzky, and D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger
direct B-cell activation. Nature 374:546.
35. Shan, D., and O. W. Press. 1995. Constitutive endocytosis and degradation of
CD22 by human B cells. J. Immunol. 154:4466.
36. Peaker, C. J., and M. S. Neuberger. 1993. Association of CD22 with the B cell
antigen receptor. Eur. J. Immunol. 23:1358.
37. Leprince, C., K. E. Draves, R. L. Geahlen, J. A. Ledbetter, and E. A. Clark. 1993.
CD22 associates with the human surface IgM-B-cell antigen receptor complex.
Proc. Natl. Acad. Sci. USA 90:3236.
38. O’Keefe, T. L., G. T. Williams, F. D. Batista, and M. S. Neuberger. 1999. De-
ficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose
to development of high affinity autoantibodies. J. Exp. Med. 189:1307.
39. Morel, L., U. H. Rudofsky, J. A. Longmate, J. Schiffenbauer, and
E. K. Wakeland. 1994. Polygenic control of susceptibility to murine systemic
lupus erythematosus. Immunity 1:219.
40. Kono, D. H., R. W. Burlingame, D. G. Owens, A. Kuramochi, R. S. Balderas,
D. Balomenos, and A. N. Theofilopoulos. 1994. Lupus susceptibility loci in New
Zealand mice. Proc. Natl. Acad. Sci. USA 91:10168.
41. Santiago, M. L., C. Mary, D. Parzy, C. Jacquet, X. Montagutelli,
R. M. E. Parkhouse, R. Lemoine, S. Izui, and L. Reininger. 1998. Linkage of a
major quantitative trait locus to Yaa gene-induced lupus-like nephritis in
(NZW  C57BL/6)F1 mice. Eur. J. Immunol. 28:4257.
42. Murakami, M., T. Tsubata, M. Okamoto, A. Shimizu, S. Kumagai, H. Imura, and
T. Honjo. 1992. Antigen-induced apoptotic death of Ly-1 B cells responsible for
autoimmune disease in transgenic mice. Nature 357:77.
43. Hippen, K. L., L. E. Tze, and T. W. Behrens. 2000. CD5 maintains tolerance in
anergic B cells. J. Exp. Med. 191:883.
44. Baumgarth, N., O. C. Herman, G. C. Jager, L. E. Brown, L. A. Herzenberg, and
J. Chen. 2000. B-1 and B-2 cell-derived IgM antibodies are nonredundant com-
ponents of the protective response to influenza virus infection. J. Exp. Med.
192:271.
6083The Journal of Immunology
115
 
 
 
 
 
 
 
 
 
 
 
IV) CONCLUDING REMARKS 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV) CONCLUDING REMARKS 
 
Systemic lupus erythematosus is a complex polygenic disease implying loss of self 
tolerance and B-cell hyperactivity (5). While multiple susceptibility loci disseminated 
throughout the whole genome have been identified and are associated with defined 
autoimmune traits (40), there exist also single mutations that are known to be critical for the 
development of an accelerated lupus-like disease in mouse models, like lpr in MRL mice or 
Yaa in BXSB males (214, 218). The development of B cells from the pro-B cell stage to 
mature B cells and plasma cells has been described in detail and specialized B-cell 
subpopulations, like B1, MZ or follicular B cells, have been identified (244, 255, 445). 
Signaling through the BCR complex, which contains surface IgM conferring a clonal 
specificity to the B cell, is important throughout B-cell development and for antibody 
production in adaptive immune responses (249). As autoreactive B cells may arise during the 
course of affinity maturation, a tight control of BCR signaling is indispensable for the 
prevention of B cell-mediated autoimmunity (323) and numerous inhibitory receptors have 
been identified in B cells (302, 446, 447).  
We have previously shown that the Yaa mutation initially isolated from male BXSB 
mice, which develop an accelerated form of lupus, could induce autoimmune phenotypes in 
predisposed but usually asymptomatic mice or accelerate the development of SLE in lupus-
prone strains (214, 215). However, the precise molecular mechanism of the Yaa defect has 
remained elusive. It has been demonstrated that Yaa is expressed in B, but not in T cells (239, 
240), and that Yaa can abrogate the protection from disease by non-permissive MHC 
haplotypes (176). A hypothesis integrating these observations proposed that Yaa could favor 
cognate interactions between B and T cells, e.g. through expression of an adhesion molecule 
on B cells. In contrast with this, our recent results presented in this report support a model in 
which the Yaa mutation increases positive signaling through the BCR complex, which might 
be of particular importance in low-affinity, autoreactive B cells. As a consequence, Yaa-
mediated dysregulation of B-cell signaling would result in alterations of B-cell homeostasis 
and autoimmunity. Nevertheless, it is important to keep in mind that the BCR is tightly 
controlled by multiple inhibitory coreceptors present on B cells (302, 446). Autoimmunity 
could therefore be favored not only by directly increasing positive BCR signaling, but also by 
deficiencies in these regulatory mechanisms. 
One of the best-studied inhibitory receptors on B cells is FcγRIIB, which belongs to the 
family of Fc receptors that recognize the Fc portion of monomeric or complexed Ig (349). The 
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low-affinity binding feature of FcγRIIB and the identification of its regulatory capacity on 
BCR signaling due to recruitment of the phosphatase SHIP suggested a role for FcγRIIB in 
the termination of antibody responses in B cell clones specific for antigen already contained 
in IC (348). Additionally, a role was proposed for FcγRIIB in the maintenance of peripheral 
tolerance of autoreactive B cells generated as a result of somatic mutations in the GC during 
immune responses against foreign microbial pathogens (340). Moreover, genetic analysis 
revealed that certain autoimmune-prone mouse strains carried a polymorphic haplotype of the 
Fcgr2 gene leading to decreased expression of FcγRIIB following B-cell activation (386, 
387). Collectively, these data suggested that deficient or mutant FcγRIIB could lead to 
impaired regulation of BCR signaling, in particular in potentially autoreactive B cells, and 
favor the development of autoimmunity (321, 323). Indeed, FcγRIIB-deficient B6 mice 
generated by homologous recombination spontaneously developed an autoimmune syndrome 
reminiscent of SLE, including anti-nuclear autoantibodies and GN (48, 49). However, further 
analysis revealed that additional genetic contributions from a permissive background were 
needed for the development of full-blown disease, thereby underlining that FcγRIIB is one, 
but not the only lupus-susceptibility gene (395). 
Another negative regulator of BCR signaling that has been extensively studied is the 
CD22 molecule. CD22 is a member of the Siglec family of adhesion molecules, which 
recognize α2-6 linked sialic acids in the sugar side chains of glycoproteins, and is endowed 
with regulatory signaling capacities due to its intracellular domain that can recruit the 
phosphatase SHP-1 (241, 396). Inhibition of B-cell signaling by CD22 was evident in 
different CD22-deficient mice, which displayed increased and prolonged intracellular Ca2+ 
flow after BCR stimulation (46, 47, 322, 415, 437), suggesting that CD22 might be implicated 
in the fine-tuning of the BCR signal rather than in its termination. This point of view was also 
supported by the analysis of the ligand-binding activities of CD22: Through interaction with 
CD22L expressed on other immune cells (especially T cells), CD22 might retain B cells in a 
lymphoid compartment that is appropriate for B cell activation, like splenic follicles. Through 
this mechanism, information on the microenvironment of B cells, including possible cell-cell 
interactions, would be transduced by CD22 and influence the threshold for B-cell activation 
(408, 436). Besides promoting cell-cell interactions (binding in trans), CD22 can also bind in 
cis to sufficiently sialylated CD22L, which include IgM of BCR or CD22 itself, present on 
the same B-cell surface (424). Control of cis-binding, e.g. through regulation of α2-6 
sialyltransferase, may present a means to modulate the balance between bound, “masked” 
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CD22 and free, “unmasked” CD22 that is available for interactions in trans (433). 
Collectively, these data suggest that CD22 integrates information on the environment and 
state of B cells and accordingly fine-tunes the intensity of BCR signaling. Notably, one 
CD22-deficient mouse carrying a mixed genetic background of B6 and 129 displayed 
significant lupus-like autoimmune manifestations (45, 46). In addition, CD22-
haploinsufficient mice were able to produce IgG anti-DNA autoantibodies in the presence of 
the Yaa mutation (418). This clearly indicates that a partial deficiency of CD22 can 
predispose to the development of SLE in combination with further lupus-susceptibility alleles. 
 
A) The Yaa mutation modifies B cell maturation and potentiates humoral autoimmune 
responses 
Given that it was difficult to directly demonstrate implication of the Yaa defect in the 
cognate interaction between B and T cells, we decided to redirect our research towards a 
putative B-cell autonomous mechanism of Yaa in the activation of B cells. More concretely, 
we have explored whether the expression of the Yaa mutation affected the development and 
activation of B cells carrying transgenes coding either for anti-RBC or anti-DNA IgM 
autoantibodies (Moll et al., 2005). The choice of these two autoreactive specificities seemed 
promising because both are present in a number of autoimmune-prone mouse strains, and 
previous publications had shown that the activation of peritoneal B1 cells in 4C8 transgenic 
B6 mice triggered a powerful autoimmune response culminating in AIHA (230, 231). In 
contrast to this, mice carrying the Sp6 IgM specific for DNA, which – like RBC – should be a 
ubiquitous antigen during tolerance induction, failed to mount lupus-like anti-DNA responses 
due to induction of anergy in transgenic B cells (233). 
We found that the presence of the Yaa mutation did not increase anti-DNA production 
in Sp6 trangenic mice, suggesting that Yaa cannot override anergy in these B cells. 
Interestingly, non-transgenic B6.Yaa mice did not spontaneously develop anti-DNA 
autoantibodies either, but displayed an autoimmune response against chromatin. These results 
strongly suggesting that the effect of Yaa depends heavily on the molecular nature of the 
autoantigen available for the interaction with BCR on autoreactive B cells. It is possible that 
the presence of multiple autoantigenic epitopes on the surface of apoptotic cells could 
facilitate the direct activation of autoreactive B cells expressing the Yaa mutation. This idea is 
consistent with the finding that Yaa promotes the spontaneous activation of autoreactive B 
cells with a specificity to cell surface antigens, such as those present on RBC. 
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The most striking feature in our study was the rapid development of fatal AIHA in 
4C8.Yaa mice. Analysis of age-matched non-transgenic Yaa controls showed that 
autoimmune responses to RBC were inclined to amplification by Yaa, and increased 
spontaneous IgM secretion in these mice could be exclusively assigned to B2 cells in the 
spleen, but not to B1 cells in the peritoneal cavity. Furthermore, we ruled out the possibility 
that 4C8 IgM production was due to Yaa-mediated escape from tolerance induction, because 
in 4C8.Yaa mice the developmental block in the bone marrow was conserved and overall B 
cell numbers in different peripheral lymphoid compartments were as low as in non-Yaa 
transgenic controls. The latter point again confirmed the long-standing postulate that Yaa does 
not interfere with apoptotic pathways active in tolerance induction (217). Our results 
prompted us to conclude that in 4C8.Yaa mice a limited number of splenic B cells, which had 
reached the organ due to “normal” leakage of central tolerance induction, had been efficiently 
activated by the action of Yaa early in life and were at the origin of AIHA. This early 
activation of autoreactive B cells is clearly dependent on the antigen specificity, and thus on 
signaling through the BCR. 
These results shed a new light on the conclusions that have been drawn from our 
additional study on the effect of the Yaa mutation on the MZ B-cell population (320). In this 
study, we have demonstrated that 2-months old BXSB and B6.Yaa males, as well as diseased 
BXSB mice, have neatly decreased levels of MZ B cells in the spleen. Notably, this 
phenotype paralleled an increased IgM secretion and accumulation of plasma cells in spleen. 
One attractive hypothesis is that the Yaa mutation promotes a rapid and selective activation of 
MZ B cells, thus resulting in the preferential depletion of this subset of B cells, which are 
efficiently triggered by blood-borne T-independent antigens. This idea can explain why 
almost normal levels of MZ B cells were restored in Sp6.Yaa mice, as Sp6 anti-DNA 
transgenic B cell are apparently anergic in the periphery. This is further consistent with the 
fact that anti-HEL transgenic mice also have increased numbers of MZ B cells, irrespectively 
of the expression of the Yaa mutation (unpublished observation). Increased BCR signaling 
likely plays a role in the diminution of MZ B cells observed in B6.Yaa and BXSB males, and 
this is in agreement with previously published observations on the importance of BCR signal 
strength in MZ B cell development (270, 448). The significance of the possible activation of 
MZ B cells by Yaa in the accelerated development of lupus-like autoimmune syndrome 
remains to be defined. However, one attractive hypothesis is that expression of the Yaa 
mutation induces a direct activation of potentially autoreactive MZ B-cells. A fraction of them 
then migrates into B-cell follicles to become efficient APC, thereby promoting subsequent T-
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cell dependent autoimmune responses. It would be of interest to determine whether the 
selective deletion of MZ B cells could downregulate the development of lupus-like 
autoimmune disease. 
 
B) Differential roles for apoptosis and FcγRIIB in the regulation of rheumatoid factor and 
anti-DNA responses 
IgG IC and DNA are biochemically different autoantigens, which are both implicated in 
B-cell mediated autoimmune responses (in RA and SLE, respectively). A prerequisite for 
autoantibody responses against self constituents is the activation of autoreactive B cells via 
their BCR. In non-autoimmune subjects, autoreactive B cells are prevented from harming the 
host through control mechanisms that can roughly be assigned to central or peripheral 
tolerance induction. One important mechanism in central tolerance is the induction of 
apoptosis, while inhibitory coreceptors on B cells are critically involved in peripheral 
tolerance (71, 302). 
One crucial inhibitory receptor on B cells is FcγRIIB, which is supposed to be able to 
terminate all antibody responses (including e.g. against nuclear antigens), and accordingly 
spontaneous production of anti-DNA autoantibodies has been reported in FcγRIIB-deficient 
B6 mice (48, 321). Our analysis in these mice revealed that FcγRIIB controlled not only anti-
DNA but also RF responses in an H2 haplotype-dependent manner (Moll et al., 2004), and 
this was in agreement with previous results on strain-specific contributions to autoimmune 
responses. In this respect, it is tempting to speculate that the control of RF responses by 
FcγRIIB is due to its direct recognition of IgG contained in IC. The power of FcγRIIB-
mediated control of B-cell activation was illustrated through the introduction of the Yaa 
mutation, which supposedly would potentiate BCR signaling after antigen recognition: 
FcγRIIB-sufficient mice with or without Yaa were negative for RF production, while in 
FcγRIIB-haploinsufficient mice (i.e. heterozygous level of FcγRIIB expression) Yaa could 
promote this autoimmune response, as well as anti-DNA production. This also suggested that 
the Yaa defect contributes to B-cell activation by potentiating somehow insufficiently 
controlled BCR signaling. Additionally, we showed that C3-opsonization apparently plays a 
significant role in anti-DNA but not in RF responses. This indicates that each autoimmune 
response can be differentially regulated by distinct BCR coreceptors, emphasizing again the 
importance of the molecular features of the autoantigens in the development of spontaneous 
autoantibody responses in SLE. 
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We have also analyzed the role of apoptosis in prevention of anti-DNA and RF 
autoimmune responses by introducing an anti-apoptotic Bcl-2 transgene, in concert with the 
Yaa mutation (75). This study revealed that deficient apoptosis was sufficient to induce anti-
DNA autoantibody production, but that RF responses needed additional genetic contribution, 
e.g. from the NZW genome. Since the Fcgr2 allele of NZW mice appears not to be defective, 
as compared with that of the NZB strain (385, 387), NZW-derived genetic factors other than 
Fcgr2 are likely to be involved in the spontaneous development of RF in Bcl-2 
overexpressing (B6 x NZW)F1 mice. In marked contrast to anti-DNA responses, which were 
increased by Yaa in Bcl-2 transgenic mice indifferent of their genetic background, the Yaa 
mutation was incapable of augmenting RF responses in the mice used in this study, which 
were all FcγRIIB+/+. However, we observed that RF production could be induced even in 
B6.Yaa mice, if they were partially defective in FcγRIIB expression. These results further 
stress the central importance of the balance between negative and positive regulators of BCR 
in the triggering and persistence of spontaneous lupus-like autoimmune responses. In 
conclusion, all our results support the idea i) that Yaa most efficiently contributes to 
autoimmunity when the control of BCR signaling displays deficiencies, ii) that anti-DNA and 
RF responses are differentially regulated, possibly due to the nature of the autoantigen 
involved, and iii) that FcγRIIB plays a particular important role in the control of RF responses 
by directly binding to IgG IC. 
 
C) Differential expression and regulation in mice of the inhibitory receptor CD22 underlines 
its role in lupus susceptibility 
At least three polymorphic forms of CD22 have been identified in mice: CD22a is 
expressed by NZW, NZB and DBA/2 mice, CD22b in B6 mice (among others), and CD22c in 
BXSB and SB mice (417, 418). The analysis of B6 x (NZW x B6.Yaa)F1 backcross mice 
revealed that the major lupus-susceptibility locus of the NZW strain peaked in the vicinity of 
the Cd22 gene on chromosome 7 (439). The significance of this region has also been 
confirmed by the analysis of B6 x (NZB x B6.Yaa)F1 backcross mice (Kikuchi et al., 2005). 
Polymorphic variations identified in NZW, NZB and BXSB (417, 418) suggested that Cd22a 
and Cd22c mice could express aberrant forms of CD22 with functional defects in the ligand-
binding site. Indeed, our flow cytometric analysis in Cd22a mice with CY34 mAb binding to 
this site revealed more heterogenous staining, as compared to Cd22b mice, which we 
interpreted as a reflection of the expression of aberrant forms of CD22 (Nitschke et al., 
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submitted). More importantly, with respect to CD22 function, we showed that CD22a 
molecules were more frequently unmasked (i.e. less CD22 bound to surface IgM) and that B 
cells from Cd22a mice displayed prolonged intracellular Ca2+ flow after activation. As all 
these findings argue in favour of a role for CD22a in the deficient negative regulation of BCR 
signaling encountered in systemic autoimmunity, it would be important to generate B6.Yaa 
mice bearing the Cd22a allele derived from non-autoimmune DBA/2 mice, and to refine its 
role for the spontaneous development of SLE-like autoimmune disease in this model. 
Our analysis of the regulation of CD22 expression in response to different activatory 
stimuli also comforted the notion that the immune system uses CD22 as a switch to fine-tune 
B-cell activation (449). In this respect, the comparison of the effect of different B-cell 
mitogens on CD22 expression in B2 and B1 cells, implicated in adaptive and innate immune 
responses, respectively, provided an interesting example: While stimulation with anti-IgM 
mAb decreased CD22 expression in B2 cells, consistent with increased BCR-mediated B-cell 
activation, B1 cells failed to modulate CD22 after this stimulus. In sharp contrast, LPS 
increased CD22 expression in B2 cells, but decreased it in B1 cells, in agreement with the 
postulated role of B1 cells in the first line of defense against bacterial pathogens (258). 
Moreover, it was striking to see that Ca2+ responses after anti-IgM stimulation were equally 
low in B1 cells from both CD22+/+ and CD22-/- mice, suggesting that CD22-mediated 
regulation of B cell activation was not necessarily a mechanism used in all B-cell 
subpopulations. However, it was recently shown that the number of MZ B cells, which have 
functional similarities with B1 cells (257, 258), was decreased in CD22-/- mice (448). 
Clearly, a comprehensive analysis of the role of CD22 in specialized B cell subpopulations, 
including a putative role for CD22 during development, would help elucidate this issue. 
 
General Conclusions 
The obvious polygenic character of SLE in humans and of lupus-like autoimmune 
disease in mice implicates that a multitude of molecular pathways, which might contribute to 
B-cell hyperactivity and systemic autoimmunity, have to be analyzed. Accordingly, this report 
has dealt with a consequent number of aspects of B cell biology, including the role of antigen 
specificity and tolerance induction in autoimmunity, maturation into different subpopulations, 
induction of effector function, negative regulation of BCR signaling, and fine-tuning of B-cell 
responsiveness through integration of extracellular information. The data generated support a 
central role for the BCR, in terms of antigen specificity and signal transduction, in the 
establishment of antibody-mediated systemic autoimmunity. What we now need to know is 
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what combination of genetic risk factors is most frequently responsible for the development of 
SLE as a BCR-related pathology. Further studies in transgenic mice might thus help to 
identify putative molecular targets, which could then be validated in the clinics. Clearly, the 
development of a therapeutic approach that tackles the molecular basis of SLE rather than 
attenuating its deteriorating symptoms remains the prime target in our field, which is situated 
at the interface of basic and applied immunology. 
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